WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Tuesday, April 04, 2006

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,JPAB,DWPI; PLUR=YES; OP=ADJ		
☐	L7	L3 or l5	160
☐	L6	l5 or l3L5	92
☐	L5	l4 and dr5	71
	DB=DWPI,JPAB,USPT,PGPB; PLUR=YES; OP=ADJ		
☐	L4	("NI-JIAN".IN. | "NI-JAIN".IN.)!	404
	DB=PGPB,USPT,JPAB,DWPI; PLUR=YES; OP=ADJ		
☐	L3	L2 and (l1.ab. or l1.ti.)	96
☐	L2	L1 adj12 ((death domain) or apoptosis)	439
☐	L1	DR5 or Apo-2 or TRAIL-R or (death receptor-5) or TRAIL-R2 or TRAILR2 or TRAIL-2 or TRAIL2 or Trick2 or Killer or Tango63e or TR6	24103

END OF SEARCH HISTORY

Hit List

First Hit | Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 160 of 160 returned.

☐ 1. Document ID: US 20060035334 A1

L7: Entry 1 of 160 File: PGPB Feb 16, 2006

PGPUB-DOCUMENT-NUMBER: 20060035334
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060035334 A1

TITLE: Apo-2 receptor

PUBLICATION-DATE: February 16, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Adams; Camellia W.	Mountain View	CA	US
Ashkenazi; Avi J.	San Mateo	CA	US
Chuntharapai; Anan	Colma	CA	US
Kim; Kyung Jin	Los Altos	CA	US

US-CL-CURRENT: 435/69.1; 435/252.33, 435/320.1, 435/358, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

☐ 2. Document ID: US 20060020114 A1

L7: Entry 2 of 160 File: PGPB Jan 26, 2006

PGPUB-DOCUMENT-NUMBER: 20060020114
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060020114 A1

TITLE: Apo-2DcR

PUBLICATION-DATE: January 26, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ashkenazi; Avi J.	San Mateo	CA	US
Baker; Kevin P.	San Mateo	CA	US
Gurney; Austin	Belmont	CA	US
Wood; William I.	San Mateo	CA	US

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/6, 435/69.1, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

☐ 3. Document ID: US 20060009387 A1

L7: Entry 3 of 160 File: PGPB Jan 12, 2006

PGPUB-DOCUMENT-NUMBER: 20060009387
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060009387 A1

TITLE: Apo-2 ligand/trail formulations

PUBLICATION-DATE: January 12, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Flores; Heather	Hayward	CA	US
Lin; Tanya P.	Bronx	NY	US
Matthews; Timothy C.	Millbrae	CA	US
Pai; Roger	Los Altos	CA	US
Shahrokh; Zahra	Weston	MA	US

US-CL-CURRENT: 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 4. Document ID: US 20050287635 A1

L7: Entry 4 of 160 File: PGPB Dec 29, 2005

PGPUB-DOCUMENT-NUMBER: 20050287635
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050287635 A1

TITLE: RTD receptor

PUBLICATION-DATE: December 29, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ashkenazl, Avi J.	San Mateo	CA	US
Gurney, Austin	Belmont	CA	US

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 530/388.22, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 5. Document ID: US 20050282230 A1

L7: Entry 5 of 160 File: PGPB Dec 22, 2005

PGPUB-DOCUMENT-NUMBER: 20050282230
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050282230 A1

TITLE: Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method

PUBLICATION-DATE: December 22, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ashkenazi, Avi J.	San Mateo	CA	US
Chuntharapai, Anan	Colma	CA	US
Kim, K. Jin	Los Altos	CA	US

US-CL-CURRENT: 435/7.1; 435/320.1, 435/334, 435/69.1, 530/388.22, 536/23.53

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 6. Document ID: US 20050282217 A1

L7: Entry 6 of 160 File: PGPB Dec 22, 2005

PGPUB-DOCUMENT-NUMBER: 20050282217
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050282217 A1

TITLE: Human tumor necrosis factor receptor TR10

PUBLICATION-DATE: December 22, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ni, Jian	Germantown	MD	US
Rosen, Craig A.	Laytonsville	MD	US

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 7. Document ID: US 20050255100 A1

L7: Entry 7 of 160 File: PGPB Nov 17, 2005

PGPUB-DOCUMENT-NUMBER: 20050255100
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050255100 A1

TITLE: Antibodies to tumor necrosis factor receptor 5

PUBLICATION-DATE: November 17, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Wei, Ying-Fei	Berkeley	CA	US
Ni, Jian	Germantown	MD	US
Gentz, Reiner L.	Belo Horizonte - Mg	MD	BR
Ruben, Steven M.	Brookeville		US

US-CL-CURRENT: 424/141.1; 424/145.1, 514/109, 514/11, 514/171, 514/263.31

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 8. Document ID: US 20050249729 A1

L7: Entry 8 of 160 File: PGPB Nov 10, 2005

PGPUB-DOCUMENT-NUMBER: 20050249729
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050249729 A1

TITLE: Anti-TRAIL-R antibody

PUBLICATION-DATE: November 10, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Mori, Eiji	Takasaki-shi		JP
Motoki, Kazuhiro	Takasaki-shi		JP
Kataoka, Shiro	Takasaki-shi		JP

US-CL-CURRENT: 424/143.1; 435/334, 530/388.22

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 9. Document ID: US 20050244876 A1

L7: Entry 9 of 160 File: PGPB Nov 3, 2005

PGPUB-DOCUMENT-NUMBER: 20050244876
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050244876 A1

TITLE: Human tumor necrosis factor receptors TR13 and TR14

PUBLICATION-DATE: November 3, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ni, Jian	Germantown	MD	US
Baker, Kevin P.	Darnestown	MD	US
Ruben, Steven M.	Brookeville	MD	US
Young, Paul E.	Gaithersburg	MD	US

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 514/12, 530/350, 530/388.22, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 10. Document ID: US 20050244857 A1

L7: Entry 10 of 160 File: PGPB Nov 3, 2005

PGPUB-DOCUMENT-NUMBER: 20050244857
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050244857 A1

TITLE: Death domain containing receptor 4

PUBLICATION-DATE: November 3, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ni, Jian	Germantown	MD	US
Rosen, Craig A.	Laytonsville	MD	US
Pan, James	Oakville	CA	CA
Gentz, Reiner L.	Belo Horizonte-Mg		BR
Dixit, Vishva M.	Los Altos Hills		US

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 11. Document ID: US 20050244417 A1

L7: Entry 11 of 160 File: PGPB Nov 3, 2005

PGPUB-DOCUMENT-NUMBER: 20050244417
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050244417 A1

TITLE: Apo-2 ligand-anti-Her-2 antibody synergism

PUBLICATION-DATE: November 3, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ashkenazi, Avi J.	San Mateo	CA	US
Phillips, Gail Lewis	San Carlos	CA	US

US-CL-CURRENT: 424/155.1; 424/178.1, 600/1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 12. Document ID: US 20050239123 A1

L7: Entry 12 of 160 File: PGPB Oct 27, 2005

PGPUB-DOCUMENT-NUMBER: 20050239123
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050239123 A1

TITLE: Human tumor necrosis receptor TR9

PUBLICATION-DATE: October 27, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ni, Jian	Germantown	MD	US
Yu, Guo-Liang	Berkeley	CA	US
Fan, Ping	Rockville	MD	US
Gentz, Reiner L.	Belo Horizonte-Mg		BR

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 13. Document ID: US 20050233958 A1

L7: Entry 13 of 160 File: PGPB Oct 20, 2005

PGPUB-DOCUMENT-NUMBER: 20050233958
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050233958 A1

TITLE: Death domain containing receptor 5

PUBLICATION-DATE: October 20, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ni, Jian	Germantown	MD	US
Gentz, Reiner L.	Belo Horizonte-MG	CA	BR
Yu, Guo-Liang	Berkeley	MD	US
Rosen, Craig A.	Laytonsville		US

US-CL-CURRENT: 514/12; 530/350, 530/388.22

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

☐ 14. Document ID: US 20050216960 A1

L7: Entry 14 of 160 File: PGPB Sep 29, 2005

PGPUB-DOCUMENT-NUMBER: 20050216960
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050216960 A1

TITLE: TRAIL-R as a negative regulator of innate immune cell responses

PUBLICATION-DATE: September 29, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Winoto, Astar	Berkeley	CA	US
Diehl, Gretchen Elizabeth	Berkeley	CA	US
Yue, Herman Heng	Berkeley	CA	US

US-CL-CURRENT: 800/8; 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

☐ 15. Document ID: US 20050186637 A1

L7: Entry 15 of 160 File: PGPB Aug 25, 2005

PGPUB-DOCUMENT-NUMBER: 20050186637
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050186637 A1

TITLE: Neutrokine-alpha and neutrokine-alpha splice variant

PUBLICATION-DATE: August 25, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Yu, Guo-Liang	Berkeley	CA	US
Ebner, Reinhard	Gaithersburg	MD	US
Ni, Jian	Germantown	MD	US
Rosen, Craig A.	Laytonsville	MD	US
Ullrich, Stephen	Rockville	MD	US

US-CL-CURRENT: 435/7.1; 424/145.1, 424/178.1, 435/335, 530/388.23

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 16. Document ID: US 20050186186 A1

L7: Entry 16 of 160 File: PGPB Aug 25, 2005

PGPUB-DOCUMENT-NUMBER: 20050186186
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050186186 A1

TITLE: Compositions for eliciting immune response and methods for using same

PUBLICATION-DATE: August 25, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Wu, Jiangping	Brossard	NY	CA
Shi, Guixiu	Saranac Lake		US

US-CL-CURRENT: 424/93.21; 435/366

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 17. Document ID: US 20050119457 A1

L7: Entry 17 of 160 File: PGPB Jun 2, 2005

PGPUB-DOCUMENT-NUMBER: 20050119457
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050119457 A1

TITLE: Human proteins

PUBLICATION-DATE: June 2, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ni, Jian	Germantown	MD	US
Rosen, Craig A.	Laytonsville	MD	US
Gentz, Reiner	Belo Horizonte-Mg	NJ	BR
Su, Jeffrey Y.	Clinton	MD	US
Krissansen, Geoffrey W.	Auckland		NZ
Feng, Ping	Germantown		US

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 530/388.1, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

---

☐ 18. Document ID: US 20050112090 A9

L7: Entry 18 of 160 File: PGPB May 26, 2005

PGPUB-DOCUMENT-NUMBER: 20050112090
PGPUB-FILING-TYPE: corrected
DOCUMENT-IDENTIFIER: US 20050112090 A9

TITLE: Death domain containing receptor 4

PUBLICATION-DATE: May 26, 2005

PRIOR-PUBLICATION:

DOC-ID	DATE
US 0136950 A1	July 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ni, Jian	Germantown	MD	US
Rosen, Craig A.	Laytonsville	MD	US
Gentz, Reiner L.	Belo-Horizonte		BR

US-CL-CURRENT: 424/85.1; 424/144.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

---

☐ 19. Document ID: US 20050089958 A1

L7: Entry 19 of 160 File: PGPB Apr 28, 2005

PGPUB-DOCUMENT-NUMBER: 20050089958
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050089958 A1

TITLE: Apo-2 ligand

PUBLICATION-DATE: April 28, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ashkenazi, Avi J.	San Mateo	CA	US
Schwall, Ralph H.	Pacifica	CA	US

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/351, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

---

☐ 20. Document ID: US 20050079172 A1

L7: Entry 20 of 160 File: PGPB Apr 14, 2005

PGPUB-DOCUMENT-NUMBER: 20050079172
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050079172 A1

TITLE: Methods and compositions for inducing apoptosis in cancer cells

PUBLICATION-DATE: April 14, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Nasoff, Marc	San Diego	CA	US
Deveraux, Quinn L.	San Diego	CA	US
Knee, Deborah A.	Del Mar	CA	US
Aza-Blanc, Pedro	San Diego	CA	US
Hampton, Garret M.	San Diego	CA	US
Wagner, Klaus	San Diego	CA	US

US-CL-CURRENT: 424/141.1; 424/143.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

---

☐ 21. Document ID: US 20050020498 A1

L7: Entry 21 of 160 File: PGPB Jan 27, 2005

PGPUB-DOCUMENT-NUMBER: 20050020498
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050020498 A1

TITLE: Apo-2 ligand/trail formulations

PUBLICATION-DATE: January 27, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Flores, Heather	Hayward	CA	US
Lin, Tanya P.	Bronx	NY	US
Matthews, Timothy C.	Millbrae	CA	US
Pai, Roger	Los Altos	CA	US
Shahrokh, Zahra	Weston	MA	US

US-CL-CURRENT: 514/12; 514/565

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

---

☐ 22. Document ID: US 20040253708 A1

L7: Entry 22 of 160 File: PGPB Dec 16, 2004

PGPUB-DOCUMENT-NUMBER: 20040253708
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040253708 A1

TITLE: Apo-2 ligand

PUBLICATION-DATE: December 16, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ashkenazi, Avi J.	San Mateo	CA	US

US-CL-CURRENT: 435/226; 435/320.1, 435/325, 435/69.1, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

---

☐ 23. Document ID: US 20040248132 A1

L7: Entry 23 of 160 File: PGPB Dec 9, 2004

PGPUB-DOCUMENT-NUMBER: 20040248132
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040248132 A1

TITLE: DR5 gene promoter and siah-1 gene promoter

PUBLICATION-DATE: December 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Sakai, Toshiyuki	Kyoto-shi		JP

US-CL-CURRENT: 435/6; 435/226, 435/320.1, 435/325, 435/69.1, 530/351, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

---

☐ 24. Document ID: US 20040214235 A1

L7: Entry 24 of 160 File: PGPB Oct 28, 2004

PGPUB-DOCUMENT-NUMBER: 20040214235
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040214235 A1

TITLE: Anti-trail-r antibodies

PUBLICATION-DATE: October 28, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Mori, Eiji	Gunma		JP
Kataoka, Shiro	Gunma		JP

US-CL-CURRENT: 435/7.2; 530/388.22

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

---

☐ 25. Document ID: US 20040197870 A1

L7: Entry 25 of 160 File: PGPB Oct 7, 2004

PGPUB-DOCUMENT-NUMBER: 20040197870
PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040197870 A1

TITLE: Human tumor necrosis factor receptor TR9

PUBLICATION-DATE: October 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ni, Jian	Germantown	MD	US
Yu, Guo-Liang	Berkeley	CA	US
Fan, Ping	Rockville	MD	US
Gentz, Reiner L.	Belo Horizonte-Mg		BR

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 26. Document ID: US 20040186051 A1

L7: Entry 26 of 160 File: PGPB Sep 23, 2004

PGPUB-DOCUMENT-NUMBER: 20040186051
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040186051 A1

TITLE: Apo-2 ligand variants and uses thereof

PUBLICATION-DATE: September 23, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Kelley, Robert F	San Bruno	CA	US
Lindstrom, Stephanie Ho	Millbrae	CA	US

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 27. Document ID: US 20040175802 A1

L7: Entry 27 of 160 File: PGPB Sep 9, 2004

PGPUB-DOCUMENT-NUMBER: 20040175802
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040175802 A1

TITLE: Neutrokine-alpha and Neutrokine-alpha splice variant

PUBLICATION-DATE: September 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Yu, Guo-Liang	Berkeley	CA	US
Ebner, Reinhard	Gaithersburg	MD	US
Ni, Jian	Germantown	MD	US

US-CL-CURRENT: 435/69.5; 435/320.1, 435/325, 530/351, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 28. Document ID: US 20040141952 A1

L7: Entry 28 of 160 File: PGPB Jul 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040141952
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040141952 A1

TITLE: Death domain containing receptor 5

PUBLICATION-DATE: July 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ni, Jian	Rockville	MD	US
Gentz, Reiner L.	Rockville	MD	US
Yu, Guo-Liang	Berkeley	CA	US
Rosen, Craig A.	Laytonsville	MD	US

US-CL-CURRENT: 424/85.1; 424/131.1, 514/12, 514/192, 514/200, 514/210.09

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 29. Document ID: US 20040136951 A1

L7: Entry 29 of 160 File: PGPB Jul 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040136951
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040136951 A1

TITLE: Death domain containing receptor 5

PUBLICATION-DATE: July 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ni, Jian	Germantown	MD	US
Gentz, Reiner L.	Belo Horizonte	CA	BR
Yu, Guo-Liang	Berkeley	MD	US
Rosen, Craig A.	Laytonsville		US

US-CL-CURRENT: 424/85.1; 424/131.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 30. Document ID: US 20040136950 A1

L7: Entry 30 of 160 File: PGPB Jul 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040136950

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040136950 A1

TITLE: Death domain containing receptor 4

PUBLICATION-DATE: July 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ni, Jian	Germantown	MD	US
Rosen, Craig A.	Laytonsville	MD	US
Gentz, Reiner L.	Belo-Horizonte		BR

US-CL-CURRENT: 424/85.1; 424/144.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 31. Document ID: US 20040048296 A1

L7: Entry 31 of 160 File: PGPB Mar 11, 2004

PGPUB-DOCUMENT-NUMBER: 20040048296
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040048296 A1

TITLE: Human tumor necrosis factor TR20 and methods based thereon

PUBLICATION-DATE: March 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ruben, Steven M.	Brookeville	MD	US
Baker, Kevin P.	Darnestown	MD	US
Ni, Jian	Germantown	MD	US

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 32. Document ID: US 20040013664 A1

L7: Entry 32 of 160 File: PGPB Jan 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040013664
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040013664 A1

TITLE: Tumor necrosis factor receptors 6 alpha & 6 beta

PUBLICATION-DATE: January 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Gentz, Reiner L.	Belo Horizonte-Mg	CA	BR
Yu, Guo-Liang	Berkeley	MD	US

Ni, Jian	Germantown	MD	US
Ebner, Reinhard	Gaithersburg	MD	US
Feng, Ping	Germantown	MD	US
Ruben, Steven M.	Brookeville		US

US-CL-CURRENT: 424/130.1; 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 33. Document ID: US 20040009552 A1

L7: Entry 33 of 160 File: PGPB Jan 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040009552
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040009552 A1

TITLE: Apo-2 receptor

PUBLICATION-DATE: January 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Adams, Camellia W.	Mountain View	CA	US
Ashkenazi, Avi J.	San Mateo	CA	US
Chuntharapai, Anan	Colma	CA	US
Kim, Kyung Jin	Los Altos	CA	US

US-CL-CURRENT: 435/69.1; 435/252.33, 435/320.1, 435/358, 530/350, 530/388.22, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 34. Document ID: US 20030198640 A1

L7: Entry 34 of 160 File: PGPB Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030198640
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030198640 A1

TITLE: Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Yu, Guo-Liang	Berkeley	CA	US
Ni, Jian	Germantown	MD	US
Rosen, Craig A.	Laytonsville	MD	US
Zhang, Jun	San Diego	CA	US
Wei, Ping	Brookeville	MD	US

US-CL-CURRENT: 424/145.1

☐ 35. Document ID: US 20030198637 A1

L7: Entry 35 of 160 File: PGPB Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030198637
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030198637 A1

TITLE: Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Zhou, Tong	Birmingham	AL	US
Kimberly, Robert P.	Birmingham	AL	US
Koopman, William J.	Indian Springs	AL	US
LoBuglio, Albert F.	Birmingham	AL	US
Buchsbaum, Donald J.	Montevallo	AL	US

US-CL-CURRENT: 424/141.1; 424/145.1, 530/388.15, 530/388.24

☐ 36. Document ID: US 20030190687 A1

L7: Entry 36 of 160 File: PGPB Oct 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030190687
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030190687 A1

TITLE: Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

PUBLICATION-DATE: October 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Zhou, Tong	Birmingham	AL	AL
Ichikawa, Kimihisa	Yokohama-shi	AL	JP
Kimberly, Robert P	Birmingham		US
Koopman, William J	Indian Springs		US

US-CL-CURRENT: 435/7.23; 424/143.1, 514/109, 514/251, 514/263.31, 514/27, 514/283, 514/34, 514/410, 514/449, 514/49, 514/8, 530/388.22, 600/1

☐ 37. Document ID: US 20030180883 A1

L7: Entry 37 of 160 File: PGPB Sep 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030180883
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030180883 A1

TITLE: Human tumor necrosis factor receptor TR10

PUBLICATION-DATE: September 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ni, Jian	Germantown	MD	US
Rosen, Craig A.	Laytonsville	MD	US

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 38. Document ID: US 20030175856 A1

L7: Entry 38 of 160 File: PGPB Sep 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030175856
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030175856 A1

TITLE: RTD RECEPTOR

PUBLICATION-DATE: September 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
ASHKENAZI, AVI J.	SAN MATEO	CA	US
GURNEY, AUSTIN	BELMONT	CA	US

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 530/388.22, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 39. Document ID: US 20030175208 A1

L7: Entry 39 of 160 File: PGPB Sep 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030175208
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030175208 A1

TITLE: Neutrokine-alpha and neutrokine-alpha splice variant

PUBLICATION-DATE: September 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Yu, Guo-Liang	Berkeley	CA	US
Ebner, Reinhard	Gaithersburg	MD	US
Ni, Jian	Germantown	MD	US

Rosen, Craig A.	Laytonsville	MD	US
Ullrich, Stephen	Rockville	MD	US
Laird, Michael	Germantown	MD	US

US-CL-CURRENT: 424/1.49; 424/1.69

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 40. Document ID: US 20030170203 A1

L7: Entry 40 of 160 File: PGPB Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170203
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030170203 A1

TITLE: Death domain containing receptors

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Yu, Guo-Liang	Berkeley	CA	US
Ni, Jian	Germantown	MD	US
Gentz, Reiner L.	Belo Horizonte	CA	BR
Dillon, Patrick J.	Carlsbad		US

US-CL-CURRENT: 424/85.1; 424/145.1, 514/11, 514/210.09

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 41. Document ID: US 20030166864 A1

L7: Entry 41 of 160 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166864
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166864 A1

TITLE: Human tumor necrosis factor delta and epsilon

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Yu, Guo-Liang	Berkeley	CA	US
Ni, Jian	Germantown	MD	US
Gentz, Reiner	Belo Horizonte-Mg		BR

US-CL-CURRENT: 530/351; 424/450, 424/85.1, 435/320.1, 435/325, 435/69.5, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 42. Document ID: US 20030153499 A1

L7: Entry 42 of 160 File: PGPB Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030153499
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030153499 A1

TITLE: Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ni, Jian	Germantown	MD	US
Ruben, Steven M.	Brookeville	MD	US

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

---

☐ 43. Document ID: US 20030148455 A1

L7: Entry 43 of 160 File: PGPB Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030148455
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030148455 A1

TITLE: Apo-2 receptor

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Adams, Camellia W.	Mountain View	CA	US
Ashkenazi, Avi J.	San Mateo	CA	US
Chuntharapai, Anan	Colma	CA	US
Kim, Kyung Jin	Los Altos	CA	US

US-CL-CURRENT: 435/69.1; 424/145.1, 435/320.1, 435/325, 435/326, 530/359, 530/388.25, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

---

☐ 44. Document ID: US 20030138915 A1

L7: Entry 44 of 160 File: PGPB Jul 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030138915
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030138915 A1

TITLE: Apo-2DcR

PUBLICATION-DATE: July 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ashkenazi, Avi J.	San Mateo	CA	US
Baker, Kevin P.	San Mateo	CA	US
Chuntharapai, Anan	Colma	CA	US
Gurney, Austin	Belmont	CA	US
Kim, Kyung Jin	Los Altos	CA	US
Wood, William I.	San Mateo	CA	US

US-CL-CURRENT: 435/69.7; 435/320.1, 435/325, 530/359, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 45. Document ID: US 20030138426 A1

L7: Entry 45 of 160 File: PGPB Jul 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030138426
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030138426 A1

TITLE: Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2

PUBLICATION-DATE: July 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ni, Jian	Germantown	MD	US
Ruben, Steven M.	Brookville	MD	US

US-CL-CURRENT: 424/146.1; 435/7.2, 530/388.26

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 46. Document ID: US 20030133932 A1

Hit List

First Hit | Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 46 through 65 of 160 returned.

☐ 46. Document ID: US 20030133932 A1

Using default format because multiple data bases are involved.

L7: Entry 46 of 160 File: PGPB Jul 17, 2003

PGPUB-DOCUMENT-NUMBER: 20030133932
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030133932 A1

TITLE: Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents

PUBLICATION-DATE: July 17, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Zhou, Tong	Birmingham	AL	US
Ichikawa, Kimihisa	Yokohama-shi	AL	JP
Kimberly, Robert P.	Birmingham	AL	US
Koopman, William J.	Indian Springs	AL	US
Ohsumi, Jun	Yokohama-shi	AL	JP
LoBuglio, Albert F.	Birmingham		US
Buchsbaum, Donald J.	Montevallo		US

US-CL-CURRENT: 424/143.1; 424/85.5, 514/171, 514/251, 514/263.31, 514/269, 514/27, 514/283, 514/34, 514/410, 514/49, 514/492, 514/561, 514/575, 514/629, 514/649, 514/733, 514/8

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

☐ 47. Document ID: US 20030129189 A1

L7: Entry 47 of 160 File: PGPB Jul 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030129189
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030129189 A1

TITLE: Tumor necrosis factor-gamma

PUBLICATION-DATE: July 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Yu, Guo-Liang	Berkeley	CA	US
Ni, Jian	Germantown	MD	US
Rosen, Craig A.	Laytonsville	MD	US
Zhang, Jun	San Diego	CA	US

US-CL-CURRENT: 424/145.1

☐ 48. Document ID: US 20030118546 A1

L7: Entry 48 of 160 File: PGPB Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030118546
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030118546 A1

TITLE: Antibodies to tumor necrosis factor 5

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Wei, Ying-Fei	Berkeley	CA	US
Ni, Jian	Rockville	MD	US
Gentz, Reiner L.	Rockville	MD	US
Ruben, Steven M.	Olney	MD	US

US-CL-CURRENT: 424/85.1; 424/146.1

☐ 49. Document ID: US 20030108516 A1

L7: Entry 49 of 160 File: PGPB Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030108516
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030108516 A1

TITLE: Death domain containing receptor 4

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ni, Jian	Rockville	MD	US
Rosen, Craig A.	Laytonsville	MD	US
Pan, James G.	Belmont	CA	US
Gentz, Reiner L.	Rockville	MD	US
Dixit, Vishva M.	Los Altos Hills	CA	US

US-CL-CURRENT: 424/85.1; 424/155.1, 514/12

☐ 50. Document ID: US 20030100074 A1

L7: Entry 50 of 160 File: PGPB May 29, 2003

PGPUB-DOCUMENT-NUMBER: 20030100074
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030100074 A1

TITLE: Methods and compositions for treating metabolic bone diseases relating to human endokine alpha

PUBLICATION-DATE: May 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Yu, Guo-Liang	Berkeley	CA	US
Ni, Jian	Germantown	MD	US
Rosen, Craig A.	Laytonsville	CA	US
Nardelli, Bernardetta			US

US-CL-CURRENT: 435/69.5; 435/320.1, 435/325, 530/351, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

---

☐ 51. Document ID: US 20030092101 A1

L7: Entry 51 of 160 File: PGPB May 15, 2003

PGPUB-DOCUMENT-NUMBER: 20030092101
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030092101 A1

TITLE: Human tumor necrosis factor receptors TR13 and TR14

PUBLICATION-DATE: May 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ni, Jian	Germantown	MD	US
Baker, Kevin P.	Darnestown	MD	US
Ruben, Steven M.	Olney	MD	US
Young, Paul E.	Gaithersburg	MD	US

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

---

☐ 52. Document ID: US 20030049732 A1

L7: Entry 52 of 160 File: PGPB Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030049732
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030049732 A1

TITLE: Apoptosis related polynucleotides, polypeptides, and antibodies

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ni, Jian	Germantown	MD	US
Young, Paul E.	Gaithersburg	MD	US
Ruben, Steven M.	Olney	MD	US

US-CL-CURRENT: 435/69.1; 435/226, 435/320.1, 435/325, 435/6, 435/7.23, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 53. Document ID: US 20030027284 A1

L7: Entry 53 of 160 File: PGPB Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027284
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030027284 A1

TITLE: TUMOR NECROSIS FACTOR-GAMMA

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
YU, GUO-LIANG	SAN MATEO	CA	US
NI, JIAN	ROCKVILLE	MD	US
ROSEN, CRAIG A.	LAYTONSVILLE	MD	US
ZHANG, JUN	BETHESDA	MD	US

US-CL-CURRENT: 435/69.5; 424/136.1, 435/320.1, 435/325, 514/12, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 54. Document ID: US 20030017161 A1

L7: Entry 54 of 160 File: PGPB Jan 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030017161
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030017161 A1

TITLE: Apo-2 receptor

PUBLICATION-DATE: January 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ashkenazi, Avi J.	San Mateo	CA	US
Chuntharapai, Anan	Colma	CA	US
Kim, Kyung Jin	Los Altos	CA	US

US-CL-CURRENT: 424/155.1; 530/387.3, 530/388.25

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 55. Document ID: US 20020192212 A1

L7: Entry 55 of 160 File: PGPB Dec 19, 2002

PGPUB-DOCUMENT-NUMBER: 20020192212
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020192212 A1

TITLE: Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine

PUBLICATION-DATE: December 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Imai, Toshio	Kyoto-shi		JP
Nishimura, Miyuki	Kyoto-shi		JP
Muramoto, Kenzo	Kyoto-shi		JP
Kuboi, Yoshikazu	Tsukuba-shi		JP

US-CL-CURRENT: 424/140.1; 435/7.23

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

---

☐ 56. Document ID: US 20020168729 A1

L7: Entry 56 of 160 File: PGPB Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020168729
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020168729 A1

TITLE: Human endokine alpha and methods of use

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Yu, Guo-Liang	Berkeley	CA	US
Ni, Jian	Rockville	MD	US
Rosen, Craig A.	Laytonsville	MD	US

US-CL-CURRENT: 435/69.5; 435/320.1, 435/325, 530/351, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

---

☐ 57. Document ID: US 20020168359 A1

L7: Entry 57 of 160 File: PGPB Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020168359
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020168359 A1

TITLE: Human tumor necrosis factor receptor TR9

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ni, Jian	Germantown	MD	US
Yu, Guo-Liang	Berkeley	CA	US
Fan, Ping	Potomac	MD	US
Gentz, Reiner L.	Rockville	MD	US

US-CL-CURRENT: 424/139.1; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 58. Document ID: US 20020164684 A1

L7: Entry 58 of 160 File: PGPB Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020164684
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020164684 A1

TITLE: Human tumor necrosis factor receptor TR9

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ni, Jian	Rockville	MD	US
Yu, Guo-Liang	San Mateo	CA	US
Fan, Ping	Gaithersburg	MD	US
Gentz, Reiner L.	Silver Spring	MD	US

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/324, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 59. Document ID: US 20020161202 A1

L7: Entry 59 of 160 File: PGPB Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020161202
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020161202 A1

TITLE: Apo-2DcR

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ashkenazi, Avi J.	San Mateo	CA	US
Baker, Kevin P.	San Mateo	CA	US
Gurney, Austin	Belmont	CA	US
Wood, William I.	San Mateo	CA	US

US-CL-CURRENT: 530/391.1; 530/350

☐ 60. Document ID: US 20020161196 A1

L7: Entry 60 of 160 File: PGPB Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020161196
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020161196 A1

TITLE: TRAIL RECEPTORS NUCLEIC ACIDS ENCODING THE SAME AND METHODS OF USE THEREOF

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Alnemri, Emad S.	Ambler	PA	US

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

☐ 61. Document ID: US 20020161195 A1

L7: Entry 61 of 160 File: PGPB Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020161195
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020161195 A1

TITLE: Trail receptors, nucleic acids encoding the same, and methods of use thereof

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Alnemri, Emad S.	Ambler	PA	US

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

☐ 62. Document ID: US 20020155109 A1

L7: Entry 62 of 160 File: PGPB Oct 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020155109
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020155109 A1

TITLE: Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2

PUBLICATION-DATE: October 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Lynch, David H.	Bainbridge Island	WA	US

US-CL-CURRENT: 424/143.1; 530/388.22

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 63. Document ID: US 20020150985 A1

L7: Entry 63 of 160 File: PGPB Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020150985
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020150985 A1

TITLE: Apo-2 receptor

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Adams, Camellia W.	Mountain View	CA	US
Ashkenazi, Avi J.	San Mateo	CA	US
Chuntharapai, Anan	Colma	CA	US
Kim, Kyung Jin	Los Altos	CA	US

US-CL-CURRENT: 435/69.1; 424/178.1, 435/252.33, 435/320.1, 435/325, 530/350, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 64. Document ID: US 20020150583 A1

L7: Entry 64 of 160 File: PGPB Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020150583
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020150583 A1

TITLE: Tumor necrosis factor receptors 6alpha & 6beta

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Gentz, Reiner L.	Rockville	MD	US
Ebner, Reinhard	Gaithersburg	MD	US
Yu, Guo-Liang	Berkeley	CA	US
Ruben, Steven M.	Olney	MD	US
Ni, Jian	Germantown	MD	US
Feng, Ping	Gaithersburg	MD	US

US-CL-CURRENT: 424/178.1; 530/389.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 65. Document ID: US 20020150534 A1

L7: Entry 65 of 160 File: PGPB Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020150534
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020150534 A1

TITLE: Tumor necrosis factor-gamma

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Yu, Guo-Liang	Berkeley	CA	US
Ni, Jian	Germantown	MD	US
Rosen, Craig A.	Laytonsville	MD	US
Zhang, Jun	Bethesda	MD	US

US-CL-CURRENT: 424/1.49; 424/145.1

Term	Documents
(3 OR 5).PGPB,USPT,JPAB,DWPI.	160
(L3 OR L5).PGPB,USPT,JPAB,DWPI.	160

Hit List

First Hit | Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 66 through 85 of 160 returned.

☐ 66. Document ID: US 20020141993 A1

Using default format because multiple data bases are involved.

L7: Entry 66 of 160 File: PGPB Oct 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020141993
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020141993 A1

TITLE: Apo-2 ligand-anti-Her-2 antibody synergism

PUBLICATION-DATE: October 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ashkenazi, Avi J.	San Mateo	CA	US
Phillips, Gail Lewis	San Carlos	CA	US

US-CL-CURRENT: 424/143.1; 424/155.1, 600/1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 67. Document ID: US 20020123116 A1

L7: Entry 67 of 160 File: PGPB Sep 5, 2002

PGPUB-DOCUMENT-NUMBER: 20020123116
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020123116 A1

TITLE: Nucleic acids encoding tumor necrosis factor (TNF) receptor homologs

PUBLICATION-DATE: September 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ashkenazi, Avi J.	San Mateo	CA	US

US-CL-CURRENT: 435/184; 514/12, 530/391.1, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 68. Document ID: US 20020115154 A1

L7: Entry 68 of 160 File: PGPB Aug 22, 2002

PGPUB-DOCUMENT-NUMBER: 20020115154
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020115154 A1

TITLE: Trail receptors, nucleic acids encoding the same, and methods of use thereof

PUBLICATION-DATE: August 22, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Alnemri, Emad S.	Ambler	PA	US

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/6, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 69. Document ID: US 20020115112 A1

L7: Entry 69 of 160 File: PGPB Aug 22, 2002

PGPUB-DOCUMENT-NUMBER: 20020115112
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020115112 A1

TITLE: Neutrokine-alpha and Neutrokine-alpha splice variant

PUBLICATION-DATE: August 22, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Yu, Guo-Liang	Berkeley	CA	US
Ebner, Reinhard	Gaithersburg	MD	US
Ni, Jian	Germantown	MD	US
Rosen, Craig A.	Laytonsville	MD	US
Ullrich, Stephen	Rockville	MD	US

US-CL-CURRENT: 435/7.2; 424/145.1, 530/388.23

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 70. Document ID: US 20020102706 A1

L7: Entry 70 of 160 File: PGPB Aug 1, 2002

PGPUB-DOCUMENT-NUMBER: 20020102706
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020102706 A1

TITLE: Apo-2DcR

PUBLICATION-DATE: August 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ashkenazi, Avi J.	San Mateo	CA	US
Baker, Kevin P.	San Mateo	CA	US
Chuntharapai, Anan	Colma	CA	US
Gurney, Austin	Belmont	CA	US
Kim, Kyung Jin	Los Altos	CA	US

Wood, William I.	San Mateo	CA	US

US-CL-CURRENT: 435/226; 435/320.1, 435/325, 435/69.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 71. Document ID: US 20020102233 A1

L7: Entry 71 of 160 File: PGPB Aug 1, 2002

PGPUB-DOCUMENT-NUMBER: 20020102233
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020102233 A1

TITLE: Apo-2 ligand

PUBLICATION-DATE: August 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ashkenazi, Avi J.	San Mateo	CA	US

US-CL-CURRENT: 424/85.1; 530/351

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 72. Document ID: US 20020098550 A1

L7: Entry 72 of 160 File: PGPB Jul 25, 2002

PGPUB-DOCUMENT-NUMBER: 20020098550
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020098550 A1

TITLE: Death domain containing receptor 5

PUBLICATION-DATE: July 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ni, Jian	Rockville	MD	US
Gentz, Reiner L.	Silver Spring	MD	US
Yu, Guo-Liang	Darnestown	MD	US
Rosen, Craig A.	Laytonsville	MD	US

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 73. Document ID: US 20020098525 A1

L7: Entry 73 of 160 File: PGPB Jul 25, 2002

PGPUB-DOCUMENT-NUMBER: 20020098525
PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020098525 A1

TITLE: Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2

PUBLICATION-DATE: July 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ni, Jian	Germantown	MD	US
Ruben, Steven M.	Olney	MD	US

US-CL-CURRENT: 435/7.9; 530/388.22

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 74. Document ID: US 20020090683 A1

L7: Entry 74 of 160 File: PGPB Jul 11, 2002

PGPUB-DOCUMENT-NUMBER: 20020090683
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020090683 A1

TITLE: TUMOR NECROSIS FACTOR-GAMMA

PUBLICATION-DATE: July 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
YU, GUO-LIANG	SAN MATEO	CA	US
NI, JIAN	ROCKVILLE	MD	US
ROSEN, CRAIG A.	LAYTONSVILLE	MD	US
ZHANG, JUN	BETHESDA	MD	US

US-CL-CURRENT: 435/69.5; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 75. Document ID: US 20020072091 A1

L7: Entry 75 of 160 File: PGPB Jun 13, 2002

PGPUB-DOCUMENT-NUMBER: 20020072091
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020072091 A1

TITLE: Death domain containing receptor 5

PUBLICATION-DATE: June 13, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ni, Jian	Rockville	MD	US
Gentz, Reiner L.	Rockville	MD	US
Yu, Guo-Liang	Berkeley	CA	US

Rosen, Craig A.	Laytonville	MD	US

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 76. Document ID: US 20020064829 A1

L7: Entry 76 of 160 File: PGPB May 30, 2002

PGPUB-DOCUMENT-NUMBER: 20020064829
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020064829 A1

TITLE: Human tumor necrosis factor delta and epsilon

PUBLICATION-DATE: May 30, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Yu, Guo-Liang	Berkeley	CA	US
Ni, Jian	Germantown	MD	US
Gentz, Reiner L.	Rockville	MD	US
Dillon, Patrick J.	Carlsbad	CA	US

US-CL-CURRENT: 435/69.1; 424/145.1, 435/320.1, 435/325, 530/351, 530/388.23, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 77. Document ID: US 20020048566 A1

L7: Entry 77 of 160 File: PGPB Apr 25, 2002

PGPUB-DOCUMENT-NUMBER: 20020048566
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020048566 A1

TITLE: Modulation of cellular apoptosis and methods for treating cancer

PUBLICATION-DATE: April 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
El-Deiry, Wafik S.	Bryn Mawr	PA	US
Bernhard, Eric J.	Philadelphia	PA	US
Burns, Timothy F.	Philadelphia	PA	US
McDonald, E. Robert III	Philadelphia	PA	US

US-CL-CURRENT: 424/93.21; 435/320.1, 514/12

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 78. Document ID: US 20020004227 A1

L7: Entry 78 of 160 File: PGPB Jan 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020004227
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020004227 A1

TITLE: Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method

PUBLICATION-DATE: January 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Ashkenazi, Avi J.	San Mateo	CA	US
Chuntharapai, Anan	Colma	CA	US
Kim, K. Jin	Los Altos	CA	US

US-CL-CURRENT: 435/69.1; 435/325, 530/388.22, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 79. Document ID: US 20010029030 A1

L7: Entry 79 of 160 File: PGPB Oct 11, 2001

PGPUB-DOCUMENT-NUMBER: 20010029030
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010029030 A1

TITLE: NOVEL TRAIL RECEPTORS, NUCLEIC ACIDS ENCODING SAME, AND METHODS OF USE THEREOF

PUBLICATION-DATE: October 11, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
ALNEMRI, EMAD S.	AMBLER	PA	US

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/7.1, 435/7.2, 514/44, 530/324, 530/387.9, 536/23.5, 800/13

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 80. Document ID: US 20010021516 A1

L7: Entry 80 of 160 File: PGPB Sep 13, 2001

PGPUB-DOCUMENT-NUMBER: 20010021516
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010021516 A1

TITLE: Tumor necrosis factor receptor 5

PUBLICATION-DATE: September 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY

Wei, Ying-Fei	San Mateo	CA	US
Gentz, Reiner	Silver Spring	MD	US
Ni, Jian	Rockville	MD	US
Ruben, Steven M.	Olney	MD	US

US-CL-CURRENT: 435/69.1; 435/320.1, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 81. Document ID: US 20010010924 A1

L7: Entry 81 of 160 File: PGPB Aug 2, 2001

PGPUB-DOCUMENT-NUMBER: 20010010924
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010010924 A1

TITLE: TUMOR NECROSIS FACTOR RELATED RECEPTOR, TR6 POLYNECLEOTIDES

PUBLICATION-DATE: August 2, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
DEEN, KEITH CHARLES	GLENMOORE	PA	US
YOUNG, PETER RONALD	LAWRENCEVILLE	NJ	US

US-CL-CURRENT: 435/69.1; 435/325, 435/6, 435/7.2, 514/2, 530/324, 530/387.9, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 82. Document ID: US 6998116 B1

L7: Entry 82 of 160 File: USPT Feb 14, 2006

US-PAT-NO: 6998116
DOCUMENT-IDENTIFIER: US 6998116 B1

TITLE: Apo-2 ligand

DATE-ISSUED: February 14, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ashkenazi; Avi J.	San Mateo	CA		US

US-CL-CURRENT: 424/85.1; 514/12, 530/350, 530/402, 930/140

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 83. Document ID: US 6969599 B2

L7: Entry 83 of 160 File: USPT Nov 29, 2005

US-PAT-NO: 6969599

DOCUMENT-IDENTIFIER: US 6969599 B2

TITLE: Nucleic acids encoding tumor necrosis factor receptor TR10

DATE-ISSUED: November 29, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Germantown	MD		
Rosen; Craig A.	Laytonsville	MD		

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 84. Document ID: US 6951738 B2

L7: Entry 84 of 160 File: USPT Oct 4, 2005

US-PAT-NO: 6951738
DOCUMENT-IDENTIFIER: US 6951738 B2

TITLE: Human tumor necrosis factor receptors TR13 and TR14

DATE-ISSUED: October 4, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Germantown	MD		
Baker; Kevin P.	Darnestown	MD		
Ruben; Steven M.	Olney	MD		
Young; Paul E.	Gaithersburg	MD		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/325, 435/455, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 85. Document ID: US 6949358 B1

L7: Entry 85 of 160 File: USPT Sep 27, 2005

US-PAT-NO: 6949358
DOCUMENT-IDENTIFIER: US 6949358 B1

TITLE: Human tumor necrosis factor receptor TR9

DATE-ISSUED: September 27, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Rockville	MD		
Yu; Guo-Liang	San Mateo	CA		
Fan; Ping	Gaithersburg	MD		
Gentz; Reiner L.	Silver Spring	MD		

Hit List

First Hit | Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 86 through 105 of 160 returned.

☐ 86. Document ID: US 6919078 B2

Using default format because multiple data bases are involved.

L7: Entry 86 of 160 File: USPT Jul 19, 2005

US-PAT-NO: 6919078
DOCUMENT-IDENTIFIER: US 6919078 B2

TITLE: Antibodies to human tumor necrosis factor receptor TR9

DATE-ISSUED: July 19, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Germantown	MD		
Yu; Guo-Liang	Berkeley	CA		
Fan; Ping	Potomac	MD		
Gentz; Reiner L.	Rockville	MD		

US-CL-CURRENT: 424/139.1; 424/178.1, 435/328, 435/334, 435/7.21, 436/501, 530/350, 530/387.3, 530/387.9, 530/388.15, 530/388.22, 530/389.1, 530/391.1, 530/391.3, 530/391.7

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 87. Document ID: US 6902910 B2

L7: Entry 87 of 160 File: USPT Jun 7, 2005

US-PAT-NO: 6902910
DOCUMENT-IDENTIFIER: US 6902910 B2
** See image for Certificate of Correction **

TITLE: Death domain containing receptor 4

DATE-ISSUED: June 7, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		
Pan; James G.	Belmont	CA		
Gentz; Reiner L.	Rockville	MD		
Dixit; Vishva M.	Los Altos Hills	CA		

US-CL-CURRENT: 435/69.7; 435/325, 435/69.1, 530/300, 530/350, 530/387.3, 530/388.22, 530/402, 536/23.1, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 88. Document ID: US 6881401 B1

L7: Entry 88 of 160 File: USPT Apr 19, 2005

US-PAT-NO: 6881401
DOCUMENT-IDENTIFIER: US 6881401 B1

TITLE: Methods of treatment of immune system related disorders using Neutrokine-alpha

DATE-ISSUED: April 19, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Berkeley	CA		
Ebner; Reinhard	Gaithersburg	MD		
Ni; Jian	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		

US-CL-CURRENT: 424/85.1; 424/185.1, 424/198.1, 514/12, 514/2, 530/350, 530/351, 530/399

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 89. Document ID: US 6872568 B1

L7: Entry 89 of 160 File: USPT Mar 29, 2005

US-PAT-NO: 6872568
DOCUMENT-IDENTIFIER: US 6872568 B1

TITLE: Death domain containing receptor 5 antibodies

DATE-ISSUED: March 29, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Rockville	MD		
Gentz; Reiner L.	Rockville	MD		
Yu; Guo-Liang	Berkeley	CA		
Rosen; Craig A.	Laytonsville	MD		

US-CL-CURRENT: 435/326; 435/330, 435/331, 435/344, 435/7.1, 530/350, 530/387.1, 530/388.1, 530/388.2, 530/388.8, 530/389.1, 530/389.7, 530/391.3, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 90. Document ID: US 6824767 B2

L7: Entry 90 of 160 File: USPT Nov 30, 2004

US-PAT-NO: 6824767
DOCUMENT-IDENTIFIER: US 6824767 B2

TITLE: Tumor necrosis factor-gamma

DATE-ISSUED: November 30, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Berkeley	CA		
Ni; Jian	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		
Zhang; Jun	Bethesda	MD		

US-CL-CURRENT: 424/85.1; 514/12, 530/324, 530/350, 530/387.3, 530/866

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

---

☐ 91. Document ID: US 6812327 B1

L7: Entry 91 of 160 File: USPT Nov 2, 2004

US-PAT-NO: 6812327
DOCUMENT-IDENTIFIER: US 6812327 B1
**** See image for Certificate of Correction ****

TITLE: Neutrokine-alpha polypeptides

DATE-ISSUED: November 2, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Berkeley	CA		
Ebner; Reinhard	Gaithersburg	MD		
Ni; Jian	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		

US-CL-CURRENT: 530/351; 424/198.1, 424/85.1, 435/69.5, 530/300, 530/350, 530/399

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

---

☐ 92. Document ID: US 6746668 B2

L7: Entry 92 of 160 File: USPT Jun 8, 2004

US-PAT-NO: 6746668
DOCUMENT-IDENTIFIER: US 6746668 B2

TITLE: Apo-2 ligand

DATE-ISSUED: June 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ashkenazi; Avi J.	San Mateo	CA		

US-CL-CURRENT: 424/85.1; 514/12, 514/149, 514/248, 514/283, 530/350, 530/402, 540/478, 544/313, 544/317, 930/140

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

☐ 93. Document ID: US 6743625 B2

L7: Entry 93 of 160 File: USPT Jun 1, 2004

US-PAT-NO: 6743625
DOCUMENT-IDENTIFIER: US 6743625 B2

TITLE: Death domain containing receptor 5

DATE-ISSUED: June 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Rockville	MD		
Gentz; Reiner L.	Rockville	MD		
Yu; Guo-Liang	Berkeley	CA		
Rosen; Craig A.	Laytonsville	MD		

US-CL-CURRENT: 435/325; 435/252.3, 435/254.11, 435/69.1, 530/350, 536/23.1, 536/23.4, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 94. Document ID: US 6740739 B1

L7: Entry 94 of 160 File: USPT May 25, 2004

US-PAT-NO: 6740739
DOCUMENT-IDENTIFIER: US 6740739 B1

TITLE: Substitutional variants of APO-2 ligand

DATE-ISSUED: May 25, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ashkenazi; Avi J.	San Mateo	CA		
Kelley; Robert F.	San Bruno	CA		
O'Connell; Mark P.	Montara	CA		
Pitti; Robert M.	El Cerrito	CA		
Schwall; Ralph A.	Pacifica	CA		

US-CL-CURRENT: 530/399; 424/184.1, 424/185.1, 424/193.1, 424/198.1, 530/350, 530/402, 530/403

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 95. Document ID: US 6716576 B1

L7: Entry 95 of 160 File: USPT Apr 6, 2004

US-PAT-NO: 6716576
DOCUMENT-IDENTIFIER: US 6716576 B1
**** See image for Certificate of Correction ****

TITLE: Method of assaying Neutrokine-.alpha. mRNA level

DATE-ISSUED: April 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Berkeley	CA		
Ebner; Reinhard	Gaithersburg	MD		
Ni; Jian	Germantown	MD		

US-CL-CURRENT: 435/6; 435/4, 536/23.1, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 96. Document ID: US 6689607 B2

L7: Entry 96 of 160 File: USPT Feb 10, 2004

US-PAT-NO: 6689607
DOCUMENT-IDENTIFIER: US 6689607 B2

TITLE: Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2

DATE-ISSUED: February 10, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Germantown	MD		
Ruben; Steven M.	Olney	MD		

US-CL-CURRENT: 435/331; 435/326, 435/328, 435/330, 435/334, 435/343.2, 435/344.1, 435/7.1, 530/387.1, 530/387.3, 530/387.7, 530/387.9, 530/388.1, 530/388.15, 530/388.22, 530/388.75, 530/388.8, 530/388.85, 530/389.1, 530/389.7, 530/391.1, 530/391.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 97. Document ID: US 6667390 B2

L7: Entry 97 of 160 File: USPT Dec 23, 2003

US-PAT-NO: 6667390
DOCUMENT-IDENTIFIER: US 6667390 B2

TITLE: Human tumor necrosis factor receptor TR9

DATE-ISSUED: December 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Rockville	MD		
Yu; Guo-Liang	San Mateo	CA		
Fan; Ping	Gaithersburg	MD		
Gentz; Reiner L.	Silver Spring	MD		

US-CL-CURRENT: 530/350; 424/178.1, 424/185.1, 424/192.1, 435/325, 435/69.1, 435/69.7, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 98. Document ID: US 6653445 B1

L7: Entry 98 of 160 File: USPT Nov 25, 2003

US-PAT-NO: 6653445
DOCUMENT-IDENTIFIER: US 6653445 B1
**** See image for Certificate of Correction ****

TITLE: Human CCV polypeptides

DATE-ISSUED: November 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		
Gentz; Reiner	Silver Spring	MD		
Su; Jeffrey Y.	Gaithersburg	MD		
Krissansen; Geoffrey W.	Auckland			NZ
Feng; Ping	Gaithersburg	MD		

US-CL-CURRENT: 530/350; 435/320.1, 435/69.1, 435/69.7, 435/7.1, 530/324, 530/325, 530/326, 530/327, 530/328, 536/23.1, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 99. Document ID: US 6642358 B1

L7: Entry 99 of 160 File: USPT Nov 4, 2003

US-PAT-NO: 6642358
DOCUMENT-IDENTIFIER: US 6642358 B1

TITLE: Receptor that binds trail

DATE-ISSUED: November 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rauch; Charles	Bainbridge Island	WA		
Walczak; Henning	Seattle	WA		

US-CL-CURRENT: 530/350; 435/252.3, 435/320.1, 435/325, 435/455, 435/69.1, 435/7.1, 530/300, 536/23.1, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 100. Document ID: US 6635482 B1

L7: Entry 100 of 160 File: USPT Oct 21, 2003

US-PAT-NO: 6635482
DOCUMENT-IDENTIFIER: US 6635482 B1
**** See image for Certificate of Correction ****

TITLE: Monoclonal antibodies to membrane neutrokine-.alpha.

DATE-ISSUED: October 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Berkeley	CA		
Ebner; Reinhard	Gaithersburg	MD		
Ni; Jian	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		

US-CL-CURRENT: 435/326; 435/328, 435/331, 435/4, 530/387.1, 530/387.3, 530/387.9, 530/388.1, 530/388.15

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 101. Document ID: US 6623941 B1

L7: Entry 101 of 160 File: USPT Sep 23, 2003

US-PAT-NO: 6623941
DOCUMENT-IDENTIFIER: US 6623941 B1

TITLE: Nucleic acids encoding human tumor necrosis factor TR20

DATE-ISSUED: September 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ruben; Steven M.	Olney	MD		
Baker; Kevin P.	Darnestown	MD		
Ni; Jian	Germantown	MD		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/325, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 102. Document ID: US 6607726 B1

L7: Entry 102 of 160 File: USPT Aug 19, 2003

US-PAT-NO: 6607726
DOCUMENT-IDENTIFIER: US 6607726 B1

TITLE: Human tumor necrosis factor receptor TR10

DATE-ISSUED: August 19, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		

US-CL-CURRENT: 424/192.1; 424/134.1, 424/185.1, 435/69.1, 435/69.7, 530/350, 530/387.3, 536/23.5

☐ 103. Document ID: US 6599719 B2

L7: Entry 103 of 160 File: USPT Jul 29, 2003

US-PAT-NO: 6599719
DOCUMENT-IDENTIFIER: US 6599719 B2

TITLE: Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha

DATE-ISSUED: July 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	San Mateo	CA		
Ni; Jian	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		

US-CL-CURRENT: 435/69.5; 435/252.3, 435/320.1, 435/69.7, 435/91.4, 530/324, 536/23.5, 536/24.1, 930/140

☐ 104. Document ID: US 6569642 B1

L7: Entry 104 of 160 File: USPT May 27, 2003

US-PAT-NO: 6569642
DOCUMENT-IDENTIFIER: US 6569642 B1

TITLE: Receptor that binds trail

DATE-ISSUED: May 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rauch; Charles	Bainbridge Island	WA		
Walczak; Henning	Seattle	WA		

US-CL-CURRENT: 435/69.1; 435/235.1, 435/252.3, 435/320.1, 435/325, 435/350, 435/455, 435/70.1, 530/350

☐ 105. Document ID: US 6562579 B1

L7: Entry 105 of 160 File: USPT May 13, 2003

US-PAT-NO: 6562579
DOCUMENT-IDENTIFIER: US 6562579 B1
**** See image for Certificate of Correction ****

TITLE: Diagnostic methods using antibodies to Neutrokine-alpha

DATE-ISSUED: May 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Berkeley	CA		
Ebner; Reinhard	Gaithersburg	MD		
Ni; Jian	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		

US-CL-CURRENT: 435/7.1; 435/7.2, 530/350, 530/387.9, 530/388.1, 530/388.23, 530/389.1, 530/391.3

Term	Documents
(3 OR 5).PGPB,USPT,JPAB,DWPI.	160
(L3 OR L5).PGPB,USPT,JPAB,DWPI.	160

Hit List

First Hit | Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 106 through 125 of 160 returned.

☐ 106. Document ID: US 6541224 B2

Using default format because multiple data bases are involved.

L7: Entry 106 of 160 File: USPT Apr 1, 2003

US-PAT-NO: 6541224
DOCUMENT-IDENTIFIER: US 6541224 B2
** See image for Certificate of Correction **

TITLE: Tumor necrosis factor delta polypeptides

DATE-ISSUED: April 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Berkeley	CA		
Ni; Jian	Germantown	MD		
Gentz; Reiner L.	Rockville	MD		
Dillon; Patrick J.	Carlsbad	CA		

US-CL-CURRENT: 435/69.5; 435/69.1, 435/69.7, 435/7.71, 435/70.1, 514/12, 514/2, 530/350, 530/351

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

☐ 107. Document ID: US 6506569 B1

L7: Entry 107 of 160 File: USPT Jan 14, 2003

US-PAT-NO: 6506569
DOCUMENT-IDENTIFIER: US 6506569 B1

TITLE: Antibodies to human tumor necrosis factor receptor TR10

DATE-ISSUED: January 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		

US-CL-CURRENT: 435/7.1; 436/501, 530/350, 530/387.1, 530/388.22, 530/389.1, 530/391.1, 530/391.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

☐ 108. Document ID: US 6503184 B1

L7: Entry 108 of 160 File: USPT Jan 7, 2003

US-PAT-NO: 6503184
DOCUMENT-IDENTIFIER: US 6503184 B1

TITLE: Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2

DATE-ISSUED: January 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Rockville	MD		
Ruben; Steven M.	Olney	MD		

US-CL-CURRENT: 514/12; 514/2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

---

☐ 109. Document ID: US 6455040 B1

L7: Entry 109 of 160 File: USPT Sep 24, 2002

US-PAT-NO: 6455040
DOCUMENT-IDENTIFIER: US 6455040 B1

TITLE: Tumor necrosis factor receptor 5

DATE-ISSUED: September 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wei; Ying-Fei	Berkeley	CA		
Ni; Jian	Rockville	MD		
Gentz; Reiner L.	Rockville	MD		
Ruben; Steven M.	Odenton	MD		

US-CL-CURRENT: 424/134.1; 424/138.1, 424/139.1, 424/143.1, 424/178.1, 435/328, 435/334, 435/7.21, 530/387.3, 530/387.9, 530/388.22

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc | Image

---

☐ 110. Document ID: US 6444640 B1

L7: Entry 110 of 160 File: USPT Sep 3, 2002

US-PAT-NO: 6444640
DOCUMENT-IDENTIFIER: US 6444640 B1

TITLE: Compositions of trail and DNA damaging drugs and uses thereof

DATE-ISSUED: September 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Nagane; Motoo	La Jolla	CA		

Cavenee; Webster	La Jolla	CA
Huang; Su	La Jolla	CA

US-CL-CURRENT: 514/2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 111. Document ID: US 6433147 B1

L7: Entry 111 of 160 File: USPT Aug 13, 2002

US-PAT-NO: 6433147
DOCUMENT-IDENTIFIER: US 6433147 B1
**** See image for Certificate of Correction ****

TITLE: Death domain containing receptor-4

DATE-ISSUED: August 13, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		
Pan; James G.	Belmont	CA		
Gentz; Reiner L.	Rockville	MD		
Dixit; Vishva M.	Los Altos Hills	CA		

US-CL-CURRENT: 530/387.3; 424/178.1, 435/252.3, 435/254.11, 435/325, 435/69.1, 530/300, 530/350, 530/402, 536/23.1, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 112. Document ID: US 6417328 B1

L7: Entry 112 of 160 File: USPT Jul 9, 2002

US-PAT-NO: 6417328
DOCUMENT-IDENTIFIER: US 6417328 B1

TITLE: Trail receptors, nucleic acids encoding the same, and methods of use thereof

DATE-ISSUED: July 9, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alnemri; Emad S.	Ambler	PA		

US-CL-CURRENT: 530/350; 435/252.3, 435/254.11, 435/320.1, 435/325, 435/471, 435/69.1, 435/71.1, 435/71.2, 536/23.1, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 113. Document ID: US 6406867 B1

L7: Entry 113 of 160 File: USPT Jun 18, 2002

US-PAT-NO: 6406867
DOCUMENT-IDENTIFIER: US 6406867 B1
**** See image for Certificate of Correction ****

TITLE: Antibody to human endokine alpha and methods of use

DATE-ISSUED: June 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Berkeley	CA		
Ni; Jian	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		

US-CL-CURRENT: 435/7.2; 424/130.1, 424/139.1, 424/141.1, 424/142.1, 424/158.1, 530/387.1, 530/387.9, 530/388.1, 530/388.15, 530/388.24, 530/389.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 114. Document ID: US 6403770 B1

L7: Entry 114 of 160 File: USPT Jun 11, 2002

US-PAT-NO: 6403770
DOCUMENT-IDENTIFIER: US 6403770 B1
**** See image for Certificate of Correction ****

TITLE: Antibodies to neutrokine-alpha

DATE-ISSUED: June 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Berkeley	CA		
Ebner; Reinhard	Gaithersburg	MD		
Ni; Jian	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		

US-CL-CURRENT: 530/387.3; 435/69.5, 435/7.1, 530/300, 530/324, 530/351, 530/388.1, 530/388.23

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 115. Document ID: US 6358508 B1

L7: Entry 115 of 160 File: USPT Mar 19, 2002

US-PAT-NO: 6358508
DOCUMENT-IDENTIFIER: US 6358508 B1

TITLE: Antibodies to human tumor necrosis factor receptor TR9

DATE-ISSUED: March 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Rockville	MD		
Yu; Guo-Liang	Berkeley	CA		
Fan; Ping	Gaithersburg	MD		
Gentz; Reiner L.	Rockville	MD		

US-CL-CURRENT: 424/139.1; 424/178.1, 530/387.9, 530/388.22, 530/389.1, 530/391.3, 530/391.7

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 116. Document ID: US 6342369 B1

L7: Entry 116 of 160 File: USPT Jan 29, 2002

US-PAT-NO: 6342369
DOCUMENT-IDENTIFIER: US 6342369 B1

TITLE: Apo-2-receptor

DATE-ISSUED: January 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ashkenazi; Avi J.	San Mateo	CA		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/254.2, 435/320.1, 435/325, 435/361, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 117. Document ID: US 6313269 B1

L7: Entry 117 of 160 File: USPT Nov 6, 2001

US-PAT-NO: 6313269
DOCUMENT-IDENTIFIER: US 6313269 B1

TITLE: Tumor necrosis factor related receptor, TR6

DATE-ISSUED: November 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deen; Keith C.	Glenmore	PA		
Young; Peter R.	Lawrenceville	NJ		
Marshall; Lisa A.	Wyndmoor	PA		
Roshak; Amy K.	East Norriton	PA		
Tan; Kong B.	Philadelphia	PA		
Truneh; Alemseged	West Chester	PA		

US-CL-CURRENT: 530/350; 435/69.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 118. Document ID: US 6261801 B1

L7: Entry 118 of 160 File: USPT Jul 17, 2001

US-PAT-NO: 6261801
DOCUMENT-IDENTIFIER: US 6261801 B1
**** See image for Certificate of Correction ****

TITLE: Nucleic acids encoding tumor necrosis factor receptor 5

DATE-ISSUED: July 17, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wei; Ying-Fei	San Mateo	CA		
Gentz; Reiner	Silver Spring	MD		
Ni; Jian	Rockville	MD		
Ruben; Steven M.	Olney	MD		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/254.2, 435/320.1, 435/348, 435/361, 435/366, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 119. Document ID: US 6252050 B1

L7: Entry 119 of 160 File: USPT Jun 26, 2001

US-PAT-NO: 6252050
DOCUMENT-IDENTIFIER: US 6252050 B1
**** See image for Certificate of Correction ****

TITLE: Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method

DATE-ISSUED: June 26, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ashkenazi; Avi J.	San Mateo	CA		
Chuntharapai; Anan	Colma	CA		
Kim; K. Jin	Los Altos	CA		

US-CL-CURRENT: 530/387.3; 424/143.1, 424/174.1, 435/334, 436/548, 530/388.15, 530/388.22, 530/389.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 120. Document ID: US 6214580 B1

L7: Entry 120 of 160 File: USPT Apr 10, 2001

US-PAT-NO: 6214580
DOCUMENT-IDENTIFIER: US 6214580 B1

TITLE: Human tumor necrosis factor receptor tr10

DATE-ISSUED: April 10, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/325, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 121. Document ID: US 6072047 A

L7: Entry 121 of 160 File: USPT Jun 6, 2000

US-PAT-NO: 6072047
DOCUMENT-IDENTIFIER: US 6072047 A
**** See image for Certificate of Correction ****

TITLE: Receptor that binds trail

DATE-ISSUED: June 6, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rauch; Charles	Bainbridge Island	WA		
Walczak; Henning	Seattle	WA		

US-CL-CURRENT: 536/23.5; 435/252.3, 435/320.1, 435/325, 435/6, 435/69.1, 530/350, 536/24.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 122. Document ID: US 6046048 A

L7: Entry 122 of 160 File: USPT Apr 4, 2000

US-PAT-NO: 6046048
DOCUMENT-IDENTIFIER: US 6046048 A
**** See image for Certificate of Correction ****

TITLE: Apo-2 ligand

DATE-ISSUED: April 4, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ashkenazi; Avi J.	San Mateo	CA		
Chuntharapai; Anan	Colma	CA		
Kim; Kyung Jin	Los Altos	CA		

US-CL-CURRENT: 435/331; 435/335, 435/336, 530/350, 530/388.1, 530/388.24, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 123. Document ID: US 6030945 A

L7: Entry 123 of 160 File: USPT Feb 29, 2000

US-PAT-NO: 6030945
DOCUMENT-IDENTIFIER: US 6030945 A

TITLE: Apo-2 ligand

DATE-ISSUED: February 29, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ashkenazi; Avi J.	San Mateo	CA		

US-CL-CURRENT: 514/12; 424/192.1, 424/198.1, 530/350, 930/140, 930/144

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc | Image

---

☐ 124. Document ID: JP 2005237370 A

L7: Entry 124 of 160 File: JPAB Sep 8, 2005

PUB-NO: JP02005237370A
DOCUMENT-IDENTIFIER: JP 2005237370 A
TITLE: Apo-2 LIGAND

PUBN-DATE: September 8, 2005

INVENTOR-INFORMATION:

NAME	COUNTRY
ASHKENAZI, AVI J	
CHUNTHARAPAI, ANAN	
KIM, KYUNG JIN	

ASSIGNEE-INFORMATION:

NAME	COUNTRY
GENENTECH INC	

APPL-NO: JP2004328142
APPL-DATE: November 11, 2004

PRIORITY-DATA: 1996US-584031 (January 9, 1996)

INT-CL (IPC): C12 N 5/10; A61 K 38/00; A61 K 39/395; A61 K 47/48; A61 P 13/08; A61 P 13/10; A61 P 35/00; A61 P 35/02; A61 P 43/00; C07 K 16/24; C12 N 15/09; C12 P 21/08

ABSTRACT:

PROBLEM TO BE SOLVED: To obtain a new cytokine which generally induces mammalian cell apoptosis and is named "Apo-2 ligand", to provide a method for using an Apo-2 ligand antibody, related to identification, isolation, and recombination production of the cytokine, and to provide a method for using a composition.

SOLUTION: This cytokine which induces the mammalian cell apoptosis and is named Apo-2 ligand is thought to be a member of a TNF (tumor necrosis factor) cytokine family. The composition containing an Apo-2 ligand chimera, a nucleic acid which encodes the Apo-2 ligand, and an antibody to the Apo-2 ligand is provided. Further, a method for using the Apo-2 ligand for the purpose of inducing the apoptosis and treating a pathological condition, such as cancer, is

provided.

☐ 125. Document ID: JP 2005232187 A

L7: Entry 125 of 160 File: JPAB Sep 2, 2005

PUB-NO: JP02005232187A
DOCUMENT-IDENTIFIER: JP 2005232187 A
TITLE: ANTIBODY SELECTIVE FOR TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND RECEPTOR AND USE THEREOF

PUBN-DATE: September 2, 2005

INVENTOR-INFORMATION:

NAME	COUNTRY
ZHOU, TONG	
ICHIKAWA, KIMIHISA	
KIMBERLY, ROBERT P	
KOOPMAN, WILLIAM J	

ASSIGNEE-INFORMATION:

NAME	COUNTRY
UAB RESEARCH FOUNDATION	

APPL-NO: JP2005113535
APPL-DATE: April 11, 2005

PRIORITY-DATA: 2000US-201344 (May 2, 2000)

INT-CL (IPC): C07 K 16/28; A61 K 39/395; A61 P 35/00; C07 K 16/46; C12 N 15/09; C12 P 21/08

ABSTRACT:

PROBLEM TO BE SOLVED: To provide an antibody selective for specific TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor DR5 not only binding to cell surface receptor but also strongly inducing apoptosis of various type of idioblasts (including tumor cells) in vivo and in vitro without requiring crosslinking nor solidification, and to provide medicinal compositions and antitumor agents which comprise the antibody as an active ingredient.

SOLUTION: The antibody is a purified antibody specifically binding to TRAIL receptor DR5, wherein the antibody (a), in vitro, has, in a soluble form, cell death inducing activity to DR5 expression target cells at ≤1 μg/ml concentration (b), in vivo, has tumoricidal activity to tumor cells expressing DR5, and (c) binds to none of TRAIL receptor DR4, DcR1 and DcR2.

Hit List

Search Results - Record(s) 126 through 145 of 160 returned.

☐ 126. Document ID: JP 2005168497 A

Using default format because multiple data bases are involved.

L7: Entry 126 of 160 File: JPAB Jun 30, 2005

PUB-NO: JP02005168497A
DOCUMENT-IDENTIFIER: JP 2005168497 A
TITLE: ANTI-TRAIL-R ANTIBODY AND ITS USE

PUBN-DATE: June 30, 2005

INVENTOR-INFORMATION:

NAME	COUNTRY
MORI, EIJI	
KATAOKA, YUKIRO	

INT-CL (IPC): C12 N 15/09; A61 K 39/395; A61 P 35/00; C07 K 16/28; C12 N 5/10; C12 P 21/08

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 127. Document ID: US 20060035334 A1

L7: Entry 127 of 160 File: DWPI Feb 16, 2006

DERWENT-ACC-NO: 2006-163859
DERWENT-WEEK: 200617

TITLE: New Apo-2 polypeptide, useful for modulating apoptosis and for treating or preventing cancer, e.g. carcinoma, lymphoma, blastoma, sarcoma, or leukemia

INVENTOR: ADAMS, C W; ASHKENAZI, A J ; CHUNTHARAPAI, A ; KIM, K J

PRIORITY-DATA: 2005US-0245053 (October 7, 2005), 1997US-046615P (May 15, 1997), 1998US-074119P (February 9, 1998), 1998US-0079029 (May 14, 1998), 2001US-0052798 (November 2, 2001), 2003US-0423448 (April 25, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20060035334 A1	February 16, 2006		064	C07K014/435

INT-CL (IPC): C07 H 21/00; C07 H 21/04; C07 K 14/435; C07 K 14/705; C12 N 5/06; C12 N 15/74; C12 P 21/06

ABSTRACTED-PUB-NO: US20060035334A
BASIC-ABSTRACT:

NOVELTY - An isolated Apo-2 polypeptide comprising amino acid residues 1-411 of a sequence comprising 411 amino acids (SEQ ID NO: 1), is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) a pharmaceutical composition comprising the polypeptide and a pharmaceutical carrier;

(2) a fusion protein comprising the polypeptide fused to a heterologous polypeptide; and

(3) a chimeric molecule comprising the polypeptide fused to a heterologous amino acid sequence.

ACTIVITY - Cytostatic. No biological data given.

MECHANISM OF ACTION - Apo-Modulator-2.

USE - The Apo-2 polypeptide is useful for modulating apoptosis. The polypeptide, composition and method are useful for treating or preventing cancer, e.g. carcinoma, lymphoma, blastoma, sarcoma, or leukemia.

☐ 128. Document ID: US 20050233958 A1

L7: Entry 128 of 160 File: DWPI Oct 20, 2005

DERWENT-ACC-NO: 2005-702301
DERWENT-WEEK: 200572

TITLE: New death domain containing receptor-5 (DR5) polypeptide, useful for treating diseases associated with reduced or increased levels of apoptosis, e.g. lung, breast, ovarian, colorectal or hematological cancer

INVENTOR: GENTZ, R L; NI, J ; ROSEN, C A ; YU, G

PRIORITY-DATA: 2004US-0979831 (November 3, 2004), 1997US-040846P (March 17, 1997), 1997US-054021P (July 29, 1997), 1998US-0042583 (March 17, 1998), 1999US-132498P (May 4, 1999), 1999US-133238P (May 7, 1999), 1999US-148939P (August 13, 1999), 2000US-0565009 (May 4, 2000), 2002US-406307P (August 28, 2002), 2002US-413747P (September 27, 2002), 2003US-0648825 (August 27, 2003), 2004US-551811P (March 11, 2004), 2004US-608429P (September 10, 2004)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20050233958 A1	October 20, 2005		140	A61K038/17

INT-CL (IPC): A61 K 38/17; C07 K 14/705; C07 K 16/28

ABSTRACTED-PUB-NO: US20050233958A
BASIC-ABSTRACT:

NOVELTY - An isolated polypeptide comprising a sequence of 411 amino acids (SEQ ID No. 2), given in the specification, or its fragment, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) a dimer, trimer, or tetramer of the polypeptide;

(2) a composition comprising the polypeptide, and a carrier;

(3) an isolated polypeptide encoded by a DNA comprising the nucleotide sequence of 1600 bp (SEQ ID No. 1), given in the specification;

(4) an isolated polypeptide comprising amino acids n2 to 133 of SEQ ID No. 2, where n2 represents an integer from -51 to 128, and where the polypeptide binds TRAIL;

(5) an isolated soluble polypeptide comprising an amino acid sequence at least 80 % identical to the sequence of amino acids 1-133 of SEQ ID No. 2;

(6) a multimer comprising the polypeptide, or at least two of the polypeptides cited above;

(7) an isolated polynucleotide encoding the polypeptide;

(8) a composition comprising the multimer, dimer, trimer or tetramer as cited above, and a carrier; and

(9) an isolated antibody that specifically binds the polypeptide.

ACTIVITY - Cytostatic. No biological data given.

MECHANISM OF ACTION - Death-domain-containing-receptor-5.

USE - The polypeptide and compositions are for useful for treating diseases associated with reduced or increased levels of apoptosis, e.g. lung, breast, ovarian, colorectal or hematological cancer.

☐ 129. Document ID: US 20050089958 A1

L7: Entry 129 of 160 File: DWPI Apr 28, 2005

DERWENT-ACC-NO: 2005-314090
DERWENT-WEEK: 200604

TITLE: New isolated soluble Apo-2 ligand polypeptides that induce mammalian cell apoptosis, useful for diagnosing, preventing or treating cancer, or in screening for agents that may treat cancer

INVENTOR: ASHKENAZI, A J; SCHWALL, R H

PRIORITY-DATA: 1996US-009755P (January 9, 1996), 1997US-0780496 (January 8, 1997), 1998US-0007886 (January 15, 1998), 1998US-0060533 (April 15, 1998), 2000US-0479252 (January 7, 2000), 2003US-0652979 (August 29, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20050089958 A1	April 28, 2005		053	C07K014/52

INT-CL (IPC): C07 K 14/52

ABSTRACTED-PUB-NO: US20050089958A
BASIC-ABSTRACT:

NOVELTY - An isolated soluble Apo-2 ligand polypeptide consisting of amino acid residues 92-281 of a sequence having 1042 bp fully defined in the specification, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a composition useful in treating a condition, comprising (i) an Apo-2 ligand polypeptide molecule and (ii) a DNA damaging agent that affects apoptosis; and

(2) a method for treating a subject with a condition that requires affecting apoptosis, comprising administering an amount of the above composition to the subject to affect apoptosis.

ACTIVITY - Cytostatic. No biological data given.

MECHANISM OF ACTION - Gene therapy.

USE - The composition and methods are useful for diagnosing, preventing or treating cancer. These may also be used in tissue typing or in screening for agents that may treat such disease.

☐ 130. Document ID: US 20050069955 A1

L7: Entry 130 of 160 File: DWPI Mar 31, 2005

DERWENT-ACC-NO: 2005-261644
DERWENT-WEEK: 200582

TITLE: Novel antibody or its fragment comprising consensus sequence that binds to cancer cell, useful for diagnosing or treating diseases such as cancer, autoimmune diseases and inflammatory diseases

INVENTOR: BEN-LEVY, R; HAGAY, Y ; KANFI, Y ; LEVANON, A ; NISGAV, Y ; PLAKSIN, D ; SZANTON, E

PRIORITY-DATA: 2003US-484061P (June 30, 2003), 2004US-0880922 (June 30, 2004)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20050069955 A1	March 31, 2005		074	G01N033/53

INT-CL (IPC): C07 K 16/18; G01 N 33/53

ABSTRACTED-PUB-NO: US20050069955A
BASIC-ABSTRACT:

NOVELTY - An antibody or its fragment (I) comprising a consensus sequence, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) a pharmaceutical composition (II), comprising (I) and a carrier;

(2) a diagnostic, prognostic, or staging kit (K1), comprising (I) and an imaging agent;

(3) an isolated or purified DNA sequence (III) encoding (I);

(4) an expression vector (IV) comprising (III);

(5) a recombinant host cell (V) comprising (IV);

(6) producing (I);

(7) selecting (M1) an antibody or its fragment, or a polypeptide, involves providing a phage display library, providing a peptide chosen from a fully defined 17 (SEQ ID No. 7) and 18 (SEQ ID No. 44 and 53) amino acid sequence given in the specification, panning the phage display library to select an scFv antibody or its fragment that binds to the peptide chosen from SEQ ID No. 7, 44, a fully defined 18 amino acid sequence (SEQ ID No. 50) given in the specification and SEQ ID No. 53, and producing the selected ScFv antibody or its fragment;

(8) a library (VII) of immunoglobulin binding domains, comprising a diverse antigen binding domain for complementary binding, where (VII) has diversity only in heavy chain CDR3;

(9) a small inorganic molecule (VIII) capable of binding to a sulfated epitope of PSGL-1, GPIb,

and/or CCR5; and

(10) a pharmaceutical composition (IX), comprising (VIII).

ACTIVITY - Cytostatic; Anti-HIV; Antiinflammatory; Immunosuppressive; Vasotropic; Cardiovascular-Gen.; Cardiant.

MECHANISM OF ACTION - Apoptosis inducer; Inhibitor of cell growth replication and growth; Inhibitor of platelet aggregation.

Mononuclear cells from B-CLL patients were separated and the cells were incubated in the presence or absence of S15-IgG or control antibodies for 10 minutes at 37 deg. C. Antihuman Fc antibodies were then added and incubated for 4-24 hours at 37 deg. C. Diseased cells (CD19+, CD5+) were then stained with apoptotic markers Annexin and TOPRO (RTM) and analyzed by fluorescence activated cell sorting (FACS). The FACS analysis showed that mononuclear cells (CD19+, CD5+) from B-CLL patients incubated in the presence of S15-IgG exhibited about 10% apoptosis within 5 hours. Addition of secondary antibodies which crosslink the S15-IgG, elicited an additional 50% of apoptosis within 5 hours.

USE - (II) is useful for treating a disease, treating cell rolling, treating an infection (where the infection is caused by HIV and the administration of (II) prevents entry of HIV), treating inflammation, inhibiting autoimmune disease, inhibiting metastasis, inhibiting growth and/or replication of tumor cells, increasing the mortality rate of tumor cells, inhibiting growth and/or replication of leukemia cells, increasing the mortality rate of leukemia cells, inhibiting growth and/or replication of B-CLL cells, altering the susceptibility of diseased cells to damage by anti-cancer agents, increasing the susceptibility of leukemia cells to damage by anti-leukemia agents, increasing the susceptibility of B-CLL cells to damage by anti-leukemia agents, inhibiting platelet aggregation, inhibiting restenosis, eliciting antibody dependent cell-mediated cytotoxicity (ADCC) (mediated by effector cells comprising of natural killer (NK) or monocytic cells), eliciting apoptosis in leukemia cells, stimulating a NK cell or a T cell, and manufacturing medicament for treating a disease. (I) is useful for diagnosing, prognosing or staging a disease in a patient, which involves providing a sample containing a cell from the patient and determining whether (I) binds to the cell of the patient, thus indicating that the patient is at risk for or has the disease. (I) is useful for purging tumor cells from a patient, which involves providing a sample containing cells from the patient and incubating the cells from the patient with (I), where the purging occurs ex vivo. (VII) is useful for selecting a sulfated epitope, which involves providing (VII), panning (VII) for a sulfated epitope that binds to the antigen binding domain, and isolating the sulfated epitope. (V) is useful for producing (I) (claimed).

(II) is useful for treating cardiovascular diseases such as myocardial infarction and inflammatory diseases.

☐ 131. Document ID: EP 1626732 A2, WO 2004103389 A2

L7: Entry 131 of 160 File: DWPI Feb 22, 2006

DERWENT-ACC-NO: 2005-031066
DERWENT-WEEK: 200615

TITLE: Inhibitors for preventing, blocking/silencing caspase-2 activity in cell death, for treating or preventing apoptosis during neurodegenerative diseases or natural killer cell-mediated apoptosis associated with immune disease

INVENTOR: BORGNE, A; CHAUVIER, D ; JACOTOT, E ; LANGONNE, A ; LECOEUR, H ; REBOUILLAT, D

PRIORITY-DATA: 2004US-553569P (March 17, 2004), 2003FR-0006190 (May 22, 2003), 2003US-529697P (December 16, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1626732 A2	February 22, 2006	E	000	A61K038/00
WO 2004103389 A2	December 2, 2004	E	125	A61K038/00

INT-CL (IPC): A61 K 38/00

ABSTRACTED-PUB-NO: WO2004103389A
BASIC-ABSTRACT:

NOVELTY - Inhibitors for preventing, blocking/silencing caspase-2 activity in cell death, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) an in vitro or in vivo inhibition of caspase-2 activity with molecule having the 22-bp sequence;

(2) molecules that disrupt the interaction between Bax and caspase-2 or to prevent caspase-2 dependent Bax cleavage;

(3) peptides derived from Bax sequence with a length of 3-40 amino acids including the sequence IQD and that can compete with the putative site of caspase-2 cleavage in Bax;

(4) pharmaceutical compositions comprising at least one caspase-2 inhibitor and a carrier;

(5) a method for blocking or preventing cell death; and

(6) a method for preventing cell death.

ACTIVITY - Neuroprotective; Antiinflammatory; Cardiant; Cytostatic; Vulnerary.

No biological data given.

MECHANISM OF ACTION - Vaccine.

USE - The caspase-2 inhibitors are useful for preparing a pharmaceutical composition for treating or preventing apoptosis during chronic degenerative diseases e.g. neurodegenerative disease including Alzheimer's disease, Huntington's disease, Parkinson's disease, Multiple sclerosis, amyotrophic lateral sclerosis, spinobulbar atrophy, prion disease, during spinal cord injury, or resulting from traumatic brain injury, cytotoxic T cell and natural killer cell-mediated apoptosis associated with autoimmune disease and transplant rejection, or to prevent cell death of cardiac cells including heart failure, cardiomyopathy, viral infection or bacterial infection of heart, myocardial ischemia, myocardial infarct, and myocardial ischemia, coronary artery by-pass graft, mitochondrial drug toxicity e.g. as a result of chemotherapy or HIV therapy, cell death during viral infection or bacterial infection, inflammation or inflammatory diseases, e.g., inflammatory bowel disease, sepsis and septic shock, cell death from follicle to ovocyte stages, from ovocyte to mature egg stages and sperm, acute hepatitis, chronic active hepatitis, hepatitis-B, and hepatitis-C, hair loss, and the hair loss due-to male-pattern baldness, radiation, chemotherapy or emotional stress, skin damage (due to exposure to high level of radiation, heat, burns, chemicals, sun and autoimmune diseases), cell death of bone marrow cells in myelodysplastic syndromes (MDS), pancreatitis, respiratory syndrome, osteoarthritis, rheumatoid arthritis, psoriasis, glomerulonephritis, atherosclerosis, graft versus host disease, retinal pericyte apoptosis, retinal neurons apoptosis, glaucoma, retinal damages resulting from ischemia, diabetic or for preserving fertility in women and men after chemotherapy, or in females and males animals (claimed).

☐ 132. Document ID: EP 1624887 A1, WO 2004100981 A1, DE 10321725 A1

L7: Entry 132 of 160 File: DWPI Feb 15, 2006

DERWENT-ACC-NO: 2005-012798

DERWENT-WEEK: 200613
COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: Composition containing hydrolase, useful as pharmaceutical or food supplement for strengthening immunity, e.g. in tumor patients, also includes antioxidants, amino acids or polysaccharides

INVENTOR: MILLER, W

PRIORITY-DATA: 2003DE-1021725 (May 14, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1624887 A1	February 15, 2006	G	000	A61K038/46
WO 2004100981 A1	November 25, 2004	G	040	A61K038/46
DE 10321725 A1	December 2, 2004		000	C12N009/00

INT-CL (IPC): A23 L 1/30; A61 K 31/07; A61 K 31/122; A61 K 31/198; A61 K 31/355; A61 K 31/375; A61 K 31/715; A61 K 31/716; A61 K 31/717; A61 K 31/718; A61 K 31/721; A61 K 31/722; A61 K 31/732; A61 K 31/733; A61 K 38/43; A61 K 38/46; A61 K 38/48; C12 N 9/00; C12 N 9/14

ABSTRACTED-PUB-NO: WO2004100981A
BASIC-ABSTRACT:

NOVELTY - Composition (A) that contains at least one hydrolase (I) and at least one of (a) antioxidants (II), i.e. vitamins, carotenoids, selenium-containing compounds and ubiquinones or (b) amino acids and/or polysaccharides.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for foods (for nutritional supplementation) or pharmaceuticals that contain (A).

ACTIVITY - Cytostatic; Antiinflammatory; Antirheumatic; Immunostimulant; Immunomodulator.

No details of tests for these activities are given.

MECHANISM OF ACTION - Activation of monocytes and natural killer cells; regulation of DNA repair and initiation of apoptosis.

USE - (A) are used as pharmaceuticals and food supplements to provide a balanced diet; to strengthen the immune system and the body's own defenses; to treat inflammation or rheumatic disorders; to regulate the immune system in situations of physical or psychological stress, or before, during and/or after antitumor treatments; and to reduce the risk of relapse or tumors and of secondary malignancies (all claimed).

ADVANTAGE - The combination of (I) with (II), amino acids and/or polysaccharides has a greater (synergistic) health-promoting effect than the same materials used individually.

☐ 133. Document ID: EP 1576179 A2, WO 2004050895 A2, AU 2003297579 A1, US 20050079172 A1, NO 200502922 A

L7: Entry 133 of 160 File: DWPI Sep 21, 2005

DERWENT-ACC-NO: 2004-450739
DERWENT-WEEK: 200562
COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: Inducing apoptosis in cancer cell, involves contacting cell with anti-DR4 or anti-DR5 affinity agent agonist and apoptosis-inducing agent

INVENTOR: AZA-BLANC, P; DEVERAUX, Q L ; HAMPTON, G M ; KNEE, D A ; NASOFF, M ; WAGNER, K

PRIORITY-DATA: 2003US-504901P (September 22, 2003), 2002US-429842P (November 27, 2002), 2003US-448960P (February 21, 2003), 2003US-494714P (August 12, 2003), 2003US-0723383 (November 25, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1576179 A2	September 21, 2005	E	000	C12Q001/00
WO 2004050895 A2	June 17, 2004	E	134	C12Q000/00
AU 2003297579 A1	June 23, 2004		000	C12Q000/00
US 20050079172 A1	April 14, 2005		000	A61K039/395
NO 200502922 A	August 17, 2005		000	A61K039/395

INT-CL (IPC): A61 K 39/395; C12 Q 0/00; C12 Q 1/00

ABSTRACTED-PUB-NO: WO2004050895A
BASIC-ABSTRACT:

NOVELTY - Inducing apoptosis in a cancer cell, involves contacting cell with anti-DR4/anti-DR5 affinity agent agonist and apoptosis-inducing agent, or with an affinity agent with binding specificity of an antibody comprising heavy chain variable region having a fully defined sequence of 118 amino acids as given in the specification, and light chain variable region having a fully defined sequence of 109 amino acids as given in the specification.

DETAILED DESCRIPTION - Inducing (M1) apoptosis in a cancer cell, involves contacting the cell with anti-DR4 or anti-DR5 affinity agent agonist and apoptosis-inducing agent, or contacting the cell with an affinity agent with the binding specificity of an antibody comprising a heavy chain variable region having a fully defined sequence of 118 amino acids (S1) as given in the specification, and a light chain variable region having a fully defined sequence of 109 amino acids (S2) as given in the specification.

INDEPENDENT CLAIMS are also included for the following:

(1) inducing (M2) apoptosis in cancer cell in an individual, involves administering an anti-DR4 or anti-DR5 affinity agent agonist, and apoptosis-inducing agent to the individual;

(2) a physiological composition comprising anti-DR4 or anti-DR5 affinity agent agonist and apoptosis-inducing agent;

(3) an affinity agent with the binding specificity of antibody (I) comprising heavy chain variable region having (S1), and a light chain variable region having (S2); and

(4) a cell that expresses (I).

ACTIVITY - Cytostatic.

In vivo efficacy of the antibodies was tested. Ten mice were injected with 5 multiply 106 colon 205 (colon tumor cells) subcutaneously at day 0. Treatment with the DR5 antibody (400 micro grams) was started on day 11. After 2 injections with 400 micro grams of DR5 the 5 treated animals showed no evidence of tumor whereas all the 5 mice given phosphate buffered saline (PBS) had large tumors. Thus the antibody appeared to be effective in vivo.

MECHANISM OF ACTION - Apoptosis inducer; Anti-DR4 or anti-DR5 agonist; Proteasome inhibitor; Inhibitor of IAP protein; Antagonist of PAK1, nsurf and JIK (claimed).

USE - (M1) is useful for inducing apoptosis in a cancer cell such as colon cancer cell or pancreatic cancer cell (claimed).

DESCRIPTION OF DRAWING(S) - The figure is a graph representing specificity of DR5 functional antibodies.

☐ 134. Document ID: DE 10232322 A1, US 20040110188 A1

L7: Entry 134 of 160 File: DWPI Jul 29, 2004

DERWENT-ACC-NO: 2004-440352
DERWENT-WEEK: 200449

TITLE: Study of genetic region UL131-128 which determines leukotropism, monocyte tropism or endothelial cell tropism in human cytomegalovirus (HCMV) in FIX-BAC and all HCMV laboratory and wild-type strains and BAC-cloned HCMV strains

INVENTOR: HAHN, G

PRIORITY-DATA: 2002DE-1032322 (July 16, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 10232322 A1	July 29, 2004		000	C12Q001/70
US 20040110188 A1	June 10, 2004		056	C12Q001/70

INT-CL (IPC): C12 P 21/04; C12 Q 1/68; C12 Q 1/70

ABSTRACTED-PUB-NO: US20040110188A
BASIC-ABSTRACT:

NOVELTY - A study of the genetic region UL131-128 which determines leukotropism, monocyte tropism and endothelial cell tropism in human cytomegalovirus (HCMV) in Fusion-Inducing-Factor-X-bacterial artificial chromosome (FIX-BAC) and all HCMV laboratory and wild-type strains as well as BAC-cloned HCMV strains such as (TowL-BAC, HB-5-BAC, TowS-BAC, TB40E-BAC, Phoebe-BAC, Powers-BAC, AD169-BAC) and their respective reconstituted viruses, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a study and synthesis of the newly identified viral transcripts running through the UL131-128 genetic region which are either spliced or unspliced, sense or anti-sense and which are encoding novel CxC, CC chemokines or other attachment, fusion and cell attraction factors;

(2) a study and synthesis of the newly disclosed protein products HCK-1, HCK-2, HCK-3, HCK-4 and HCK-5 as well as other potential proteins encoded by the UL132-UL128 and UL131-128 genetic region of FIX-BAC, TowL-BAC, HB-5-BAC, TowS-BAC, TB40E-BAC, Phoebe-BAC, Powers-BAC, AD169-BAC, their respective reconstituted viruses, wild-type and laboratory strains;

(3) production of monoclonal antibodies against HCK-1, HCK-2, HCK-3, HCK-4 and HCK-5, synthesis of chemo-therapeutic agents interfering with HCK-1 to HCK-5 (e.g. small molecules, anti-sense RNA, siRNA);

(4) construction and study of cell lines which express or secrete HCK-1 to HCK-5;

(5) study of tissue tropism and pathogenesis of HCMV in vitro and in vivo by constructing virus mutants which express HCK-1 to HCK-5 or the newly identified transcripts (95-3, 95-8, 95-11, 128A, 128B) or other as yet unidentified transcripts of the UL132-128 or UL131-128 region;

(6) study of the transcriptional and posttranscriptional regulatory mechanisms which regulate or modify the expression of HCK-1 to HCK-5 or other UL132-128 or UL131-128 encoded chemokine and microfusion inducing factors regarding tissue tropism, pathogenesis of HCMV, other herpesviruses as well as DNA and RNA viruses;

(7) expression of HCK-1 to HCK-5 or the above newly identified transcripts in human or animal cells, particularly immune cells, to study or influence trafficking of such cells;

(8) study of HCK-1 to HCK-5 or the newly identified transcripts in connection with CxC and CC

chemokine receptor mediated entry of HCMV, other Herpesviruses, DNA and RNA viruses (e.g. HIV) into target cells and study of cell adherence mechanisms;

(9) structural analyses of HCK-1 to HCK-5 and other chemokine, cytokine adherence and microfusion factors encoded by the UL132-128 or UL131-128 genetic locus;

(10) study of co-infection or transfection of target cells (expressing HCK-1 to HCK-5) by HCMV and other DNA and RNA viruses, especially HIV virus; and

(11) study of HCK-1 to HCK-5 or the newly identified transcripts in vivo, in vitro and in animal models in connection with the development of vascular damage, arteritis, vasculitis, arteriosclerosis and stenosis of the vessel wall and mechanisms of protection against such diseases.

ACTIVITY - Virucide; Immunosuppressive; Cytostatic; Antiarteriosclerotic; Vasotropic; Antiinflammatory; Antirheumatic.

No biological data given.

MECHANISM OF ACTION - Gene therapy.

USE - The newly identified virus encoded chemokines HCK-1 to HCK-5 or the newly identified transcripts or therapeutic agents directed against them are used for therapy of virus-induced diseases, autoimmune disease, cancer, atherosclerosis, vasculitis, rheumatoid disease, gene therapy, vector development, vaccine development, study of trafficking and migration of leukocytes, monocytes, dendritic cells, natural killer cells, T-cells, B-cells, study of latency and reactivation of HCMV, induction or prevention of apoptosis, activation or resistance of virally infected target cells to NK cells and T cells (claimed).

☐ 135. Document ID: US 20040009552 A1

L7: Entry 135 of 160 File: DWPI Jan 15, 2004

DERWENT-ACC-NO: 2004-090468
DERWENT-WEEK: 200617

TITLE: New Apo-2 polypeptides and encoding nucleic acid molecules, useful for diagnosing, preventing or treating cancer, and in tissue typing or in generating antibodies or transgenic animals

INVENTOR: ADAMS, C W; ASHKENAZI, A J ; CHUNTHARAPAI, A ; KIM, K J

PRIORITY-DATA: 2003US-0423448 (April 25, 2003), 1997US-046615P (May 15, 1997), 1998US-074119P (February 9, 1998), 1998US-0079029 (May 14, 1998), 2001US-0052798 (November 2, 2001), 2002US-0288917 (November 6, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20040009552 A1	January 15, 2004		053	C07K014/705

INT-CL (IPC): C07 K 14/705; C07 K 16/28; C12 N 1/21; C12 N 5/06; C12 N 15/74; C12 P 21/02

ABSTRACTED-PUB-NO: US20040009552A
BASIC-ABSTRACT:

NOVELTY - An isolated Apo-2 polypeptide, or its extracellular or death domain sequence, is new. The polypeptide comprises amino acid residues 1-411 of a 411 amino acid sequence (S1), given in the specification, or a sequence having at least 80 % identity with native sequence Apo-2 polypeptide comprising residues 1-411 of S1. The extracellular domain sequence comprises

residues 54-182 of S1, and the death domain sequence comprises residues 324-391 of S1.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) an isolated nucleic acid comprising a DNA encoding the new polypeptide, or its extracellular domain sequence or death domain sequence, or a DNA encoding an Apo-2 antibody;

(2) a vector comprising the nucleic acid;

(3) a host cell comprising the vector;

(4) producing an Apo-2 polypeptide, comprising culturing the host cell under conditions sufficient to express Apo-2 polypeptide, and recovering the expressed Apo-2 polypeptide from the culture;

(5) an Apo-2 polypeptide obtained by expressing the polypeptide encoded by the cDNA insert in ATCC deposit accession number 209021;

(6) a non-human, transgenic or knock-out animal which contains cells that express DNA encoding Apo-2 polypeptide, or cells having an altered gene encoding Apo-2 polypeptide;

(7) an antibody that specifically binds to an Apo-2 polypeptide;

(8) a hybridoma cell line producing the antibody;

(9) a chimeric molecule comprising the new Apo-2 polypeptide or the extracellular domain sequence, or the antibody, fused to a heterologous amino acid sequence;

(10) a dimeric molecule comprising the Apo-2 antibody and a heterologous antibody; or a homodimeric molecule comprising a first Apo-2 antibody and a second Apo-2 antibody;

(11) producing an Apo-2 antibody, comprising culturing the host cell under conditions where the DNA is expressed;

(12) a composition comprising the antibody and a pharmaceutical carrier;

(13) inducing apoptosis in mammalian cancer cells, comprising exposing mammalian cancer cells to an amount of the Apo-2 agonistic antibody;

(14) treating mammalian cancer cells, comprising exposing mammalian cancer cells to an agent that activates Apo-2; and

(15) an article of manufacture comprising a container and a composition contained within the container, where the composition includes the above Apo-2 polypeptide or Apo-2 antibody.

ACTIVITY - Cytostatic.

No biological data given.

MECHANISM OF ACTION - Gene therapy.

USE - The composition and methods are useful in diagnosing, treating or preventing cancer. The polypeptide and nucleic acid molecule may also be used in tissue typing, in generating antibodies or in generating transgenic animals.

☐ 136. Document ID: JP 2005517021 W, WO 2003066661 A2, AU 2002366430 A1, EP 1409544 A2, US 20040147725 A1

L7: Entry 136 of 160 File: DWPI Jun 9, 2005

DERWENT-ACC-NO: 2003-679536
DERWENT-WEEK: 200538

TITLE: Human death receptor monoclonal antibody useful for treating e.g. cancer, rheumatoid arthritis and allergic diseases, comprises antibody which competitively inhibits binding of hybridoma monoclonal antibody by binding to receptor

INVENTOR: CHUNTHARAPAI, A; KIM, K J

PRIORITY-DATA: 2001US-303220P (July 3, 2001), 2003US-0480730 (December 12, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2005517021 W	June 9, 2005		074	C07K016/28
WO 2003066661 A2	August 14, 2003	E	055	C07K000/00
AU 2002366430 A1	September 2, 2003		000	C07K000/00
EP 1409544 A2	April 21, 2004	E	000	C07K014/705
US 20040147725 A1	July 29, 2004		000	C07K016/30

INT-CL (IPC): A61 K 39/00; A61 K 39/395; A61 P 35/00; A61 P 43/00; C07 K 0/00; C07 K 14/705; C07 K 16/28; C07 K 16/30; C07 K 16/46; C12 N 5/10; C12 N 5/16; C12 N 5/18; C12 N 15/02; G01 N 33/574

ABSTRACTED-PUB-NO: WO2003066661A

BASIC-ABSTRACT:

NOVELTY - An isolated anti-human death receptor-4 (DR4) monoclonal antibody (A1) comprises an antibody binding to DR4 receptor and competitively inhibits binding of the monoclonal antibody (A2) produced by the hybridoma deposited as ATCC PTA-3359-3361 to the receptor.

The DR4 receptor comprises 1-218 amino acids of the sequence as given in the specification.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) the hybridoma deposited as ATCC PTA-3359-3361;

(2) the monoclonal antibody (A2) produced by the hybridoma;

(3) a pharmaceutical composition comprising (A1) and a carrier;

(4) a method of inducing apoptosis in mammalian cells comprising exposing the cells to (A1);

(5) a kit (I) containing a container and (A1) or its antigen binding fragment within the container; and

(6) a kit (II) containing two containers and instructions for using (A2) or its antigen binding fragment. One container contains a composition comprising (A1), and has a label on it indicating its use to induce apoptosis. The other container contains a buffer.

ACTIVITY - Cytostatic; Antiinflammatory; Dermatological; Immunosuppressive; Antirheumatic; Antiarthritic; Antiallergic; Antipsoriatic; Antianemic; Antithyroid; Hemostatic; Thyromimetic; Antidiabetic; Nephrotropic; Neuroprotective; Virucide; Hepatotropic; Antiulcer; Antiasthmatic; Anti-HIV; Antibacterial; Antifungal; Protozoacide; Antiparasitic.

MECHANISM OF ACTION - Apoptosis inducer; Apoprotein-2 (Apo-2) ligand induced apoptosis inhibitor; Caspase 3/8/10 and FADD activator.

The efficacy of crosslinked human DR4 antibodies - 1G11 antibodies to induce apoptosis was evaluated on 9D cells. The 9D cells (5 multiply 105) were suspended in complete RPMI medium (supplemented with 10% fetal calf serum, glutamine, nonessential amino acids, penicillin, streptomycin, and sodium pyruvate) and incubated with DR4 antibodies (10 micro g/100 micro l) on ice for 15 minutes (t1). The cells were then incubated with goat anti-human IgG-Fc (100 micro g/ml) (t2) in RPMI medium at 37 deg. C for 24 hours in the presence of 7% carbon dioxide (CO2). After incubation, the cells were washed with phosphate buffered saline, then suspended

in binding buffer (200 micro l). The cells were then incubated with FITC-Annexin V (10 micro l) and propidium iodide in the dark for 15 minutes and then analyzed by fluorescence activated cell sorter analysis. The apoptotic 9D cells (%) were 40/70 in t1/t2 cultures.

The results showed that 1G11 antibodies induced apoptosis of 9D cells when cross-linked with anti-Fc IgG.

USE - (A1) Is used for inducing apoptosis in mammalian cells (e.g. 9D cells, colon, colorectal and lung cancer cells) (claimed). (A1) is also used for treating cancer (e.g. glioma, Hodgkin's lymphoma and ovarian cancer), immune-mediated inflammatory diseases and infectious diseases (e.g. systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathies such as polymyositis, Sjogren's disease, systemic vasculitis, sarcoidosis, autoimmune hemolytic anemia, autoimmune thrombocytopenia, idiopathic thrombocytopenic purpura, Hashimoto's thyroiditis, Grave's disease, diabetes mellitus, glomerulonephritis, multiple sclerosis, idiopathic demyelinating polyneuropathy, Guillain-Barre syndrome, hepatitis caused by hepatitis A-E and other non-hepatotropic viruses, primary biliary cirrhosis, granulomatous hepatitis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, erythema, contact dermatitis, psoriasis, allergic diseases, asthma, allergic rhinitis, atopic dermatitis, urticaria, eosinophilic pneumonia, idiopathic pulmonary fibrosis, transplantation associated diseases (e.g. graft rejection and graft versus host disease), AIDS, bacterial infections, fungal, protozoal and parasitic infections. Also used in diagnostic assays to detecting expression or overexpression of DR4 in specific cells and tissues.

ADVANTAGE - The human DR4 antibodies are specifically binds to the human DR4 and/or modulates biological activities associated with DR4 and/or its ligand.

☐ 137. Document ID: US 20030148455 A1

L7: Entry 137 of 160 File: DWPI Aug 7, 2003

DERWENT-ACC-NO: 2003-897574
DERWENT-WEEK: 200617

TITLE: New Apo-2 polypeptide or its extracellular or death domain sequence, useful for modulating apoptosis in mammalian cancer cells or for generating transgenic or knockout animals

INVENTOR: ADAMS, C W; ASHKENAZI, A J ; CHUNTHARAPAI, A ; KIM, K J

PRIORITY-DATA: 2002US-0288917 (November 6, 2002), 1997US-046615P (May 15, 1997), 1998US-074119P (February 9, 1998), 1998US-0079029 (May 14, 1998), 2001US-0052798 (November 2, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20030148455 A1	August 7, 2003		064	A61K039/395

INT-CL (IPC): A61 K 39/395; C07 H 21/04; C07 K 14/775; C07 K 16/22; C12 N 5/06; C12 P 21/02

ABSTRACTED-PUB-NO: US20030148455A
BASIC-ABSTRACT:

NOVELTY - A new isolated Apo-2 polypeptide comprises amino acid residues 1-411 of a sequence having 411 amino acids (S1) fully defined in the specification, or a sequence that is at least 80% identical to a native sequence Apo-2 polypeptide comprising S1. The Apo-2 polypeptide comprises an extracellular domain comprising amino acid residues 54-182 of S1. Its isolated death domain sequence comprises amino acid residues 324-391 of S1.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a process of producing an Apo-2 polypeptide, comprising culturing the host cell under

conditions sufficient to express Apo-2 polypeptide and recovering the Apo-2 polypeptide from the culture;

(2) a non-human transgenic or knockout animal which contains cells that express DNA encoding Apo-2 polypeptide, or cells having an altered gene encoding Apo-2 polypeptide;

(3) an antibody which specifically binds to an Apo-2 polypeptide;

(4) a hybridoma cell line which produces the antibody;

(5) a chimeric molecule comprising the above antibody or the Apo-2 polypeptide or its extracellular domain sequence fused to a heterologous amino acid sequence;

(6) a dimeric molecule comprising the Apo-2 antibody and a heterologous antibody; or a homodimeric molecule comprising a first Apo-2 antibody and a second Apo-2 antibody;

(7) an isolated nucleic acid comprising a DNA encoding the polypeptide or its extracellular or death domain sequence, or the above Apo-2 antibody;

(8) a vector comprising the above nucleic acid;

(9) a host cell comprising the vector;

(10) a method of producing an Apo-2 antibody, comprising culturing the above host cell under conditions where the DNA is expressed;

(11) a composition comprising the antibody and a carrier;

(12) methods of treating or inducing apoptosis in mammalian cancer cells, comprising exposing mammalian cancer cells to an amount of the Apo-2 agonistic antibody cited above or to an agent that activates Apo-2; and

(13) an article of manufacture comprising a container and a composition contained within the container, where the composition includes the above Apo-2 polypeptide or antibody.

ACTIVITY - Cytostatic.

MECHANISM OF ACTION - Gene therapy.

USE - The composition and methods are useful in inducing apoptosis in mammalian cancer cells. These may also be used in diagnostic procedures for tissue-specific typing and in generating transgenic or knockout animals that are useful in development and screening of reagents.

☐ 138. Document ID: JP 2003540352 X, WO 2003038087 A1, EP 1439225 A1, AU 2002349524 A1, US 20040248132 A1

L7: Entry 138 of 160 File: DWPI Feb 24, 2005

DERWENT-ACC-NO: 2003-449354
DERWENT-WEEK: 200516

TITLE: Nucleic acid that functions as a promoter useful the in treatment of cancer

INVENTOR: SAKAI, T

PRIORITY-DATA: 2001JP-0309179 (October 4, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC

JP 2003540352 X	February 24, 2005		036	C12N015/09
WO 2003038087 A1	May 8, 2003	J	053	C12N015/09
EP 1439225 A1	July 21, 2004	E	000	C12N015/09
AU 2002349524 A1	May 12, 2003		000	C12N015/09
US 20040248132 A1	December 9, 2004		000	C12Q001/68

INT-CL (IPC): C07 H 21/04; C12 N 1/15; C12 N 1/19; C12 N 1/21; C12 N 5/10; C12 N 9/64; C12 N 15/09; C12 Q 1/02; C12 Q 1/68; G01 N 33/15; G01 N 33/50; G01 N 33/566

ABSTRACTED-PUB-NO: WO2003038087A
BASIC-ABSTRACT:

NOVELTY - Nucleic acid (I) that functions as a promoter, comprises nucleotides 1029-1034 or 1075-1080 of a fully defined sequence, given in the specification, or a nucleic acid with a maximum of 6 bases upstream and/or downstream of the sequence, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) Screening for substances that control promoter activity;

(2) Substances identified by the screening method;

(3) Vectors comprising (I) and a reporter gene; and

(4) Cells comprising the vectors.

ACTIVITY - Cytostatic.

No biological data given.

MECHANISM OF ACTION - The DR5 gene and Siah-1 gene are associated with cancer control via apoptosis and cell cycle disruption.

USE - Substances identified by the screening method are useful in the treatment of cancer (claimed). Human Saos2 cells with null p53 was transfected with p53 expression plasmid p53 and CMV-neoBam. After 24 hours luciferase activity in the cell solution was tested, but p53 did not cause any significant increase in activity. Therefore there was the possibility that p53 expressed Siah-1 via a different part to the p53 bonding region of the Siah-1 promoter. From this, it can be seen that substances that express Siah-1 via the Siah-1 promoter may cause the p53 pathway to occur normally even when the p53 protein is missing. No supporting data given.

☐ 139. Document ID: CN 1655814 A, WO 2003038043 A2, US 20030133932 A1, AU 2002360307 A1, KR 2004070349 A, KR 2004081422 A, EP 1506285 A2, NO 200402266 A, JP 2005519871 W, ZA 200403573 A, CN 1630516 A, MX 2004004184 A1

L7: Entry 139 of 160 File: DWPI Aug 17, 2005

DERWENT-ACC-NO: 2003-421518
DERWENT-WEEK: 200572

TITLE: Inducing apoptosis and inhibiting proliferation of target cells expressing DR5, by contacting the target cell with an antibody that binds TNF-related apoptosis-inducing ligand receptor DR5 and with therapeutic agents

INVENTOR: BUCHSBAUM, D J; ICHIKAWA, K ; KIMBERLY, R P ; KOOPMAN, W J ; LOBUGLIO, A F ; OSHUMI, J ; ZHOU, T ; OHSUMI, J

PRIORITY-DATA: 2002US-391478P (June 24, 2002), 2001US-346402P (November 1, 2001), 2002US-

0281479 (October 25, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
CN 1655814 A	August 17, 2005		000	A61K039/395
WO 2003038043 A2	May 8, 2003	E	274	C12N000/00
US 20030133932 A1	July 17, 2003		000	A61K038/21
AU 2002360307 A1	May 12, 2003		000	C12N000/00
KR 2004070349 A	August 7, 2004		000	C07K016/28
KR 2004081422 A	September 21, 2004		000	A61K039/395
EP 1506285 A2	February 16, 2005	E	000	C12N001/00
NO 200402266 A	July 23, 2004		000	C07K016/28
JP 2005519871 W	July 7, 2005		188	A61K039/395
ZA 200403573 A	August 31, 2005		276	C12N000/00
CN 1630516 A	June 22, 2005		000	A61K031/337
MX 2004004184 A1	February 1, 2005		000	C12N000/00000

INT-CL (IPC): A61 K 31/337; A61 K 31/404; A61 K 31/4745; A61 K 31/519; A61 K 31/522; A61 K 31/525; A61 K 31/56; A61 K 31/704; A61 K 31/7072; A61 K 38/16; A61 K 38/21; A61 K 39/395; A61 K 41/00; A61 K 45/00; A61 K 45/06; A61 P 1/00; A61 P 3/10; A61 P 5/14; A61 P 7/02; A61 P 7/04; A61 P 7/06; A61 P 9/10; A61 P 11/06; A61 P 13/12; A61 P 15/00; A61 P 17/00; A61 P 17/06; A61 P 19/02; A61 P 21/04; A61 P 25/00; A61 P 29/00; A61 P 31/04; A61 P 31/12; A61 P 33/06; A61 P 35/00; A61 P 37/02; A61 P 37/06; A61 P 37/08; C07 H 21/04; C07 K 16/28; C12 N 0/00; C12 N 0/00000; C12 N 1/00; C12 P 21/06

ABSTRACTED-PUB-NO: WO2003038043A
BASIC-ABSTRACT:

NOVELTY - Selectively inducing apoptosis in- and inhibiting (M1) proliferation of target cells expressing DR5, comprising contacting the cell with an antibody that specifically binds tumor necrosis factor (TNF)- related apoptosis-inducing ligand (TRAIL) receptor DR5, where the antibody, in its soluble form, has in vivo and in vitro apoptosis-inducing activity in the cell expressing DR5, and contacting the cell with one or more therapeutic agents, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) treating (M2) a subject having an inflammatory or autoimmune disease, by administering an antibody that specifically binds a TRAIL receptor DR5, and administering a therapeutic agent; and

(2) a composition comprising the above mentioned antibody.

ACTIVITY - Nephrotropic; Antiarteriosclerotic; Cardiant; Antiasthmatic; Antiallergic; Antiinflammatory; Antidiabetic; Hemostatic; Neuroprotective; Antiinfertility; Immunosuppressive; Dermatological; Antianemic; Antirheumatic; Antiarthritic; Thyromimetic.

MECHANISM OF ACTION - Inducer of apoptosis; Inhibitor of target cell proliferation; Antibody therapy.

Induction of apoptosis in vitro in malignant cells. To determine whether TRA-8 induced apoptosis in transformed cells in vitro, all DR5-positive tumor cells were examined for their susceptibility to apoptosis induced either by TRA-8 or TRAIL. Target cells (1 multiply 103 per well) were cultured in 69-well plates in the presence of the indicated concentrations of soluble TRAIL plus crosslinker or TRA-8. Cell viability was determined using ATPLite kit, the MTT Cell proliferation/viability kit and staining of dead cells and analyzed by flow cytometry. At end of culture, cells were stained with 10 micro g/ml PI and PI negative cells were gated as viable cells. For analysis of condensed nuclei of hepatocytes, cells were stained with 10 ng/ml Hoechst 33352 and analyzed by flow cytometry. The TRA-8 antibody was capable of inducing apoptosis in the majority of the malignant human glioma cell lines (9/10), in 2 of the 3 prostate cancer cell lines, and in 2 of the 4 DR5-positive hematopoietic cell lines. It did not induce apoptosis in the Molt-4 cell line, which expressed almost undetectable cell surface levels of DR5. The levels of susceptibility of the cells to TRA-8-mediated apoptosis varied

considerably among the cell lines.

USE - M1 is useful for inducing apoptosis in target cell and inhibiting proliferation of target cell expressing DR5, where the target cell is an abnormally proliferating synovial cells (e.g. rheumatoid arthritis synovial cell), activated immune cell (e.g. activated lymphocyte), neutrophil, or virally infected cell. M2 is useful for treating a subject having inflammatory and autoimmune diseases. The inflammatory or autoimmune disease are selected from systemic lupus erythematosus, Hashimoto's disease, rheumatoid arthritis, graft-versus-host disease, Sjogren's syndrome, pernicious anemia, Addison disease, scleroderma, Goodpasture's syndrome, Crohn's disease, autoimmune hemolytic anemia, sterility, myasthenia gravis, multiple sclerosis, Basedow's disease, thrombotic, thrombocytopenia, thrombopenia purpura, insulin dependent diabetes mellitus, allergy, asthma, atopic disease, arteriosclerosis, myocarditis, cardiomyopathy, glomerular nephritis, and hypoplastic anemia. (All claimed.)

☐ 140. Document ID: US 20020150985 A1

L7: Entry 140 of 160 File: DWPI Oct 17, 2002

DERWENT-ACC-NO: 2003-198287
DERWENT-WEEK: 200617

TITLE: New Apo-2 polypeptides and polynucleotides, useful for inducing apoptosis in mammalian cells, in vivo or ex vivo gene therapy, in quantitative diagnostic assays, or in generating antibodies against Apo-2

INVENTOR: ADAMS, C W; ASHKENAZI, A J ; CHUNTHARAPAI, A ; KIM, K J

PRIORITY-DATA: 2001US-0052798 (November 2, 2001), 1997US-046615P (May 15, 1997), 1998US-074119P (February 9, 1998), 1998US-0079029 (May 14, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20020150985 A1	October 17, 2002		064	C07H021/04

INT-CL (IPC): A61 K 39/395; C07 H 21/04; C07 K 14/705; C12 N 5/06; C12 P 21/02

ABSTRACTED-PUB-NO: US20020150985A
BASIC-ABSTRACT:

NOVELTY - An isolated Apo-2 polypeptide having a fully defined sequence of 411 amino acids (I) given in the specification or having at least 80% amino acid sequence identity with (I), is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) an isolated extracellular domain sequence of Apo-2 polypeptide comprising amino acid residues 54-182 of (I);

(2) an isolated death domain sequence of Apo-2 polypeptide comprising amino acid residues 324-391 of (I);

(3) a chimeric molecule comprising the Apo-2 polypeptide above or the extracellular domain sequence of (1) fused to a heterologous amino acid sequence;

(4) an isolated nucleic acid comprising a DNA encoding the Apo-2 polypeptide, the extracellular domain sequence or the death domain sequence defined above;

(5) a vector comprising the nucleic acid;

(6) a host cell comprising the vector;

(7) producing an Apo-2 polypeptide by culturing the host cell for the expression of the Apo-2 polypeptide and recovering the expressed Apo-2 polypeptide from the culture;

(8) an Apo-2 polypeptide obtained or obtainable by expressing the polypeptide encoded by the cDNA insert under ATCC deposit accession number 209021;

(9) a non-human transgenic animal that contains cells that express DNA encoding Apo-2 polypeptide;

(10) a non-human knockout animal which contains cells having an altered gene encoding Apo-2 polypeptide;

(11) an antibody that specifically binds to an Apo-2 polypeptide;

(12) a hybridoma cell line which produces the antibody of (11);

(13) a chimeric molecule comprising the antibody of (11) fused to a heterologous amino acid sequence;

(14) a dimeric molecule comprising the Apo-2 antibody and a heterologous antibody;

(15) a homodimeric molecule comprising a first Apo-2 antibody and a second Apo-2 antibody;

(16) isolated nucleic acids comprising a DNA encoding an antibody defined above;

(17) a vector comprising the nucleic acid;

(18) a host cell comprising the vector;

(19) producing an Apo-2 antibody by culturing the host cell to express the DNA;

(20) a composition comprising the antibody of (11) and a carrier;

(21) inducing apoptosis in mammalian cancer cells by exposing mammalian cancer cells to an Apo-2 agonistic antibody or to an agent that activates Apo-2; and

(22) an article of manufacture comprising a container and a composition consisting of an Apo-2 polypeptide or Apo-2 antibody contained within the container.

ACTIVITY - None given.

MECHANISM OF ACTION - Gene therapy.

USE - The Apo-2 polypeptide is useful for inducing apoptosis in mammalian cells, in vivo or ex vivo gene therapy, in quantitative diagnostic assays, as a control against samples containing unknown quantities of Apo-2, in generating antibodies, in affinity purification techniques, and in competitive-type receptor binding assays when labeled with, for instance, radioiodine, enzymes, or fluorophores. Nucleic acids encoding Apo-2 may be used as a diagnostic for tissue-specific typing.

☐ 141. Document ID: CN 1553807 A, US 20020150552 A1, AU 2002339919 A1, JP 2005503796 W

L7: Entry 141 of 160 File: DWPI Dec 8, 2004

DERWENT-ACC-NO: 2003-198262
DERWENT-WEEK: 200517

TITLE: Composition useful for treating cancer, viral infection and inflammatory conditions such as asthma, comprises a mixture of human cytokines produced by a human cell line which

overexpresses a cytokine regulatory factor

INVENTOR: BROWNING, L; LAU, A S ; OSSINA, N ; WAN, W H

PRIORITY-DATA: 2001US-0952843 (September 11, 2001), 2000US-0660468 (September 12, 2000), 2002US-0105100 (March 21, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
CN 1553807 A	December 8, 2004		000	A61K038/19
US 20020150552 A1	October 17, 2002		031	A61K038/19
AU 2002339919 A1	March 24, 2003		000	A61K038/21
JP 2005503796 W	February 10, 2005		135	C12N015/09

INT-CL (IPC): A61 K 9/14; A61 K 38/00; A61 K 38/19; A61 K 38/20; A61 K 38/21; A61 K 38/22; A61 L 9/04; A61 P 31/12; A61 P 35/00; C07 K 14/52; C07 K 14/525; C07 K 14/53; C07 K 14/535; C07 K 14/54; C12 N 15/09; C12 P 21/00; C12 P 21/02

ABSTRACTED-PUB-NO: US20020150552A

BASIC-ABSTRACT:

NOVELTY - Composition (I) comprising mixture of human cytokines produced by culturing human cell line capable of producing mixture of cytokines, where the cell line overexpresses cytokine regulatory factor (CF) or anti-apoptotic protein (AP), treating CF- or AP-overexpressing cell line to effect enhanced production of mixture of cytokines, and collecting cytokines produced by the cultured CF- or AP-overexpressing cell line.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for producing (M1) a mixture of human cytokines in a cell culture, which involves culturing a human cell line capable of producing the mixture of cytokines, selecting or modifying the cultured human cell line where a CF is overexpressed by the cell line, treating the cultured, CF-overexpressing cell line to effect cytokine production, and collecting the cytokines produced by the cultured treated cell line.

ACTIVITY - Virucide; Cytostatic; Antiinflammatory; Anti-HIV; Antiasthmatic; Antiallergic; Antirheumatic; Antiarthritic.

No biological data given.

MECHANISM OF ACTION - Immune response modulator.

USE - (I) is useful in cancer treatment, where the cytokines produced include two or more cytokines chosen from interleukin-2 (IL-2), IL-12, IL-15, interferon-alpha (IFN- alpha), IFN-beta , IFN- gamma , IFN- omega , tumor necrosis factor-alpha (TNF- alpha), natural killer enhancing factor (NKEF), natural killer cell stimulatory factor (NKSF), TNF-related-apoptosis-inducing-ligand (TRAIL) and granulocyte macrophage colony-stimulating factor (GM-CSF). (I) is useful in treating viral infection, where the cytokines produced include two or more cytokines chosen from IFN- alpha , IFN- beta , IFN- gamma , IFN- omega , transforming growth factor beta (TGF- beta), IL-8, IL-12 and GM-CSF. (I) is also useful for treating an inflammatory condition, where the cytokines produced include two or more cytokines chosen from IL-4, IL-5, IL-6, IL-10, IFN- beta , IFN- gamma and TGF- beta (claimed). (I) is useful for treating cancer including solid tumors, melanomas, leukemias, and other types of cancers or neoplasms; viral infection including infection by human immunodeficiency virus (HIV), hepatitis viruses such as hepatitis B virus (HBV), hepatitis C virus (HCV) and other human-pathogenic viruses; and inflammation including asthma, allergies, and rheumatoid arthritis.

ADVANTAGE - (M1) provides increased production of the mixture of human cytokines in cell culture.

☐ 142. Document ID: US 6444640 B1

L7: Entry 142 of 160 File: DWPI Sep 3, 2002

DERWENT-ACC-NO: 2002-749312
DERWENT-WEEK: 200281

TITLE: Composition useful for treating cancer, comprises DR5 binding ligand such as tumor necrosis factor related apoptosis inducing ligand, and DNA damaging agent

INVENTOR: CAVENEE, W; HUANG, S ; NAGANE, M

PRIORITY-DATA: 1999US-0409336 (September 30, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6444640 B1	September 3, 2002		012	A61K038/00

INT-CL (IPC): A61 K 38/00

ABSTRACTED-PUB-NO: US 6444640B
BASIC-ABSTRACT:

NOVELTY - A composition (I) useful for treating a condition, comprises a DR5 binding ligand such as tumor necrosis factor related apoptosis inducing ligand (TRAIL), and a DNA damaging agent sufficient to affect apoptosis, is new.

ACTIVITY - Cytostatic. A total of 21 mice were inoculated, subcutaneously, with 2 multiply 10 to the power of 6 human glioblastoma cell U87MG, which were allowed to form established tumors. 13 days after the inoculation, tumors were established. Mice were then divided into four different treatment groups. The first group received only the drug vehicle (4 animals), the second group (4 animals) received 500 micro gram of tumor necrosis factor related apoptosis inducing ligand (TRAIL) per day, the third group (4 animals), received 3 mg/kg of cis-diamminedichloroplatinum (CDDP) per day, and the last group (9 animals), were dosed with both drugs. For the control, a combination of bacterial lysate and normal saline was used, to correspond to the drug combination. The results showed that four of the mice who received the combination therapy showed complete tumor regression, and one showed progressive regression.

MECHANISM OF ACTION - None given.

USE - (I) is useful for treating a subject with a condition that requires affecting apoptosis, where the condition is cancer, preferably glioma, by administering an amount of (I) to the subject sufficient to affect apoptosis (claimed). (I) is useful for treating conditions involving rapid cellular turnover, and for treating neoplasias and diseases involving proliferative lesions and glioblastomas.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 143. Document ID: US 20020102706 A1

L7: Entry 143 of 160 File: DWPI Aug 1, 2002

DERWENT-ACC-NO: 2002-697823
DERWENT-WEEK: 200472

TITLE: Novel isolated Apo-2DcR polypeptide useful for modulating apoptosis in mammalian cells

INVENTOR: ASHKENAZI, A J; BAKER, K P ; CHUNTHARAPAI, A ; GURNEY, A ; KIM, K J ; WOOD, W I

PRIORITY-DATA: 1997US-049911P (June 18, 1997), 1998US-0096500 (June 12, 1998), 2001US-0887879 (June 21, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20020102706 A1	August 1, 2002		058	C12N009/64

INT-CL (IPC): C12 N 5/06; C12 N 9/64; C12 P 21/02

ABSTRACTED-PUB-NO: US20020102706A
BASIC-ABSTRACT:

NOVELTY - Isolated Apo-2DcR polypeptide (I) having at least about 80% amino acid sequence identity with native sequence Apo-2DcR polypeptide comprising amino acid residues 1-259 of a sequence (S1) of 259 amino acids fully defined in the specification, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) an isolated native sequence Apo-2DcR polypeptide (II) comprising amino acid residues 1-259 of S1 or comprising amino acid residues -40 to 259 of a sequence (S2) of 299 amino acids fully defined in the specification;

(2) an isolated extracellular domain sequence (III) of Apo-2DcR polypeptide comprising amino acid residues 1-161 of S1 or comprising amino acid residues 1 to X, where X is any one of amino acid residues 161-236 of S1;

(3) a chimeric molecule (IV) comprising (I) or the extracellular domain sequence of Apo-2DcR polypeptide comprising amino acid residues 1-161 of S1, fused to a heterologous amino acid sequence;

(4) an antibody (V) which binds to (I) or to an isolated extracellular domain sequence of Apo-2DcR polypeptide comprising amino acid residues 1-161 of S1;

(5) a hybridoma cell line (VI) which produces (V);

(6) an isolated nucleic acid (VII) comprising a nucleotide sequence encoding (I) or an isolated extracellular domain sequence (III) of Apo-2DcR polypeptide comprising amino acid residues 1-161 of S1;

(7) a vector (VIII) comprising (VII);

(8) a host cell (IX) comprising (VIII);

(9) a non-human transgenic animal (X) which contains cells that express nucleic acid encoding Apo-2DcR polypeptide;

(10) a non-human knockout animal (XI) which contains cells having an altered gene encoding Apo-2DcR polypeptide; and

(11) a composition (XII) comprising (I), an isolated extracellular domain sequence of Apo-2DcR polypeptide comprising amino acid residues 1-161 of S1, (V) and a carrier.

ACTIVITY - None given.

MECHANISM OF ACTION - Modulator of apoptosis.

The capability of inducing cell death (apoptosis) by Apo-2 was determined. Hela cells or human 293 cells were transiently transfected by calcium phosphate precipitation or electroporation with a pRK5 vector or pRK5-based plasmids encoding Apo-2 and/or CrmA. Apoptosis was assessed for 24 hours after transfection by morphology. The result showed that Apo-2 transfected 293 cells underwent marked apoptosis.

USE - (I) is useful for modulating apoptosis in mammalian cells, by exposing the cells to Apo-2DcR polypeptide, where the cells are further exposed to Apo-2 ligand. (I) and (V) are useful for manufacturing an article comprising a container and a composition contained within the

container, where the composition includes Apo-2DcR polypeptide or Apo-2DcR antibodies. The article of manufacture further comprises instructions for using the Apo-2DcR polypeptide or Apo-2DcR antibodies in vivo or ex vivo. (VII) is useful effectively producing Apo-2DcR polypeptide, by culturing (IX) (all claimed). (IV) is therapeutically useful to inhibit Apo-2L activities. The Apo-2DcR antibodies are useful therapeutically, which cross-react with other receptors for Apo-2 ligand useful to block excessive apoptosis (in neurodegenerative diseases) or to block potentially autoimmune/inflammatory effects. Apo-2DcR antibodies are also useful in immunohistochemistry staining assays or diagnostic assays for Apo-2DcR, e.g. detecting its expression in specific cells, tissues or serum, and for the affinity purification of Apo-2DcR from recombinant cell culture or natural sources. (VII) is useful as a diagnostic for tissue-specific typing and for the preparation of Apo-2DcR. (VII) is useful to generate either transgenic or knock out animals which, in turn useful in the development and screening of therapeutically useful reagent and also to clone genomic DNA encoding Apo-2DcR or an appropriate sequence of it. Apo-2DcR are useful in quantitative diagnostic assays as a control against the samples containing unknown quantities of Apo-2DcR. Apo-2DcR preparations are useful in generating antibodies, as standards in assays for Apo-2DcR, in affinity purification techniques, and in competitive-type receptor binding assays. Apo-2DcR are employed to identified alternative forms of Apo-2DcR and modified forms of Apo-2DcR such as Apo-2DcR-IgG chimeric molecules, and are useful as immunogen in producing anti-Apo-2DcR antibodies.

☐ 144. Document ID: CN 1527721 A, WO 200222848 A2, EP 1318834 A2, JP 2004529851 W

L7: Entry 144 of 160 File: DWPI Sep 8, 2004

DERWENT-ACC-NO: 2002-351894
DERWENT-WEEK: 200478

TITLE: Composition for treating viral infection, cancer and inflammatory disorders, comprises mixture of human cytokines produced by cytokine regulatory factor and/or anti-apoptotic protein overexpressing cell line

INVENTOR: BROWNING, L; LAU, A S ; OSSINA, N ; WAN, W H

PRIORITY-DATA: 2000US-0660468 (September 12, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
CN 1527721 A	September 8, 2004		000	A61K038/19
WO 200222848 A2	March 21, 2002	E	062	C12P021/00
EP 1318834 A2	June 18, 2003	E	000	A61K038/19
JP 2004529851 W	September 30, 2004		119	C07K014/52

INT-CL (IPC): A61 K 38/00; A61 K 38/19; A61 K 38/21; A61 P 29/00; A61 P 31/12; A61 P 35/00; C07 K 14/52; C12 P 21/00; C12 P 21/02

ABSTRACTED-PUB-NO: WO 200222848A
BASIC-ABSTRACT:

NOVELTY - A composition comprising a mixture of human cytokines (CKs) produced by culturing a human cell line capable of producing a mixture of CKs, where the cell line is capable of overexpressing a cytokine regulatory factor (CRF) or an anti-apoptotic protein, treating the cell line to enhance production of a mixture of CKs, and collecting the CKs produced by the cultured, CRF or anti-apoptotic-overexpressing cell line, is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for producing (M) a mixture of human CKs in cell culture, by culturing a human cell line capable of producing the mixture of human CKs, selecting or modifying the cultured human cell line, where a CRF is overexpressed by the cell line, treating the cultured, CRF-overexpressing cell line to effect CK production, and

collecting the CKs produced by the cultured, treated cell line.

ACTIVITY - Cytostatic; Virucide; Antiinflammatory.

MECHANISM OF ACTION - Regulator of immune and inflammatory response; Inhibitor of apoptosis. No supporting data is given.

USE - The composition is useful for treating cancer, viral infection and an inflammatory condition. (M) is useful for producing a mixture of human CKs such as two or more interleukin-2 (IL-2), IL-12, IL-15, interferon- alpha (IFN- alpha), IFN- beta , IFN- gamma , IFN- omega , tumor necrosis factor- alpha , natural killer enhancing factor (NKEF), natural killer cell stimulatory factor (NKSF), tumor necrosis factor (TNF)-related-apoptosis-inducing-ligand (TRAIL) and granulocyte macrophage colony-stimulating factor (GM-CSF), for use in cancer treatment, IFN- alpha , IFN- beta , IFN- gamma , IFN- omega , transforming growth factor- beta (TGF- beta), IL-8, IL-12, GM-CSF, for use in treating viral infection, and IL-4, IL-5, IL-6, IL-10, IFN- beta , IFN- gamma and TGF- beta for use in treating inflammatory conditions (claimed).

☐ 145. Document ID: JP 2004509078 W, WO 200209755 A2, AU 200179055 A, EP 1303293 A2, US 20040005314 A1

L7: Entry 145 of 160 File: DWPI Mar 25, 2004

DERWENT-ACC-NO: 2002-268997
DERWENT-WEEK: 200422

TITLE: Use of CPT-11 which is a chemotherapeutic agent of the topoisomerase I inhibitor class, and Apo-2 ligand receptor agonist for enhancing apoptosis in mammalian cells, or for treating cancer in a mammal

INVENTOR: ESCANDON, E; FOX, J A ; KELLEY, S K ; XIANG, H

PRIORITY-DATA: 2000US-221256P (July 27, 2000), 2003US-0333712 (January 23, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2004509078 W	March 25, 2004		148	A61K038/00
WO 200209755 A2	February 7, 2002	E	084	A61K039/395
AU 200179055 A	February 13, 2002		000	A61K039/395
EP 1303293 A2	April 23, 2003	E	000	A61K038/17
US 20040005314 A1	January 8, 2004		000	A61K039/395

INT-CL (IPC): A61 K 31/4745; A61 K 38/00; A61 K 38/17; A61 K 39/395; A61 K 45/00; A61 N 5/00; A61 P 35/00; A61 P 37/00; A61 P 43/00; C12 N 15/09; A61 K 31:47; A61 K 39/395; A61 K 31:47; A61 K 38/17

ABSTRACTED-PUB-NO: WO 200209755A
BASIC-ABSTRACT:

NOVELTY - Use of CPT-11 (a chemotherapeutic agent of the topoisomerase I inhibitor class) (I) and Apo-2 ligand receptor agonist (II) for enhancing (M) apoptosis in mammalian cells, or for treating cancer in a mammal. The mammalian cells are exposed to (I) about 6-72 hours prior to exposure to (II).

ACTIVITY - Cytostatic.

Athymic nude mice were injected subcutaneously with 5 million COLO205 colon carcinoma cells and the tumors allowed to grow to about 120 mm3. Tumor-bearing mice were randomized into 4 groups

at 9 mice per group and treated with either vehicle (20 mM Tris, 8% Trehalose, 0.01 Tween-20, pH 7.5), Apo-2L (30 mg/kg/day on days 0-4 and 7-11), or CPT-11 (80 mg/kg/day on days 0, 4, and 8), or a combination of Apo-2L (30 mg/kg/day on days 0-4 and 7-11 plus CPT-11 (80 mg/kg/day on days 0, 4 and 8). Tumor volumes were determined at the indicated days over 34 days. Apo-2L or CPT-11, each suppressed tumor growth during the treatment period, although tumor growth resumed several days later in all 9 animals of each group. In contrast, the combination of Apo-2L with CPT-11 caused substantial tumor shrinkage, resulting in complete tumor elimination in 8 out of 9 animals in the combination treatment group. The results indicated that combinations of Apo-2 ligand and CPT-11 treatment synergistically inhibited growth of cancer cells in vivo.

MECHANISM OF ACTION - Inducer of apoptosis; Apo-2L receptor agonist; upregulates DR4 or DR5 receptor in mammalian cells (claimed).

USE - (M) is useful for enhancing apoptosis and treating cancer in patients having cancer (claimed).

ADVANTAGE - Combined Apo2L and CPT-11 treatment led to degradation of p21 and to upregulation of DR4 and DR5 receptors, directing cancer cells towards an apoptotic pathway rather than cell cycle arrest and possible DNA repair, thus providing enhanced anti-tumor activity.

Term	Documents
(3 OR 5).PGPB,USPT,JPAB,DWPI.	160
(L3 OR L5).PGPB,USPT,JPAB,DWPI.	160

Hit List

First Hit | Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 146 through 160 of 160 returned.

☐ 146. Document ID: US 6342369 B1

Using default format because multiple data bases are involved.

L7: Entry 146 of 160 File: DWPI Jan 29, 2002

DERWENT-ACC-NO: 2002-224941
DERWENT-WEEK: 200617
COPYRIGHT 2006 DERWENT INFORMATION LTD
TITLE: New nucleic acids encoding an Apo-2 ligand, useful for activating or stimulating apoptosis in cancer cells, thus especially useful in the treatment of cancer, or in enhancing immune-mediated cell death

INVENTOR: ASHKENAZI, A J

PRIORITY-DATA: 1998US-0079029 (May 14, 1998), 1997US-046615P (May 15, 1997), 1998US-074119P (February 9, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6342369 B1	January 29, 2002		068	C12P021/02

INT-CL (IPC): C07 H 21/04; C12 P 21/02

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

☐ 147. Document ID: AU 2001259366 B2, WO 200183560 A1, AU 200159366 A, NO 200205253 A, EP 1287035 A1, CZ 200203917 A3, US 20030190687 A1, US 20030198637 A1, KR 2003055177 A, CN 1440424 A, JP 2004502409 W, ZA 200209230 A, BR 200110547 A, HU 200400951 A2, MX 2002010823 A1, IN 200201603 P3, NZ 522881 A, JP 2005232187 A, NO 200504145 A

L7: Entry 147 of 160 File: DWPI Sep 8, 2005

DERWENT-ACC-NO: 2002-049338
DERWENT-WEEK: 200568
COPYRIGHT 2006 DERWENT INFORMATION LTD

TITLE: Novel antibody specific for tumor necrosis factor-related apoptosis-inducing ligand, useful for inhibiting cell proliferation in cancer

INVENTOR: ICHIKAWA, K; KIMBERLY, R P ; KOOPMAN, W J ; ZHOU, T ; BUCHSBAUM, D J ; LOBUGLIO, A F

PRIORITY-DATA: 2000US-201344P (May 2, 2000), 2003US-0275180 (March 5, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 2001259366 B2	September 8, 2005		000	C07K016/00
WO 200183560 A1	November 8, 2001	E	228	C07K016/00
AU 200159366 A	November 12, 2001		000	
NO 200205253 A	December 18, 2002		000	C07K016/28

EP 1287035 A1	March 5, 2003	E	000	C07K016/00
CZ 200203917 A3	May 14, 2003		000	C07K016/24
US 20030190687 A1	October 9, 2003		000	A61N005/00
US 20030198637 A1	October 23, 2003		000	A61K039/395
KR 2003055177 A	July 2, 2003		000	A61K039/395
CN 1440424 A	September 3, 2003		000	C07K016/00
JP 2004502409 W	January 29, 2004		342	C12N015/02
ZA 200209230 A	May 26, 2004		444	A01N000/00
BR 200110547 A	June 22, 2004		000	C07K016/00
HU 200400951 A2	July 28, 2004		000	C07K016/00
MX 2002010823 A1	May 1, 2004		000	A01N043/04
IN 200201603 P3	December 11, 2004	E	000	C07K016/00
NZ 522881 A	May 27, 2005		000	C07K016/00
JP 2005232187 A	September 2, 2005		109	C07K016/28
NO 200504145 A	December 18, 2002		000	A61K039/395

, MX 2002010823 A1 , IN 200201603 P3 , NZ 522881 A INT-CL (IPC): A01 N 0/00; A01 N 43/04; A61 K 31/337; A61 K 31/4745; A61 K 31/522; A61 K 31/525; A61 K 31/704; A61 K 31/7048; A61 K 38/14; A61 K 39/395; A61 K 45/06; A61 K 48/00; A61 N 5/00; A61 P 1/04; A61 P 3/10; A61 P 5/18; A61 P 7/06; A61 P 9/10; A61 P 13/12; A61 P 15/00; A61 P 17/00; A61 P 21/04; A61 P 25/00; A61 P 29/00; A61 P 35/00; A61 P 37/08; A61 P 43/00; C07 H 21/02; C07 K 16/00; C07 K 16/24; C07 K 16/28; C07 K 16/30; C07 K 16/46; C07 K 19/00; C12 N 1/15; C12 N 1/19; C12 N 1/21; C12 N 5/00; C12 N 5/10; C12 N 5/12; C12 N 15/00; C12 N 15/02; C12 N 15/09; C12 N 15/13; C12 N 15/63; G01 N 33/574

ABSTRACTED-PUB-NO: WO 200183560A
BASIC-ABSTRACT:

NOVELTY - An antibody which recognizes a tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor DR5, is new. The antibody has apoptosis-inducing activity to a cell expressing DR5 in vivo.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a monoclonal antibody produced by mouse-mouse hybridoma TRA-8 having ATCC accession number PTA-1428;

(2) inhibiting cell proliferation comprising exposing cells expressing DR5 to an antibody capable of binding to it;

(3) a mobilized antibody interacting with a tumor necrosis factor ligand receptor selected from Dr5, Dr5, DrD1, DrR2 or OPG, and inducing apoptosis in a cell expressing the receptor;

(4) a mobilized antibody capable of selectively binding an agonistic or antagonistic tumor necrosis factor ligand receptor epitope;

(5) process of treating an apoptosis related disease, comprising exposing a target tissue expressing the apoptosis related disease to the novel antibody, or antibody of (1);

(6) a fusion protein comprising:

(a) an antigenic TRAIL receptor amino acid sequence having at least ten bases; and coupled to

(b) an immunoglobulin protein capable of eliciting an immune response within a subject;

(7) gene therapy, comprising:

(a) transfecting target cells with a vector comprising an expressible TRAIL receptor nucleic acid sequence;

(b) expressing on the cells a TRAIL receptor encoded for by the TRAIL receptor nucleic acid sequence; and

(c) exposing the cells to an antibody selective for binding the TRAIL receptor;

(8) a nucleotide or amino acid sequence comprising a coding sequence for a selectively heavy chain immunoglobulin of an antibody capable of recognizing DR5;

(9) a nucleotide, or amino acid sequence comprising a coding sequence for TRA-8 light chain immunoglobulin of an antibody capable of recognizing DR5;

(10) an antibody selective for human DR5, comprising a humanized heavy chain immunoglobulin and a humanized light chain immunoglobulin;

(11) an amino acid sequence comprising a coding sequence for humanized heavy or light chain immunoglobulin of an antibody of (10);

(12) a nucleotide sequence comprising a coding sequence for humanized light chain immunoglobulin of an antibody of (10);

(13) a vector, comprising the nucleotide sequence of (8) and/or (9), and a regulatory sequence operably linked to it;

(14) a plasmid comprising a nucleic acid sequence encoding a heavy or light chain humanized immunoglobulin of an antibody of (10);

(15) a host cell transformed with the vector of (13), or the plasmid of (14);

(16) producing a humanized DR5 antibody, comprising:

(a) transforming a host cell with a vector encoding at least one of a humanized immunoglobulin light or heavy chain, and a vector encoding the light or heavy chain if either is absent from the first vector; and

(b) incubating the transformed host;

(17) process for inhibiting cell proliferation comprising contacting a target cell with a humanized DR5 antibody;

(18) a commercial kit for inducing cell death, comprising a humanized antibody selective for human DR5 packaged in a contained, along with instructions for use as a therapeutic against expressing DR5;

(19) process for increasing NFkB levels in a cell, comprising administering a amount of a DR5 selectively recognizing antibody; and

(20) an antibody which recognizes a TRAIL receptor DR5, and which does not recognize TRAIL receptors DR4, DcR1, or DcR2.

ACTIVITY - Cytostatic.

MECHANISM OF ACTION - TRAIL receptor agonist.

USE - For preparing a therapeutic for selective apoptosis of abnormal or dysregulated cells, and for inhibiting cell proliferation in a cell, preferably a human breast, ovary, colon, hematopoietic, prostate, lymphatic, lung, glioma or liver cancer cell. A therapeutic agent may also be administered, preferably paclitaxel, taxol, cycloheximide, carboplatin, chlorambucil, cisplatin, colchichine, cyclophosphamide, daunorubicin, dactinomycin, diethylstilbestrol, doxorubicin, etoposide, 5-fluorouracil, floxuridine, melphalan, methotrexate, mitomycin, 6-mercaptopurine, teniposide, 6-thioguanin, vincristine, or vinblasine. (All claimed). The antibody is used to treat an autoimmune disease, systemic lupus erythematosus, Hashimoto's disease, rheumatoid arthritis, graft-versus-host disease, Sjogren's syndrome, Chron's disease, pernicious anemia, Addison disease, scleroderma, Goodpasture's syndrome, autoimmune hemolytic anemia, sterility, myasthenia gravis, multiple sclerosis, Basedow's disease, thrombopenia purpura, insulin-dependent diabetes mellitus, allergy, atopic disease, arteriosclerosis, myocarditis, cardiomyopathy, glomerular nephritis, hypoplastic anemia, rejection after organ transplantation, and numerous malignancies of lung, prostate, liver, ovary, lymphatic or breast tissue.

☐ 148. Document ID: EP 1616882 A2, WO 200119861 A2, AU 200074943 A, EP 1226161 A2, JP 2003510253 W

L7: Entry 148 of 160 File: DWPI Jan 18, 2006

DERWENT-ACC-NO: 2001-266005
DERWENT-WEEK: 200606

TITLE: Inducing apoptosis in mammalian cells for treating cancer, comprises exposing mammalian cells or cancer cells expressing Apo-2 receptor, to Apo-2 agonist antibody

INVENTOR: ASHKENAZI, A J; CHUNTHERAPAI, A ; KIM, K J ; ASHKENAZI, A ; KIM, K

PRIORITY-DATA: 1999US-0396710 (September 15, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1616882 A2	January 18, 2006	E	000	C07K016/18
WO 200119861 A2	March 22, 2001	E	090	C07K014/00
AU 200074943 A	April 17, 2001		000	C07K014/00
EP 1226161 A2	July 31, 2002	E	000	C07K014/00
JP 2003510253 W	March 18, 2003		127	C07K016/18

INT-CL (IPC): A61 K 39/395; A61 P 35/00; C07 K 14/00; C07 K 16/18; C07 K 16/28; C12 N 5/06; C12 N 15/02; C12 N 15/09; C12 P 21/08

ABSTRACTED-PUB-NO: WO 200119861A
BASIC-ABSTRACT:

NOVELTY - Inducing apoptosis in mammalian cells (I) expressing Apo-2 receptor, and treating cancer, comprising exposing (I) or mammalian cancer cells to an Apo-2 agonist antibody (II) is new.

ACTIVITY - Cytostatic.

MECHANISM OF ACTION - Inducer of apoptosis. Apo-2 antibodies were tested for its activity to induce Apo-2 mediated 9D cell apoptosis. 9D cells were incubated with varying concentrations of antibodies in 100 mu l complete RPMI media at 4 deg. C for 15 minutes. The cells were then incubated for 5 minutes at 37 deg. C with or without 10 mu g of goat anti-mouse IgG Fc antibody in 300 mu l of complete RPMI. Apoptosis of the cells was determined by FACS after staining with FITC-annexin V binding to phosphatidylserine. The 3F11.39.7 antibody (in the absence of the goat anti-mouse IgG Fc) induced apoptosis in the 9D cells as compared to the control antibodies. Agonistic activity, however, was enhanced by Apo-2 receptor cross-linking in the presence of the goat anti-mouse IgG Fc. This enhanced apoptosis by the combination of antibodies is comparable to the apoptotic activity of Apo-2L in 9D cells.

USE - (II) is useful for inducing apoptosis and for treating mammalian cancer e.g., lung cancer, colon cancer, and glioma (claimed).

☐ 149. Document ID: US 6046048 A

L7: Entry 149 of 160 File: DWPI Apr 4, 2000

DERWENT-ACC-NO: 2000-282690
DERWENT-WEEK: 200532

TITLE: New isolated monoclonal antibodies having antigen specificity for Apo-2 ligand, e.g. 2G6, 2E11 or 5C2, useful for detecting the expression of Apo-2 ligand serum, and for treating diseases associated with increased apoptosis

INVENTOR: ASHKENAZI, A J; CHUNTHARAPAI, A ; KIM, K J

PRIORITY-DATA: 1996US-009755P (January 9, 1996), 1997US-0780496 (January 8, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6046048 A	April 4, 2000		046	C12N005/16

INT-CL (IPC): C12 N 5/16

ABSTRACTED-PUB-NO: US 6046048A
BASIC-ABSTRACT:

NOVELTY - The hybridoma cell lines deposited under American Type Culture Collection Accession Number ATCC HB-12256, HB-12257, HB-12258 and HB-12259, are new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) Apo-2 ligand monoclonal antibodies produced by the novel cell lines; and

(2) isolated Apo-2 ligand monoclonal antibodies which:

(a) bind an Apo-2 ligand polypeptide comprising residues 114-281 of a 281 amino acid sequence (I), fully defined in the specification; and

(b) bind to the same Apo-2 ligand epitope as the monoclonal antibodies 1D1, 2G6, 2E11, or 5C2, produced by the hybridoma cell line deposited under ATCC Accession Numbers HB-12257, HB-12259, HB-12256 and HB-12258, respectively.

ACTIVITY - Antiapoptotic; anti-necrotic; cytostatic.

MECHANISM OF ACTION - Apo-2 ligand activity blocker. The 9D cells treated with the Apo-2 ligand showed 50% apoptotic cells above the untreated, control cells. The 9D cells treated with Apo-2 ligand plus the 2E11, 5C2, 2G6 or 1D1 antibodies showed 0%, 6%, 26% and 48% apoptotic cells above the untreated control, respectively. These results show that the 5C2, 2E11 and 2G6 antibodies are blocking antibodies while the 1D1 antibody is a non-blocking antibody. The most potent activity was observed with the 5C2 antibody. The antigen specificities of the 4 antibodies were also tested in an enzyme linked immunosorbant assay (ELISA). Microtiter wells were coated with 2 mu g/ml lymphotoxin, or Apo-2 ligand. Monoclonal antibodies 1D1, 2G6, 2E11 and 5C2 were tested at a concentration of 10 mu g/ml. The results of the assay showed that monoclonal antibodies 2G6, 2E11 and 5C2 were specific for Apo-2 ligand.

USE - The Apo-2 ligand antibodies may be used in diagnostic assays for Apo-2 ligand, e.g. detecting its expression in specific cells, tissues, or serum. The antibodies may also be employed as therapeutics. For instance, anti-Apo-2 ligand antibodies which block Apo-2 ligand activity, like Apo-2 ligand-induced apoptosis, may be employed to treat pathological conditions or diseases associated with increased apoptosis. They are also useful for the affinity purification of Apo-2 ligand from recombinant cell culture or natural sources. The Apo-2 ligand itself may be used to treat diseases e.g. cancer, by inducing apoptosis in cells.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc | Image

---

☐ 150. Document ID: AU 2003204560 A1, WO 9964461 A2, AU 9945611 A, EP 1086138 A2, JP 2002517223 W

DERWENT-ACC-NO: 2000-097520
DERWENT-WEEK: 200464

TITLE: Preparation of antibodies using 2 or more different antigens, used for producing antibodies against Apo-2 ligand receptors useful for inducing apoptosis, particularly in cancer cells

INVENTOR: ASHKENAZI, A J; CHUNTHARAPAI, A ; KIM, K J

PRIORITY-DATA: 1998US-0096637 (June 12, 1998), 2003AU-0204560 (June 5, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 2003204560 A1	July 24, 2003		000	C07K016/00
WO 9964461 A2	December 16, 1999	E	057	C07K016/00
AU 9945611 A	December 30, 1999		000	C07K016/00
EP 1086138 A2	March 28, 2001	E	000	C07K016/28
JP 2002517223 W	June 18, 2002		098	C12N015/02

INT-CL (IPC): A61 K 39/00; A61 K 39/395; A61 P 35/00; C07 K 16/00; C07 K 16/28; C12 N 1/15; C12 N 1/19; C12 N 1/21; C12 N 5/10; C12 N 15/02; C12 N 15/85; C12 P 21/08; G01 N 33/531; C12 P 21/08; C12 R 1:91

ABSTRACTED-PUB-NO: WO 9964461A
BASIC-ABSTRACT:

NOVELTY - Method (I) for producing antibodies by immunizing an animal with at least two different antigens (ag) is new.

DETAILED DESCRIPTION - Method (I) for producing antibodies, comprises:

(a) immunizing an animal with at least two different antigens, to generate polyclonal antibodies (PAbs) against each antigen in the animal;

(b) preparing monoclonal antibodies (MAbs) using immune cells of the above animal; and

(c) screening the MAbs to identify one or more MAbs which bind to each antigen.

INDEPENDENT CLAIMS are also included for the following:

(1) a method as in (A) further comprising isolating nucleic acid encoding a MAb selected from step (c) as in (A) and producing the MAb or a variant in a host cell transformed with nucleic acid encoding the MAb or a variant;

(2) an antibody which specifically cross-reacts with 2 or more different Apo-2L receptors;

(3) an antibody having the biological characteristics of a MAb selected from 3H1.18.10, 3H3.18.5 and 3D5.1.10;

(4) a hybridoma cell line which produces a MAb selected from 3H1.18.10, 3H3.14.5 and 3D5.1.10;

(5) isolated nucleic acid comprising DNA encoding an antibody as in (2);

(6) a vector comprising a nucleic acid as in (5);

(7) a host cell comprising a vector as in (6); and

(8) method of inducing apoptosis in mammalian cancer cells comprising exposing the cells to (an agonistic version of) (2).

ACTIVITY - Immunomodulatory, cytostatic, neuroprotective.

MECHANISM OF ACTION - Apo-2L receptor (ant)agonists.

USE - The antibodies obtained can be used for therapy. The Apo-2L receptor antibodies can be used for enhancing immune-mediated cell death in cells expressing Apo-2L receptors. Agonistic antibodies which specifically cross-react with 2 or more different Apo-2L receptors can be used for inducing apoptosis in mammalian cancer cells (claimed). Antagonistic antibodies can be used for blocking apoptosis, e.g. in neurodegenerative disease, or to block potential autoimmune/inflammatory effects of Apo-2 resulting from NF- approx. kB activation. The antibodies can also be used for detection, diagnosis and affinity purification.

ADVANTAGE - The method can reduce the number of animals that need to be immunized and sacrificed in order to make 2 or more MAbs with differing antigen-binding specificities. Sera titers from animals immunized with a mixture of antigens are similar to those achieved in animals immunized with a single antigen.

☐ 151. Document ID: WO 9954737 A1, AU 9879408 A

L7: Entry 151 of 160 File: DWPI Oct 28, 1999

DERWENT-ACC-NO: 2000-052707
DERWENT-WEEK: 200014

TITLE: Determining granzyme in a liquid sample

INVENTOR: HACK, C E; SPAENY-DEKKING, L

PRIORITY-DATA: 1998US-0062528 (April 17, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9954737 A1	October 28, 1999	E	039	G01N033/573
AU 9879408 A	November 8, 1999		000	G01N033/573

INT-CL (IPC): C07 K 16/44; G01 N 33/573; G01 N 33/577

ABSTRACTED-PUB-NO: WO 9954737A
BASIC-ABSTRACT:

NOVELTY - A method for determining a granzyme in a liquid sample, comprises subjecting the liquid sample to an immunoassay for detecting the presence or measuring the level of the granzyme. The immunoassay uses a monoclonal antibody capable of specifically binding the granzyme. The granzyme are granule associated enzymes of the granule-exocytosis pathway of T-cell or natural killer cell induced cell apoptosis.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1) a granzyme-specific monoclonal antibody capable of binding the granzyme in non-denatured state; (2) a monoclonal antibody capable of specifically binding a soluble complex of a granzyme and an inhibitor of the granzyme; (3) an immunoassay kit for determining a granzyme in a liquid sample, which kit comprises a monoclonal antibody capable of specifically binding the granzyme; and (4) a method for diagnosing activation of the immune system in an animal, comprising: (a) preparing a liquid sample of a body fluid; and (b) subjecting the liquid sample to an immunoassay to detect the presence or measure the level of a granzyme.

USE - The level of granzyme, or the level of the complex of granzyme and granzyme inhibitor, in the sample is used as a marker for degranulation of cytotoxic T-lymphocytes (CTL) and/or natural killer (NK) cells, and thus as a marker for activation of the immune system (all claimed).

☐ 152. Document ID: US 20040180049 A1, WO 9937684 A1, AU 9923382 A, EP 1053256 A1, JP 2002500877 W, AU 2003213463 A1, US 20040120947 A1

L7: Entry 152 of 160 File: DWPI Sep 16, 2004

DERWENT-ACC-NO: 1999-469117
DERWENT-WEEK: 200461

TITLE: New antibodies to death receptor 4, used for modulating activities associated with Apo-2 ligand, particularly apoptosis, useful for treating diseases and pathological conditions, e.g. cancer

INVENTOR: CHUNTHARAPAI, A; KIM, K J ; ASHKENAZI, A ; DODGE, K ; ASHKENAZI, A J

PRIORITY-DATA: 1998US-072481P (January 26, 1998), 2003AU-0213463 (July 11, 2003), 1999US-0237299 (January 25, 1999), 1999US-0322875 (May 28, 1999), 2000US-0584166 (May 25, 2000), 2003US-0660128 (September 11, 2003), 2003US-0630329 (July 30, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20040180049 A1	September 16, 2004		000	A61K039/395
WO 9937684 A1	July 29, 1999	E	041	C07K016/28
AU 9923382 A	August 9, 1999		000	C07K016/28
EP 1053256 A1	November 22, 2000	E	000	C07K016/28
JP 2002500877 W	January 15, 2002		050	C12N015/09
AU 2003213463 A1	August 14, 2003		000	C07K016/28
US 20040120947 A1	June 24, 2004		000	A61K039/395

INT-CL (IPC): A61 K 39/395; A61 P 35/00; C07 K 16/28; C07 K 16/30; C07 K 16/46; C12 N 5/06; C12 N 5/10; C12 N 5/20; C12 N 15/09; C12 N 15/13; C12 P 21/08

ABSTRACTED-PUB-NO: WO 9937684A
BASIC-ABSTRACT:

NOVELTY - An antibody (A) which specifically binds to death receptor 4 (DR4) is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a hybridoma cell line which produces (A);

(2) an isolated nucleic acid encoding (A);

(3) a method of inducing apoptosis in mammalian cells comprising exposing mammalian cells to a DR4 agonist antibody;

(4) a dimeric molecule comprising a DR4 antibody linked to a heterologous immunoglobulin;

(5) the hybridoma cell line deposited under American type culture collection number ATCC HB-12454;

(6) the hybridoma cell line deposited under American type culture collection number ATCC HB-12455; and

(7) an article of manufacture comprising a container and a composition contained within the container, where the composition includes a DR4 antibody.

USE - The DR4 antibodies may be agonistic, antagonistic or blocking antibodies. The DR4 antibodies are capable of modulating biological activities associated with Apo-2 ligand, in particular, apoptosis, and thus are useful in the treatment of various diseases and pathological conditions, including cancer. The antibodies can also be used for detection and diagnosis.

☐ 153. Document ID: WO 9936535 A1, AU 9923251 A, EP 1045906 A1, JP 2002508962 W, US 6740739 B1, AU 2003204487 A1

L7: Entry 153 of 160 File: DWPI Jul 22, 1999

DERWENT-ACC-NO: 1999-444397
DERWENT-WEEK: 200532

TITLE: A novel cytokine, designated Apo-2 ligand, useful for inducing apoptosis in mammalian cancer cells

INVENTOR: ASHKENAZI, A J; KELLEY, R F ; O'CONNELL, M P ; PITTI, R M ; SCHWALL, R H ; O'CONNEL, M T ; SCHWALL, R A

PRIORITY-DATA: 1998US-0060533 (April 15, 1998), 1998US-0007886 (January 15, 1998), 2000US-0582450 (June 26, 2000), 2003AU-0204487 (June 2, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9936535 A1	July 22, 1999	E	086	C12N015/12
AU 9923251 A	August 2, 1999		000	C12N015/12
EP 1045906 A1	October 25, 2000	E	000	C12N015/12
JP 2002508962 W	March 26, 2002		126	C12N015/09
US 6740739 B1	May 25, 2004		000	C07K014/525
AU 2003204487 A1	June 26, 2003		000	C12N015/12

INT-CL (IPC): A61 K 38/00; A61 K 38/17; A61 K 39/385; A61 P 35/00; A61 P 43/00; C07 K 14/475; C07 K 14/52; C07 K 14/525; C07 K 14/705; C07 K 16/24; C07 K 16/28; C12 N 1/19; C12 N 1/21; C12 N 5/10; C12 N 15/09; C12 N 15/12; C12 N 15/62

ABSTRACTED-PUB-NO: WO 9936535A
BASIC-ABSTRACT:

NOVELTY - A novel cytokine, designated Apo-2 ligand (Apo-2L), is new.

DETAILED DESCRIPTION - An isolated soluble Apo-2L comprises or consists (essentially) of amino acid residues 91-281 (preferably 92-281) of a 281 amino acid sequence (given in the specification).

INDEPENDENT CLAIMS are also included for the following:

(1) an isolated Apo-2L (Apo-2L(a)) having at least about 80% amino acid sequence identity with Apo-2L as above;

(2) a chimeric polypeptide comprising Apo-2L fused to a heterologous polypeptide sequence (preferably a tag polypeptide sequence);

(3) an isolated nucleic acid sequence (I) comprising DNA encoding Apo-2L;

(4) a vector comprising (I);

(5) a host cell comprising the vector of (4);

(6) production of Apo-2L comprising culturing the host cell of (5) and recovering Apo-2L from the host cell culture; and

(7) a soluble Apo-2L produced by expressing in CHO cells a gene encoding a full-length human Apo-2L.

ACTIVITY - Cytostatic; Apoptotic.

MECHANISM OF ACTION - Cytokine; Anti-Apo-2L Antibody.

USE - Apo-2L is useful for inducing apoptosis in mammalian cancer cells (claimed). This is useful for the treatment of cancer. Apo-2L can be used to induce apoptosis for pathological conditions characterized by decreased levels of apoptosis, e.g. autoimmune disorders like lupus and immune-mediated glomerular nephritis and cancer. Apo-2L and its nucleic acid coding sequence can also be used in quantitative and screening diagnostic techniques. Anti-Apo-2L antibodies can be used to treat diseases associated with increased apoptosis.

☐ 154. Document ID: WO 9910484 A1, AU 9884850 A, EP 1009817 A1, JP 2001513994 W, AU 2003200137 A1

L7: Entry 154 of 160 File: DWPI Mar 4, 1999

DERWENT-ACC-NO: 1999-254218
DERWENT-WEEK: 200477

TITLE: A new polypeptide, designated RTD

INVENTOR: ASHKENAZI, A J; GURNEY, A

PRIORITY-DATA: 1997US-0918874 (August 26, 1997), 2003AU-0200137 (January 15, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9910484 A1	March 4, 1999	E	032	C12N015/00
AU 9884850 A	March 16, 1999		000	C12N015/00
EP 1009817 A1	June 21, 2000	E	000	C12N015/00
JP 2001513994 W	September 11, 2001		089	C12N015/09
AU 2003200137 A1	April 17, 2003		000	C12N015/00

INT-CL (IPC): A01 K 67/027; A61 K 38/00; C07 K 14/705; C07 K 16/28; C07 K 19/00; C12 N 1/15; C12 N 1/19; C12 N 1/21; C12 N 5/10; C12 N 15/00; C12 N 15/09; C12 P 21/02; C12 P 21/08; C12 Q 1/02; C12 P 21/08; C12 R 1:91

ABSTRACTED-PUB-NO: WO 9910484A
BASIC-ABSTRACT:

NOVELTY - An isolated native RTD polypeptide (I), defined in the specification as having 386 amino acids, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) isolated RTD polypeptide comprising residues 56-386 of sequence (I);

(2) isolated native RTD polypeptide having 80 %, preferably 95 % identity to sequence (I);

(3) isolated extracellular domain sequences of RTD polypeptide comprising:

(a) residues 56-212 of (I); or

(b) fragments of (a) which retain biological activity of a native RTD polypeptide;

(4) a chimeric molecule comprising an RTD polypeptide fused to a heterologous amino acid sequence;

(5) an antibody which specifically binds to an RTD polypeptide;

(6) isolated nucleic acid comprising a sequence encoding (I) or the domain sequence of (3);

(7) a vector comprising the above nucleic acid;

(8) a host cell comprising the above vector;

(9) a process for producing an RTD polypeptide by culture of the above cell;

(10) a non-human transgenic animal containing cells that express nucleic acid encoding RTD polypeptide;

(11) a non-human knockout animal containing cells having an altered gene encoding RTD polypeptide;

(12) a method of modulating apoptosis in mammalian cells by exposing them to RTD polypeptide, particularly where they are also exposed to Apo-2 ligand; and

(13) an article of manufacture comprising a container and a composition within the container, where the composition includes RTD polypeptide or RTD antibodies.

ACTIVITY - Inhibitory;

Human 293 cells (1x106) were transfected by calcium phosphate precipitation with 4 mu g pRK5 or pRK5-based plasmids encoding RTD (clone DNA35663 or clone DNA 35664) or DR5 along with 1 mu g pRK5 encoding green fluorescent protein. The cells were treated 24 hours later with 0.5 mu g/ml Apo-2 ligand, stained with 10 mu g/ml Hoechst dye 33342, and double positive cells were scored for apoptotic morphology under a fluorescent microscope. Results showed that cells transfected with either of the RTD cDNA clones were significantly less sensitive to Apo-2 ligand-induced apoptosis.

MECHANISM OF ACTION - Ligand-binding;

RTD, DR5 or TNFR1 immunoadhesin (2.5 mu g) was incubated with 125I-labelled soluble Apo-2 ligand in the absence or presence of 1 mu g unlabeled ligand for 1 hour at room temperature. Complexes were precipitated by protein A sepharose and resolved by electrophoresis under reducing conditions on a 4-20% gradient SDS polyacrylamide gel. Results showed that RTD and DR5 but not the TNFR1 immunoadhesin co-precipitated with labeled ligand, and that this co-precipitation was blocked by excess unlabeled ligand. BIACORE analysis showed that RTD immunoadhesin bound to Apo-2 ligand, but not to other apoptosis-inducing family members TNF-alpha , lymphotoxin- alpha and Fas ligand.

USE - RTD can be employed therapeutically to modulate apoptosis and/or NF-kappaB activation by Apo-2 ligand or another ligand that RTD binds to in mammalian cells (disclosed). RTD polypeptide and nucleic acid sequences can also be used as a diagnostic tool for tissue-specific typing, in quantitative diagnostic assays, to generate antibodies for immunoassays and affinity purification techniques, or in competitive-type receptor binding assays (disclosed).

ADVANTAGE - None given.

☐ 155. Document ID: US 20020161196 A1, WO 9909165 A1, AU 9887844 A, EP 1003864 A1, US 20010029030 A1, JP 2001514888 W, US 6417328 B1, US 20020115154 A1, US 20020161195 A1

DERWENT-ACC-NO: 1999-181035
DERWENT-WEEK: 200274

TITLE: Newly isolated polynucleotide encoding a mammalian TRAIL receptor protein - useful for screening for (ant)agonists that modulate the apoptotic activity mediated by DR5 or TRAIL-R3 proteins

INVENTOR: ALNEMRI, E S

PRIORITY-DATA: 1997US-055906P (August 15, 1997), 1998US-0134618 (August 14, 1998), 2002US-0067615 (February 4, 2002), 2002US-0076754 (February 12, 2002), 2002US-0076773 (February 12, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20020161196 A1	October 31, 2002		000	C07K014/705
WO 9909165 A1	February 25, 1999	E	071	C12N015/12
AU 9887844 A	March 8, 1999		000	C12N015/12
EP 1003864 A1	May 31, 2000	E	000	C12N015/12
US 20010029030 A1	October 11, 2001		000	G01N033/53
JP 2001514888 W	September 18, 2001		082	C12N015/09
US 6417328 B1	July 9, 2002		000	C07K014/715
US 20020115154 A1	August 22, 2002		000	C12Q001/68
US 20020161195 A1	October 31, 2002		000	C07K014/705

INT-CL (IPC): A01 K 67/00; A01 K 67/027; A01 K 67/33; A01 N 43/04; A61 K 31/70; C07 H 21/04; C07 K 14/705; C07 K 14/715; C07 K 16/28; C12 N 1/15; C12 N 1/19; C12 N 1/21; C12 N 5/06; C12 N 5/10; C12 N 15/09; C12 N 15/11; C12 N 15/12; C12 N 15/63; C12 N 15/85; C12 P 21/02; C12 P 21/06; C12 P 21/08; C12 Q 1/68; G01 N 33/15; G01 N 33/50; G01 N 33/53; G01 N 33/566; G01 N 33/567

ABSTRACTED-PUB-NO: US 6417328B
BASIC-ABSTRACT:

NOVELTY - An isolated polynucleotides (I) - (III) encoding a mammalian TRAIL receptor selected from DR5 and TRAIL-R3 proteins (including splice variant cDNA sequences, and active fragments), is new.

DETAILED DESCRIPTION - An isolated polynucleotide encoding a mammalian TRAIL receptor, comprises: (a) DNA encoding one of amino acid sequences (I) - (III); (b) DNA encoding biologically active DR5 or TRAIL-R3, and which hybridizes to the DNA of (a) under moderate stringency; (c) degenerate DNA with respect to (a) and (b) encoding biologically active DR5 or TRAIL-R3; and (d) splice variant cDNA sequences of any of (a) - (c).

INDEPENDENT CLAIMS are also included for the following: (1) a vector containing the polynucleotide; (2) recombinant cells containing the polynucleotide; (3) an antisense oligonucleotide that specifically binds to mRNA encoded by the polynucleotide; (4) an isolated mammalian protein (I) - (III) encoded by the polynucleotide; (5) production of the protein selected from a group comprising DR5, TRAIL-R3, and their splice variants; (6) an antibody that specifically binds to the protein; and (7) a transgenic non-human mammal expressing an exogenous polynucleotide encoding the protein.

ACTIVITY - Antigenic; apoptotic. Apoptosis activity of DR5 and TRAIL-R3 proteins was tested using the mammalian double expression vector pRSC (Akporiaye et al., (1997) BioTech. 22:68). The figure showed that expression of DR5 (not TRAIL-R3) induces apoptosis in human MCF7 cells.

MECHANISM OF ACTION - Inducer (DR5 only); antagonist (TRAIL-R3 only). Transient expression of TRAIL-R3, which does not normally contain a death domain, was incapable of inducing apoptosis in MCF7 cells (See figure).

USE - The antibody is useful for detecting mammalian DR5 or TRAIL-R3 proteins in a sample

(claimed). Recombinant cells are useful in bioassays for screening for (ant)agonists of DR5 or TRAIL-R3 proteins (claimed). (Ant)agonists identified by the assay are useful for modulating the apoptotic activity mediated by DR5 or TRAIL-R3 proteins (claimed).

Apoptosis related conditions which are treated in this way, include cancer (e.g. lymphomas and carcinomas), autoimmune diseases (e.g. systemic lupus erythematosus and immune-mediated glomerulonephritis), viral infections (e.g. herpes virus, poxvirus and adenovirus), degenerative disorders (e.g. Alzheimer's disease and Parkinson's disease), amyotrophic lateral sclerosis, retinitis pigmentosa, cerebellar degeneration, myelodysplastic syndromes (e.g. aplastic anemia) and ischemic injury (e.g. myocardial infarction and stroke).

The polynucleotides can also be used to treat these diseases. The antisense oligonucleotide forms a composition that is useful for i inhibiting expression of a human DR5 or TRAIL-R3 protein (claimed).
ABSTRACTED-PUB-NO:

US20010029030A EQUIVALENT-ABSTRACTS:

NOVELTY - An isolated polynucleotides (I) - (III) encoding a mammalian TRAIL receptor selected from DR5 and TRAIL-R3 proteins (including splice variant cDNA sequences, and active fragments), is new.

DETAILED DESCRIPTION - An isolated polynucleotide encoding a mammalian TRAIL receptor, comprises: (a) DNA encoding one of amino acid sequences (I) - (III); (b) DNA encoding biologically active DR5 or TRAIL-R3, and which hybridizes to the DNA of (a) under moderate stringency; (c) degenerate DNA with respect to (a) and (b) encoding biologically active DR5 or TRAIL-R3; and (d) splice variant cDNA sequences of any of (a) - (c).

INDEPENDENT CLAIMS are also included for the following: (1) a vector containing the polynucleotide; (2) recombinant cells containing the polynucleotide; (3) an antisense oligonucleotide that specifically binds to mRNA encoded by the polynucleotide; (4) an isolated mammalian protein (I) - (III) encoded by the polynucleotide; (5) production of the protein selected from a group comprising DR5, TRAIL-R3, and their splice variants; (6) an antibody that specifically binds to the protein; and (7) a transgenic non-human mammal expressing an exogenous polynucleotide encoding the protein.

ACTIVITY - Antigenic; apoptotic. Apoptosis activity of DR5 and TRAIL-R3 proteins was tested using the mammalian double expression vector pRSC (Akporiaye et al., (1997) BioTech. 22:68). The figure showed that expression of DR5 (not TRAIL-R3) induces apoptosis in human MCF7 cells.

MECHANISM OF ACTION - Inducer (DR5 only); antagonist (TRAIL-R3 only). Transient expression of TRAIL-R3, which does not normally contain a death domain, was incapable of inducing apoptosis in MCF7 cells (See figure).

USE - The antibody is useful for detecting mammalian DR5 or TRAIL-R3 proteins in a sample (claimed). Recombinant cells are useful in bioassays for screening for (ant)agonists of DR5 or TRAIL-R3 proteins (claimed). (Ant)agonists identified by the assay are useful for modulating the apoptotic activity mediated by DR5 or TRAIL-R3 proteins (claimed).

Apoptosis related conditions which are treated in this way, include cancer (e.g. lymphomas and carcinomas), autoimmune diseases (e.g. systemic lupus erythematosus and immune-mediated glomerulonephritis), viral infections (e.g. herpes virus, poxvirus and adenovirus), degenerative disorders (e.g. Alzheimer's disease and Parkinson's disease), amyotrophic lateral sclerosis, retinitis pigmentosa, cerebellar degeneration, myelodysplastic syndromes (e.g. aplastic anemia) and ischemic injury (e.g. myocardial infarction and stroke).

The polynucleotides can also be used to treat these diseases. The antisense oligonucleotide forms a composition that is useful for i inhibiting expression of a human DR5 or TRAIL-R3 protein (claimed).

NOVELTY - An isolated polynucleotides (I) - (III) encoding a mammalian TRAIL receptor selected from DR5 and TRAIL-R3 proteins (including splice variant cDNA sequences, and active fragments), is new.

DETAILED DESCRIPTION - An isolated polynucleotide encoding a mammalian TRAIL receptor, comprises: (a) DNA encoding one of amino acid sequences (I) - (III); (b) DNA encoding

biologically active DR5 or TRAIL-R3, and which hybridizes to the DNA of (a) under moderate stringency; (c) degenerate DNA with respect to (a) and (b) encoding biologically active DR5 or TRAIL-R3; and (d) splice variant cDNA sequences of any of (a) - (c).

INDEPENDENT CLAIMS are also included for the following: (1) a vector containing the polynucleotide; (2) recombinant cells containing the polynucleotide; (3) an antisense oligonucleotide that specifically binds to mRNA encoded by the polynucleotide; (4) an isolated mammalian protein (I) - (III) encoded by the polynucleotide; (5) production of the protein selected from a group comprising DR5, TRAIL-R3, and their splice variants; (6) an antibody that specifically binds to the protein; and (7) a transgenic non-human mammal expressing an exogenous polynucleotide encoding the protein.

ACTIVITY - Antigenic; apoptotic. Apoptosis activity of DR5 and TRAIL-R3 proteins was tested using the mammalian double expression vector pRSC (Akporiaye et al., (1997) BioTech. 22:68). The figure showed that expression of DR5 (not TRAIL-R3) induces apoptosis in human MCF7 cells.

MECHANISM OF ACTION - Inducer (DR5 only); antagonist (TRAIL-R3 only). Transient expression of TRAIL-R3, which does not normally contain a death domain, was incapable of inducing apoptosis in MCF7 cells (See figure).

USE - The antibody is useful for detecting mammalian DR5 or TRAIL-R3 proteins in a sample (claimed). Recombinant cells are useful in bioassays for screening for (ant)agonists of DR5 or TRAIL-R3 proteins (claimed). (Ant)agonists identified by the assay are useful for modulating the apoptotic activity mediated by DR5 or TRAIL-R3 proteins (claimed).

Apoptosis related conditions which are treated in this way, include cancer (e.g. lymphomas and carcinomas), autoimmune diseases (e.g. systemic lupus erythematosus and immune-mediated glomerulonephritis), viral infections (e.g. herpes virus, poxvirus and adenovirus), degenerative disorders (e.g. Alzheimer's disease and Parkinson's disease), amyotrophic lateral sclerosis, retinitis pigmentosa, cerebellar degeneration, myelodysplastic syndromes (e.g. aplastic anemia) and ischemic injury (e.g. myocardial infarction and stroke).

The polynucleotides can also be used to treat these diseases. The antisense oligonucleotide forms a composition that is useful for i inhibiting expression of a human DR5 or TRAIL-R3 protein (claimed).

US20020115154A

NOVELTY - An isolated polynucleotides (I) - (III) encoding a mammalian TRAIL receptor selected from DR5 and TRAIL-R3 proteins (including splice variant cDNA sequences, and active fragments), is new.

DETAILED DESCRIPTION - An isolated polynucleotide encoding a mammalian TRAIL receptor, comprises: (a) DNA encoding one of amino acid sequences (I) - (III); (b) DNA encoding biologically active DR5 or TRAIL-R3, and which hybridizes to the DNA of (a) under moderate stringency; (c) degenerate DNA with respect to (a) and (b) encoding biologically active DR5 or TRAIL-R3; and (d) splice variant cDNA sequences of any of (a) - (c).

INDEPENDENT CLAIMS are also included for the following: (1) a vector containing the polynucleotide; (2) recombinant cells containing the polynucleotide; (3) an antisense oligonucleotide that specifically binds to mRNA encoded by the polynucleotide; (4) an isolated mammalian protein (I) - (III) encoded by the polynucleotide; (5) production of the protein selected from a group comprising DR5, TRAIL-R3, and their splice variants; (6) an antibody that specifically binds to the protein; and (7) a transgenic non-human mammal expressing an exogenous polynucleotide encoding the protein.

ACTIVITY - Antigenic; apoptotic. Apoptosis activity of DR5 and TRAIL-R3 proteins was tested using the mammalian double expression vector pRSC (Akporiaye et al., (1997) BioTech. 22:68). The figure showed that expression of DR5 (not TRAIL-R3) induces apoptosis in human MCF7 cells.

MECHANISM OF ACTION - Inducer (DR5 only); antagonist (TRAIL-R3 only). Transient expression of TRAIL-R3, which does not normally contain a death domain, was incapable of inducing apoptosis in MCF7 cells (See figure).

USE - The antibody is useful for detecting mammalian DR5 or TRAIL-R3 proteins in a sample (claimed). Recombinant cells are useful in bioassays for screening for (ant)agonists of DR5 or

TRAIL-R3 proteins (claimed). (Ant)agonists identified by the assay are useful for modulating the apoptotic activity mediated by DR5 or TRAIL-R3 proteins (claimed).

Apoptosis related conditions which are treated in this way, include cancer (e.g. lymphomas and carcinomas), autoimmune diseases (e.g. systemic lupus erythematosus and immune-mediated glomerulonephritis), viral infections (e.g. herpes virus, poxvirus and adenovirus), degenerative disorders (e.g. Alzheimer's disease and Parkinson's disease), amyotrophic lateral sclerosis, retinitis pigmentosa, cerebellar degeneration, myelodysplastic syndromes (e.g. aplastic anemia) and ischemic injury (e.g. myocardial infarction and stroke).

The polynucleotides can also be used to treat these diseases. The antisense oligonucleotide forms a composition that is useful for i inhibiting expression of a human DR5 or TRAIL-R3 protein (claimed).

WO 9909165A

☐ 156. Document ID: WO 9902653 A1, AU 9884003 A

L7: Entry 156 of 160 File: DWPI Jan 21, 1999

DERWENT-ACC-NO: 1999-120857
DERWENT-WEEK: 199910

TITLE: A new nucleic acid encodes a p53-induced protein (Killer) - which induces apoptosis and is useful in the diagnosis and treatment of neoplastic diseases

INVENTOR: EL-DEIRY, W S

PRIORITY-DATA: 1998US-077661P (March 11, 1998), 1997US-052305P (July 11, 1997), 1997US-054710P (August 4, 1997), 1997US-060473P (September 30, 1997), 1998US-077526P (March 11, 1998), 1998US-077628P (March 11, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9902653 A1	January 21, 1999	E	044	C12N005/00
AU 9884003 A	February 8, 1999		000	C12N005/00

INT-CL (IPC): C12 N 5/00; C12 N 15/00; C12 N 15/10; C12 N 15/12; C12 N 15/63

ABSTRACTED-PUB-NO: WO 9902653A
BASIC-ABSTRACT:

A new isolated nucleic acid (N1), comprises an open reading frame of part or all of a gene located on human chromosome 8p21, which encodes part or all of a mammalian, p53-inducible, apoptosis-mediating protein, comprising amino-terminal extracellular receptor, transmembrane, and death domains.

Also claimed are:

(1) a vector for mammalian cell transformation, comprising (N1); (2) a mammalian cell transformed with the vector;

(3) an oligonucleotide of 10-100 nucleotides, which specifically hybridises with a predetermined portion of (N1);

(4) an isolated nucleic acid molecule having a sequence which: (a) is the 1139bp single-stranded sequence (I) fully defined in the specification, or (b) is an allelic variant or natural mutant of sequence (I), or (c) hybridises with part or all of sequence I or its complement and encodes a polypeptide substantially the same as part or all of that encoded by

sequence I, or (d) encodes part or all of the 411 amino acid sequence (II) fully defined in the specification;

(5) a protein produced by expression of (N1);

(6) antibodies immunospecific for the above protein;

(7) a protein produced by expression of one of the nucleic acids defined in (4);

(8) antibodies immunospecific for the above protein;

(9) a non-human genetically engineered mammal, preferably a mouse, which is unable to produce a functional protein normally produced by expression of (N1)

USE - The nucleic acid molecule, it's encoded signal transduction protein and antibodies of the invention are useful in the diagnosis and treatment of neoplastic diseases (disclosed). The invention is also useful to produce animal model systems.

☐ 157. Document ID: WO 9851793 A1, AU 9877963 A, EP 981618 A1, JP 2001511653 W, AU 740858 B, AU 200214720 A, US 20030017161 A1, AU 2005203183 A1

L7: Entry 157 of 160 File: DWPI Nov 19, 1998

DERWENT-ACC-NO: 1999-045228
DERWENT-WEEK: 200560

TITLE: Human Apo-2 polypeptide inducing apoptosis - useful to treat conditions linked with decreased apoptosis e.g. cancer, and produce antibodies to increase or decrease apoptosis

INVENTOR: ADAMS, C W; ASHKENAZI, A J ; CHUNTHARAPAI, A ; KIM, K J

PRIORITY-DATA: 1998US-0020746 (February 9, 1998), 1997US-0857216 (May 15, 1997), 2002AU-0014720 (January 30, 2002), 2002US-0207295 (July 29, 2002), 2005AU-0203183 (July 21, 2005)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9851793 A1	November 19, 1998	E	134	C12N015/12
AU 9877963 A	December 8, 1998		000	C12N015/12
EP 981618 A1	March 1, 2000	E	000	C12N015/12
JP 2001511653 W	August 14, 2001		148	C12N015/09
AU 740858 B	November 15, 2001		000	C12N015/12
AU 200214720 A	March 14, 2002		000	A61K038/17
US 20030017161 A1	January 23, 2003		000	A61K039/395
AU 2005203183 A1	August 18, 2005		000	C12N015/12

INT-CL (IPC): A01 K 67/027; A61 K 38/00; A61 K 38/17; A61 K 39/395; A61 P 35/00; A61 P 43/00; C07 K 14/715; C07 K 16/24; C07 K 16/28; C07 K 16/42; C07 K 16/44; C07 K 16/46; C07 K 19/00; C12 N 1/19; C12 N 1/21; C12 N 5/10; C12 N 15/09; C12 N 15/12; C12 N 15/62; C12 P 21/02; C12 P 21/08

ABSTRACTED-PUB-NO: WO 9851793A
BASIC-ABSTRACT:

Polypeptide having at least 80 % identity to 411 amino acid sequence (I) given in the specification for Apo-2 is new. Also claimed are: (1) isolated extracellular domain sequence of Apo-2 comprising amino acids: (a) 54-182, or (b) 1-182 of (I); (2) isolated death domain sequence of Apo-2 comprising amino acids 324-391 of (I); (3) isolated DNA polynucleotide

encoding Apo-2, (1a) or (2); (4) vector containing DNA as in (3), optionally operably linked to host-recognised control sequences; (5) host cells (e.g. CHO, E. coli or yeast cells) comprising vector; (6) non-human transgenic animals containing (5) or cells with altered gene for Apo-2 expression; (7) antibodies specifically binding Apo-2; (8) hybridoma cell lines producing antibody; (9) chimeric molecule comprising Apo-2, (1a) or antibody fused to heterologous amino acid sequence; (10) dimeric molecule comprising antibody and heterologous antibody, and (11) DNA encoding specific single-chain antibodies 16E2, 20E6 or 24C4, vectors comprising DNA and host cells comprising vector.

USE - Apo-2 can be used therapeutically to induce apoptosis in mammalian cells, useful to treat conditions associated with decreased apoptosis e.g. cancer. Apo-2 is believed to be a new tumour necrosis factor (TNF) receptor (TNFR); TNF cytokines can induce apoptosis, thought to be initiated by binding to TNFRs, and Apo-2 triggered caspase-dependent apoptosis. It can be used to identify agents activating Apo-2, useful to treat mammalian cancer cells (claimed), and to produce Apo-2 chimeras useful therapeutically (e.g. those containing immunoglobulin sequences can be inhibit apoptosis) or diagnostically (e.g. those comprising an epitope tag polypeptide allow Apo-2 detection and purification using anti-tag antibodies). It can be used to produce antibodies which can be combined with a (particularly pharmaceutically acceptable) carrier in compositions (claimed) or used to produce dimeric molecules (especially homodimeric molecules comprising first and second Apo-2 antibodies; claimed). Agonistic (especially single-chain; claimed) antibodies can be administered to induce apoptosis in mammalian cancer cells (claimed), and antagonistic antibodies used to block excessive apoptosis (e.g. in neurodegenerative diseases). Apo-2 antibodies may also be used diagnostically e.g. to detect Apo-2 expression in cells/tissues and in Apo-2 purification. Polynucleotides encoding Apo-2 may be used diagnostically and to produce transgenic animals (e.g. mice or rats) as in (6) (e.g. knockout animals) (claimed), useful to develop and screen therapeutics. Kits comprising Apo-2 or Apo-2 antibodies are provided (claimed).

☐ 158. Document ID: CN 1184315 C, WO 9841629 A2, AU 9867635 A, EP 970213 A2, MX 9908486 A1, CN 1275162 A, KR 2000076364 A, NZ 337795 A, JP 2001520513 W, US 20020072091 A1, AU 747635 B, US 20020098550 A1, NZ 508381 A, AU 2002300603 A1, US 20040141952 A1, CN 1624128 A

L7: Entry 158 of 160 File: DWPI Jan 12, 2005

DERWENT-ACC-NO: 1998-531568
DERWENT-WEEK: 200620

TITLE: New isolated death domain containing receptor 5 - used to develop products for treating e.g. cancers, auto:immune disorders, viral infections, inflammation, graft-versus-host disease or neuro:degenerative disorders

INVENTOR: NI, J; ROSEN, C A ; GENTZ, R L ; GUO-LIANG, Y ; JIAN, N ; YU, G ; SU, J Y

PRIORITY-DATA: 1997US-054021P (July 29, 1997), 1997US-040846P (March 17, 1997), 1998US-0042583 (March 17, 1998), 1999US-132498P (May 4, 1999), 1999US-133238P (May 7, 1999), 1999US-148939P (August 13, 1999), 2000US-0565009 (May 4, 2000), 2001US-0874138 (June 6, 2001), 2001US-0005842 (December 7, 2001), 2002AU-0300603 (August 9, 2002), 2004US-0774622 (February 10, 2004)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
CN 1184315 C	January 12, 2005		000	C12N015/12
WO 9841629 A2	September 24, 1998	E	089	C12N015/12
AU 9867635 A	October 12, 1998		000	
EP 970213 A2	January 12, 2000	E	000	C12N015/12
MX 9908486 A1	January 1, 2000		000	C12N015/12
CN 1275162 A	November 29, 2000		000	C12N015/12
KR 2000076364 A	December 26, 2000		000	C12N015/12

NZ 337795 A	June 29, 2001	000	C07K016/28
JP 2001520513 W	October 30, 2001	104	C12N015/09
US 20020072091 A1	June 13, 2002	000	C12P021/02
AU 747635 B	May 16, 2002	000	C12N015/12
US 20020098550 A1	July 25, 2002	000	C07K014/705
NZ 508381 A	September 27, 2002	000	C07K016/28
AU 2002300603 A1	February 13, 2003	000	C12N015/12
US 20040141952 A1	July 22, 2004	000	A61K038/19
CN 1624128 A	June 8, 2005	000	C12N015/28

, CN 1624128 A INT-CL (IPC): A61 K 31/00; A61 K 31/397; A61 K 31/407; A61 K 31/496; A61 K 31/545; A61 K 31/704; A61 K 38/00; A61 K 38/17; A61 K 38/19; A61 K 39/395; A61 P 9/10; A61 P 25/28; A61 P 35/00; A61 P 37/06; C07 H 21/04; C07 K 14/495; C07 K 14/525; C07 K 14/575; C07 K 14/705; C07 K 14/715; C07 K 16/18; C07 K 16/28; C12 N 1/21; C12 N 5/06; C12 N 5/10; C12 N 15/09; C12 N 15/12; C12 N 15/28; C12 N 15/62; C12 N 15/63; C12 P 21/02

ABSTRACTED-PUB-NO: US20020072091A
BASIC-ABSTRACT:

An isolated polynucleotide (I) comprises a nucleotide sequence (NS) at least 95% identical to a sequence selected from: (a) a NS encoding a polypeptide comprising amino acids from -51 to 360 of a sequence shown; (b) a NS encoding a polypeptide comprising amino acids from -50 to 360 of a sequence shown; (c) a NS encoding a polypeptide comprising amino acids from 1 to 360 of a sequence shown; (d) a NS encoding a polypeptide having an amino acid sequence encoded by a cDNA clone contained in ATCC 97920; (e) a NS encoding a mature DR5 polypeptide having an amino acid sequence encoded by a cDNA clone contained in ATCC 97920; (f) a NS encoding a DR5 extracellular domain; (g) a NS encoding a DR5 transmembrane domain; (h) a NS encoding a DR5 intracellular domain; (i) a NS encoding a DR5 death domain; and (j) a NS complementary to any of the NSs in (a)-(i).

Also claimed are:

(1) an isolated polynucleotide (PN) comprising a sequence (PNS) which hybridises under stringent hybridisation conditions to (I), where the PN which hybridises does not hybridise under stringent hybridisation conditions to a PN having a NS consisting of only adenosine nucleotides or of only thymidine nucleotides;

(2) an isolated NAM comprising a PN which encodes an amino acid sequence of an epitope-bearing portion of a DR5 polypeptide having an amino acid sequence as in (a)-(i) above; (3) a recombinant vector comprising (I) or a polynucleotide as in (2);

(4) a recombinant host cell containing (I) or a polynucleotide as in (2);

(5) an isolated DR5 polypeptide comprising an amino acid sequence at least 95% identical to an amino acid sequence selected from (a)-(i) as above or as in (2);

(6) an isolated antibody that binds specifically to a DR5 polypeptide as in (5);

(7) an isolated PN having a sequence at least 95% identical to a sequence selected from: (a) a NS of clone HAPBU13R; (b) a NS of clone HSBBU76R; (c) a NS of a portion of a sequence shown, where the portion comprises at least 50 contiguous nucleotides from nucleotide 284 to 1,362; and (d) a NS complementary to any of the NSs in (a)-(c);

(8) a fusion protein comprising the peptide as in (5) fused to a hetrologous polypeptide.

USE - The DR5 (death domain containing receptor 5) is a novel member of the tumour necrosis factor (TNF) family of receptors. Agonists which increase DR5 mediated signalling can be used to treat diseases in which decreased apoptosis is exhibited, e.g. cancers, autoimmune disorders (such as systemic lupus erythematosis and immune-related glomerulonephritis rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft versus host disease, acute graft rejection, chronic graft rejection, rheumatoid arthritis, osteoarthritis, psoriasis, septicemia, and inflammatory bowel disease. Antagonists which decrease DR5 mediated signalling can be used to treat diseases in which

apoptosis is exhibited, e.g. AIDS, neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration), myelodysplastic syndromes (such as aplastic anaemia), ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia. The products can also be used for detection, diagnosis and drug screening.
ABSTRACTED-PUB-NO:

US20020098550A EQUIVALENT-ABSTRACTS:

NOVELTY - A method for treating graft-versus-host disease, viral infection, cancer, leukemia, immunodeficiency, or an autoimmune disorder comprising administering an antibody (I) to amino acids -51 to 360 of Death domain containing receptor (DR5) and a second agent, is new.

DETAILED DESCRIPTION - A method for treating graft-versus-host disease, viral infection, cancer, leukemia, immunodeficiency, or an autoimmune disorder comprising administering an antibody (I) to amino acids -51 to 360 of Death domain containing receptor (DR5) and a second agent, is new. DR5 is a member of the tumor necrosis factor (TNF) family of receptors and comprises a defined 411 amino acid sequence (P1), given in the specification.

The second therapeutic agent is selected from TRAIL, a TNF, a TNF blocking agent, an immunosuppressive agent, an antibiotic, an antiinflammatory agent, a chemotherapeutic agent, and a cytokine.

INDEPENDENT CLAIMS are also included for the following:

(1) a composition comprising (I) and the second therapeutic agent; and

(2) an isolated polypeptide comprising residues 1-133 of P1 covalently attached to polyethylene glycol (PEG), where PEG has an average molecular weight of 2000-20000.

ACTIVITY - Immunosuppressive; antiviral; cytostatic; osteopathic; antiarthritic; antipsoriatic; antibacterial; antiinflammatory; gastrointestinal general; vasotropic.

Experimental details are described but no results are given.

MECHANISM OF ACTION - Gene therapy.

Experimental details are described but no results are given.

USE - The method is useful for the treatment of graft-versus-host disease, viral infection, cancer, leukemia, immunodeficiency, or an autoimmune disorder.

(I) is useful for treating or preventing diseases and conditions associated with increased cell survival and/or insensitivity to apoptosis-inducing agents such as solid tissue cancers and leukemias. Antagonists of DR5 are useful for inhibiting T-cell mediated immune responses as well as preventing and/or treating diseases and conditions associated with T-cell mediated immune responses such as graft-versus-host responses, osteoarthritis, psoriasis, septicemia, inflammatory bowel disease, autoimmune diseases and leukemia. DR5 polynucleotides and polypeptides are useful for diagnosis, prevention and/or treatment of parasitic, bacterial, and viral infections, restenosis and autoimmune disorders.

An isolated polynucleotide (I) comprises a nucleotide sequence (NS) at least 95% identical to a sequence selected from: (a) a NS encoding a polypeptide comprising amino acids from -51 to 360 of a sequence shown; (b) a NS encoding a polypeptide comprising amino acids from -50 to 360 of a sequence shown; (c) a NS encoding a polypeptide comprising amino acids from 1 to 360 of a sequence shown; (d) a NS encoding a polypeptide having an amino acid sequence encoded by a cDNA clone contained in ATCC 97920; (e) a NS encoding a mature DR5 polypeptide having an amino acid sequence encoded by a cDNA clone contained in ATCC 97920; (f) a NS encoding a DR5 extracellular domain; (g) a NS encoding a DR5 transmembrane domain; (h) a NS encoding a DR5 intracellular domain; (i) a NS encoding a DR5 death domain; and (j) a NS complementary to any of the NSs in (a)-(i).

Also claimed are:

(1) an isolated polynucleotide (PN) comprising a sequence (PNS) which hybridises under

stringent hybridisation conditions to (I), where the PN which hybridises does not hybridise under stringent hybridisation conditions to a PN having a NS consisting of only adenosine nucleotides or of only thymidine nucleotides;

(2) an isolated NAM comprising a PN which encodes an amino acid sequence of an epitope-bearing portion of a DR5 polypeptide having an amino acid sequence as in (a)-(i) above; (3) a recombinant vector comprising (I) or a polynucleotide as in (2);

(4) a recombinant host cell containing (I) or a polynucleotide as in (2);

(5) an isolated DR5 polypeptide comprising an amino acid sequence at least 95% identical to an amino acid sequence selected from (a)-(i) as above or as in (2);

(6) an isolated antibody that binds specifically to a DR5 polypeptide as in (5);

(7) an isolated PN having a sequence at least 95% identical to a sequence selected from: (a) a NS of clone HAPBU13R; (b) a NS of clone HSBBU76R; (c) a NS of a portion of a sequence shown, where the portion comprises at least 50 contiguous nucleotides from nucleotide 284 to 1,362; and (d) a NS complementary to any of the NSs in (a)-(c);

(8) a fusion protein comprising the peptide as in (5) fused to a hetrologous polypeptide.

USE - The DR5 (death domain containing receptor 5) is a novel member of the tumour necrosis factor (TNF) family of receptors. Agonists which increase DR5 mediated signalling can be used to treat diseases in which decreased apoptosis is exhibited, e.g. cancers, autoimmune disorders (such as systemic lupus erythematosis and immune-related glomerulonephritis rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft versus host disease, acute graft rejection, chronic graft rejection, rheumatoid arthritis, osteoarthritis, psoriasis, septicemia, and inflammatory bowel disease. Antagonists which decrease DR5 mediated signalling can be used to treat diseases in which apoptosis is exhibited, e.g. AIDS, neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration), myelodysplastic syndromes (such as aplastic anaemia), ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia. The products can also be used for detection, diagnosis and drug screening.

WO 9841629A

☐ 159. Document ID: DE 69832178 E, WO 9835986 A1, AU 9866505 A, EP 1005488 A1, US 6072047 A, NZ 336929 A, MX 9907234 A1, AU 735686 B, JP 2002514069 W, US 6569642 B1, US 6642358 B1, MX 217643 B, EP 1005488 B1

L7: Entry 159 of 160 File: DWPI Dec 8, 2005

DERWENT-ACC-NO: 1998-480767
DERWENT-WEEK: 200581

TITLE: New TRAIL receptor protein and related oligomers, nucleic acid, vectors - used to inhibit TRAIL activity, e.g. in cases of thrombocytic purpura, clotting in small blood vessels etc., also for diagnosis

INVENTOR: RAUCH, C; WALCZAK, H

PRIORITY-DATA: 1997US-0883036 (June 26, 1997), 1997US-0799861 (February 13, 1997), 1997US-0815255 (March 12, 1997), 1997US-0829536 (March 28, 1997), 1997US-0869852 (June 4, 1997), 2000US-0536201 (March 27, 2000), 2000US-0578392 (May 25, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 69832178 E	December 8, 2005		000	C07K014/435
WO 9835986 A1	August 20, 1998	E	056	C07K014/435
AU 9866505 A	September 8, 1998		000	C07K014/435
EP 1005488 A1	June 7, 2000	E	000	C07K014/435
US 6072047 A	June 6, 2000		000	C07H021/04
NZ 336929 A	November 24, 2000		000	C07K016/28
MX 9907234 A1	January 1, 2000		000	C07K014/435
AU 735686 B	July 12, 2001		000	C07K014/435
JP 2002514069 W	May 14, 2002		070	C12N015/09
US 6569642 B1	May 27, 2003		000	C07H021/04
US 6642358 B1	November 4, 2003		000	C07K014/00
MX 217643 B	November 18, 2003		000	C07H021/04
EP 1005488 B1	November 2, 2005	E	000	C07K014/435

INT-CL (IPC): A61 K 38/00; A61 P 43/00; C07 H 21/04; C07 K 14/00; C07 K 14/435; C07 K 14/705; C07 K 14/715; C07 K 16/28; C12 N 1/15; C12 N 1/19; C12 N 1/21; C12 N 5/10; C12 N 15/00; C12 N 15/09; C12 N 15/12; C12 N 15/19; C12 N 15/63; C12 P 21/08

ABSTRACTED-PUB-NO: US 6072047A
BASIC-ABSTRACT:

Purified TRAIL-receptor polypeptide (TRAIL-R; TRAIL = tumour necrosis factor-related apoptosis-inducing ligand) that can bind TRAIL and includes the sequence VPANEGD.

Also new are:

(1) oligomers containing 2-4 TRAIL-R molecules;

(2) isolated TRAIL-R DNA (I), its fragments and DNA or RNA complements;

(3) expression vectors containing (I);

(4) host cells containing this vector, and

(5) antibodies (Ab) against TRAIL-R, and its antigen-binding fragments.

USE - TRAIL-R is used:

(i) to purify or inhibit activity of TRAIL, in vitro or in vivo, particularly its apoptosis-inducing action;

(ii) to measure amounts of TRAIL;

(iii) to identify TRAIL-expressing cells;

(iv) as carrier for therapeutic or diagnostic agents to such cells;

(v) as reagents for study effects of inhibiting TRAIL/TRAIL-R interactions.

TRAIL-R, or its nucleic acid, can be used to treat conditions involving defective or inadequate TRAIL-R, e.g. thrombotic thrombocytopaenic purpura, haemolytic-uraemic syndrome, clotting of small blood vessels, systemic lupus erythematosus and TRAIL-mediated apoptosis of T cells in human immune deficiency virus infections.

Ab are used for detection or purification of TRAIL-R, and to inhibit TRAIL/TRAIL-R interaction, i.e. to treat the above diseases; also agonist antibodies can be used to induce apoptosis in some cancer or virus-infected cells.

(I) can be used to detect abnormal TRAIL-R genes and as antisense therapeutics.

TRAIL-R may be administered in soluble form or it is immobilised on a solid support and used

for extracorporeal treatment of blood.
ABSTRACTED-PUB-NO:

WO 9835986A EQUIVALENT-ABSTRACTS:

Purified TRAIL-receptor polypeptide (TRAIL-R; TRAIL = tumour necrosis factor-related apoptosis-inducing ligand) that can bind TRAIL and includes the sequence VPANEGD.

Also new are:

(1) oligomers containing 2-4 TRAIL-R molecules;

(2) isolated TRAIL-R DNA (I), its fragments and DNA or RNA complements;

(3) expression vectors containing (I);

(4) host cells containing this vector, and

(5) antibodies (Ab) against TRAIL-R, and its antigen-binding fragments.

USE - TRAIL-R is used:

(i) to purify or inhibit activity of TRAIL, in vitro or in vivo, particularly its apoptosis-inducing action;

(ii) to measure amounts of TRAIL;

(iii) to identify TRAIL-expressing cells;

(iv) as carrier for therapeutic or diagnostic agents to such cells;

(v) as reagents for study effects of inhibiting TRAIL/TRAIL-R interactions.

TRAIL-R, or its nucleic acid, can be used to treat conditions involving defective or inadequate TRAIL-R, e.g. thrombotic thrombocytopaenic purpura, haemolytic-uraemic syndrome, clotting of small blood vessels, systemic lupus erythematosus and TRAIL-mediated apoptosis of T cells in human immune deficiency virus infections.

Ab are used for detection or purification of TRAIL-R, and to inhibit TRAIL/TRAIL-R interaction, i.e. to treat the above diseases; also agonist antibodies can be used to induce apoptosis in some cancer or virus-infected cells.

(I) can be used to detect abnormal TRAIL-R genes and as antisense therapeutics.

TRAIL-R may be administered in soluble form or it is immobilised on a solid support and used for extracorporeal treatment of blood.

☐ 160. Document ID: US 6998116 B1, WO 9725428 A1, AU 9718248 A, EP 873407 A1, US 6030945 A, AU 729279 B, JP 2001510321 W, US 20020102233 A1, US 6746668 B2, US 20040253708 A1, JP 2005237370 A

L7: Entry 160 of 160 File: DWPI Feb 14, 2006

DERWENT-ACC-NO: 1997-372867
DERWENT-WEEK: 200613

TITLE: Novel cytokine, Apo-2 ligand and corresponding DNA - used to induce apoptosis for the treatment of breast and colon cancer

INVENTOR: ASHKENAZI, A J; CHUNTHARAPAI, A ; KIM, K J

PRIORITY-DATA: 1996US-0584031 (January 9, 1996), 1999US-0459808 (December 13, 1999), 2001US-0934465 (August 21, 2001), 2004US-0861685 (June 4, 2004)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6998116 B1	February 14, 2006		000	A61K038/19
WO 9725428 A1	July 17, 1997	E	072	C12N015/28
AU 9718248 A	August 1, 1997		000	C12N015/28
EP 873407 A1	October 28, 1998	E	000	C12N015/28
US 6030945 A	February 29, 2000		000	A61K038/18
AU 729279 B	February 1, 2001		000	C12N015/28
JP 2001510321 W	July 31, 2001		108	C12N015/02
US 20020102233 A1	August 1, 2002		000	C07K014/52
US 6746668 B2	June 8, 2004		000	A61K038/18
US 20040253708 A1	December 16, 2004		000	C12N009/64
JP 2005237370 A	September 8, 2005		053	C12N005/10

INT-CL (IPC): A01 K 67/027; A61 K 31/337; A61 K 31/4745; A61 K 38/00; A61 K 38/18; A61 K 38/19; A61 K 39/395; A61 K 47/48; A61 P 13/08; A61 P 13/10; A61 P 35/00; A61 P 35/02; A61 P 43/00; C07 H 21/04; C07 K 14/435; C07 K 14/46; C07 K 14/52; C07 K 14/525; C07 K 16/24; C12 N 5/10; C12 N 5/18; C12 N 9/64; C12 N 15/02; C12 N 15/09; C12 N 15/28; C12 N 15/62; C12 N 15/86; C12 P 21/08

ABSTRACTED-PUB-NO: US 6030945A
BASIC-ABSTRACT:

An isolated biologically active Apo-2 ligand comprising amino acids 114-281, 41-281, 15-281 or 1-281, of the 281 residue sequence given in the specification, is new. Also claimed are: (1) a chimeric polypeptide comprising the Apo-2 ligand fused to a heterologous polypeptide; (2) isolated nucleic acid (I) encoding Apo-2; (3) a vector comprising (I); (4) a host cell comprising the vector of (3); (5) production of Apo-2 ligand comprising culturing the host cell of (4) and recovering the ligand form the culture; (6) an antibody, preferably monoclonal, which binds to Apo-2 ligand; (7) a hybridoma cell line which produces the antibody of (6); (8) a non-human transgenic animal, which contains cells that express (I); and (9) a non-human, knockout animal, preferably a rat or mouse, which contains cells having an altered gene encoding Apo-2 ligand.

USE - The Apo-2 ligand is a novel cytokine which is useful for stimulating apoptosis in mammalian cells. The ligand is used for the treatment of a mammal having cancer, especially breast or colon cancer (claimed). Containers containing a composition containing the Apo-2 ligand are included in the scope of the invention. The Apo-2 ligand antibodies may be used in diagnostic assays for Apo-2 ligand, and for affinity purification of Apo-2 ligand.
ABSTRACTED-PUB-NO:

US20020102233A EQUIVALENT-ABSTRACTS:

An isolated biologically active Apo-2 ligand comprising amino acids 114-281, 41-281, 15-281 or 1-281, of the 281 residue sequence given in the specification, is new. Also claimed are: (1) a chimeric polypeptide comprising the Apo-2 ligand fused to a heterologous polypeptide; (2) isolated nucleic acid (I) encoding Apo-2; (3) a vector comprising (I); (4) a host cell comprising the vector of (3); (5) production of Apo-2 ligand comprising culturing the host cell of (4) and recovering the ligand form the culture; (6) an antibody, preferably monoclonal, which binds to Apo-2 ligand; (7) a hybridoma cell line which produces the antibody of (6); (8) a non-human transgenic animal, which contains cells that express (I); and (9) a non-human, knockout animal, preferably a rat or mouse, which contains cells having an altered gene encoding Apo-2 ligand.

USE - The Apo-2 ligand is a novel cytokine which is useful for stimulating apoptosis in mammalian cells. The ligand is used for the treatment of a mammal having cancer, especially breast or colon cancer (claimed). Containers containing a composition containing the Apo-2 ligand are included in the scope of the invention. The Apo-2 ligand antibodies may be used in diagnostic assays for Apo-2 ligand, and for affinity purification of Apo-2 ligand.

An isolated biologically active Apo-2 ligand comprising amino acids 114-281, 41-281, 15-281 or 1-281, of the 281 residue sequence given in the specification, is new. Also claimed are: (1) a chimeric polypeptide comprising the Apo-2 ligand fused to a heterologous polypeptide; (2) isolated nucleic acid (I) encoding Apo-2; (3) a vector comprising (I); (4) a host cell comprising the vector of (3); (5) production of Apo-2 ligand comprising culturing the host cell of (4) and recovering the ligand form the culture; (6) an antibody, preferably monoclonal, which binds to Apo-2 ligand; (7) a hybridoma cell line which produces the antibody of (6); (8) a non-human transgenic animal, which contains cells that express (I); and (9) a non-human, knockout animal, preferably a rat or mouse, which contains cells having an altered gene encoding Apo-2 ligand.

USE - The Apo-2 ligand is a novel cytokine which is useful for stimulating apoptosis in mammalian cells. The ligand is used for the treatment of a mammal having cancer, especially breast or colon cancer (claimed). Containers containing a composition containing the Apo-2 ligand are included in the scope of the invention. The Apo-2 ligand antibodies may be used in diagnostic assays for Apo-2 ligand, and for affinity purification of Apo-2 ligand.

WO 9725428A

Term	Documents
(3 OR 5).PGPB,USPT,JPAB,DWPI.	160
(L3 OR L5).PGPB,USPT,JPAB,DWPI.	160